Effect-Based Analysis of Endocrine Disrupting Chemical Mixtures in Breast Milk and Possible Health Consequences for Human Infants. by Collet, Bérénice Constance
VU Research Portal
Effect-Based Analysis of Endocrine Disrupting Chemical Mixtures in Breast Milk and




Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Collet, B. C. (2021). Effect-Based Analysis of Endocrine Disrupting Chemical Mixtures in Breast Milk and
Possible Health Consequences for Human Infants. s.n.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl




EFFECT-BASED ANALYSIS OF ENDOCRINE 
DISRUPTING CHEMICAL MIXTURES IN BREAST 





ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. V. Subramaniam, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de Faculteit der Bètawetenschappen 
op woensdag 3 maart 2021 om 13.45 uur 
in de aula van de universiteit, 





Bérénice Constance Collet 
geboren te Charleville-Mézières, Frankrijk 
Chapter One 
2 
promotor:            prof.dr. A. Brouwer 
copromotoren:   dr. B. van der Burg 
          prof.dr. C.A.M. van Gestel 



















Author:  Bérénice Constance Collet 
Cover design:  Bregje Jaspers (Proefschrift Ontwerp) & Heshan Gunasekara 
Printed by: Ipskamp Printing 
 
ISBN:  978-94-6421-239-6 
This research was financially supported by the European Union’s Horizon 2020 





















List of Abbreviations .................................................................................................................. 9 
General Introduction ............................................................................................................... 13 
Antagonistic Activity Towards the Androgen Receptor Independent from Natural Sex 
Hormones in Human Milk Samples from the Norwegian HUMIS Cohort ............................. 29 
Anti-Androgenic Compounds in Breast Milk and Possible Association with Cryptorchidism 
Among Norwegian Boys in the HUMIS Birth Cohort ............................................................. 59 
Evaluation of A Panel of In Vitro Methods for Assessing Thyroid Receptor Β and Transthyretin 
Transporter Disrupting Activities ............................................................................................ 83 
Possible Role of Per- and Polyfluoroalkylated Substances (PFAS) in the Thyroid-Related 
Endocrine Activity Observed in Breast Milk Samples from the Norwegian HUMIS Cohort . 115 
Summary, Conclusions and Future Outlook ......................................................................... 137 
Supporting Information ......................................................................................................... 147 
Samenvatting ......................................................................................................................... 158 
Résumé .................................................................................................................................. 160 
Curriculum Vitae.................................................................................................................... 163 
List of Publications ................................................................................................................ 165 











AR: androgen receptor 
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The research described in this thesis investigates the presence of endocrine disrupting 
chemicals (EDCs) in human breast milk samples, using extraction- and effect-based analytical 
methods. In addition, studies have been performed to investigate the chemical nature of the 
EDC activities, using bioassay directed fractionation and chemical identification methods. 
Furthermore, possible associations between the EDCs and infant health outcome such as 
cryptorchidism have been studied using samples and data from the Norwegian HUMIS 
(HUman MIlk Study) cohort.    
Breast milk contamination and child adverse outcomes: the Norwegian 
HUMIS Cohort 
As a natural source of nutrients and antibodies, breast milk is acknowledged to have 
many benefits for both infants and nursing mothers e.g. reduced risk of childhood diseases, 
infections, obesity, cardiovascular disease, and breast- and ovarian cancer (Ballard and 
Morrow 2013; Chowdhury et al. 2015; Sankar et al. 2015; Victora et al. 2016). Breastfeeding 
has always been highly encouraged and was declared as ‘one of the most effective ways to 
ensure child health and survival’ by the World Health Organization (WHO 2015). Over the 
past few decades, many studies further detailed the importance of exclusive breastfeeding 
during the first six months of life with regard to early infancy development and growth (WHO 
2015). In parallel, a raising concern emerged from diverse toxicological studies presenting 
breastfeeding as a potential source of exposure to exogenous substances with possible 
endocrine active properties (Forns et al. 2015; Main et al. 2007; Massart et al. 2005; Sonawane 
1995; Thomsen et al. 2010). 
A variety of chemicals have been found to be able to interfere with some aspects of the 
endocrine system, e.g., estrogen-, androgen-, thyroid hormone action, which may result in the 
alteration of functions of the endocrine system and potential short- and long-term adverse 
effects in humans and wildlife species (Andersson et al. 2012; Colborn et al. 1993; Fucic et al. 
2012; Schreiber et al. 2020). In 1996, a large international working group officially classified 
these hormonally active agents under the designation ‘endocrine disrupting chemicals’ (EDCs; 
IPCS 2002). Nowadays, these are defined as follows: ‘An endocrine disruptor is an exogenous 
substance or mixture that alters function(s) of the endocrine system and consequently causes 
adverse health effects in an intact organism, or its progeny, or (sub)populations’ (IPCS 2002). 
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To this day, many chemicals have been identified or suspected to be EDCs in experimental and 
wildlife studies although only a relatively limited number of them have been properly assessed 
with respect to human health effects and few are regulated (Bergman et al. 2012). 
Even though studies highlighted the presence of potential EDCs in human milk, their 
origins and possible impacts on human health are still unclear (Andersson et al. 2012; Colborn 
et al. 1993; Iszatt et al. 2019; Kang et al. 2016; Solomon and Weiss 2002; Stefanidou et al. 
2009). Since 2003, the population-based HUMIS (HUman MIlk Study) birth-cohort aims to 
investigate the impact of an early-life exposure on child health while identifying key factors 
contributing to human milk contamination (Eggesbø et al. 2009). For that purpose, the 
Norwegian Institute of Public Health collected 2606 breast milk samples from mother and 
child pairs originating from six Norwegian counties. Participating mothers were asked to fill 
in questionnaires at different time points (time of recruitment, after parturition at one, six, 
twelve, twenty-four months and seven years of age), providing information about lifestyle 
habits, breastfeeding patterns, and child’s health outcomes including endocrine-dependent 
defects such as cryptorchidism i.e. undescended testis.  
Subsequent chemical target analysis and case-studies showed the presence of 
environmental toxicants in HUMIS samples e.g. polychlorinated substances (PCBs), 
perfluoroalkyl substances (PFAS), brominated flame retardants, hexachlorobenzene (HCB), 
dioxins and dioxin-like compounds, and their possible association with health outcomes in 
children (Eggesbø et al. 2009; Forns et al. 2015; Iszatt et al. 2016). Although target 
investigations are of interest, EDCs can work additively, synergistically, or antagonistically 
and as a result, may lead to variable effects depending on the composition and concentration 
of the chemical mixtures. This implies that the sole investigation of individual compounds, or 
subclasses, such as persistent or non-persistent EDCs cannot provide enough information to 
accurately predict adverse outcomes derived from breastfeeding-based exposure (Heys et al. 
2016; Kortenkamp 2014; Rajapakse et al. 2002). Therefore, there is a growing need of 
developing suitable assessment methods covering the combined effects of the total EDC load 
present in human milk. 
EDC exposure: possible implication in endocrine-related diseases 
Over the last decades, there has been a significant increase in the incidence of 
endocrine-related cancers e.g. thyroid, testicular, prostate, and sexual deformities in parallel 
with a drastic drop in fertility rates (Carlsen et al. 1995; Mascarenhas et al. 2012; United 
Nations Department of Economic and Social Affairs Population Division 2020; Wild et al. 
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2020). Throughout the past years, numerous pieces of evidence suggested the possible 
involvement of environmental toxicants, with endocrine disrupting properties, in the rising 
prevalence of hormonal-related diseases. While the role of genetics is not to be overlooked, the 
quick pace of these unprecedented changes affecting human health suggests that they cannot 
be purely attributed to inheritance factors.  
In 1993, Sharpe and Skakkebaek showed that in utero exposure to the xenoestrogen 
diethylstilbestrol (DES) could affect male reproductive development leading to impaired 
fertility and a higher risk of endocrine cancer at adult age. Subsequently, many other 
toxicological studies revealed that EDCs, in particular estrogen-like and anti-androgenic 
substances, are strong actors in increasing male birth defects including cryptorchidism and 
hypospadias i.e. penile malformation (Bai et al. 2017; Gray et al. 2000; Sharpe and 
Skakkebaek 2003; Vinggaard et al. 2005b). 
From fetal development to further maturation during infancy, childhood and puberty, 
the reproductive system highly depends on multiple endocrine actions (Marty et al. 2003; 
Müller and Skakkebaek 1992; Stiles and Jernigan 2010). For this reason, this system is a very 
sensitive target of potential mother-child EDCs exchanges, including placental transfer during 
fetal development and post-natal exposure through breastfeeding. Ethical and legal 
constraints are severely limiting the direct assessment of perinatal exposure to exogenous 
chemicals, therefore, identifying a suitable proxy for estimating EDCs activity during these 
critical periods is of major interest. 
Breast milk: non-invasive matrix and invaluable source of information 
Breast milk is a unique matrix, defined as a primary source of nutrition of many 
newborns and directly provided by women’s breasts. It is the only non-invasive body fluid 
capable of offering information regarding the mother’s chemical burden, including EDCs, 
which can also be a suitable proxy to her child’s perinatal exposure conditions (Esteban and 
Castaño 2009). Due to its high lipid content, breast milk is often used for monitoring lipophilic 
pollutants such as persistent organic pollutants (POPs), known to distribute equally in all fat 
compartments of the body (Kanja et al. 1992; Waliszewski et al. 2001; WHO 2007). 
Considering their potential hormonal disrupting properties, POPs and other organic toxicants 
may be detrimental to the endocrine system, including reproductive functions (Gregoraszczuk 
and Ptak 2013; WHO 2007). Moreover, they tend to remain in the food chain and in fat-rich 
tissues where their concentration builds-up over lifetime. This bioaccumulation can constitute 
a problematic chemical body burden for future mothers and contributes to the development 
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of an unfavorable environment for the growing fetus. This exposure can potentially continue 
during infancy through transfer of the load of chemicals from mother to child via 
breastfeeding. To reach a better understanding of such an early-life exposure impact on a 
child’s reproductive development, it is essential to identify key targets involved in 
environmental pollutants- and general EDC toxicity. 
Sex steroids: key targets of EDCs-induced reprotoxicity 
The action of natural hormones relies on their ability to navigate from their 
endogenous point of synthesis to their target tissues, where they can interact with specific 
endogenous receptors. Estrogens, i.e. estrone (E1), 17α-estradiol, 17β-estradiol (E2), and 
estriol (E3) bind with high affinity to nuclear estrogen receptor alpha (ERα) and estrogen 
receptor beta (ERβ) while androgens such as androstenedione, dehydroepiandrosterone 
(DHEA), dihydrotestosterone (DHT) and testosterone, are natural ligands of the androgen 
receptor (AR). Following activation, these nuclear receptors form dimers that undergo 
translocation into the nucleus of the target cell, where they bind to specific hormone 
responsive elements on the DNA subsequently triggering the transcription of associated genes. 
Over the past years, many classes of chemicals were proven to be able to replace natural 
hormones from their natural protein carriers and hormonal receptors. Because of their 
estrogen-like activities, several phthalates, insecticides, and flame retardants as well as natural 
phytoestrogens and mycotoxins were placed in the xenoestrogen sub-category of EDCs 
(Bergman et al. 2012). These toxicants are known to mimic the action of endogenous estrogens 
possibly leading to the uncontrolled activation, or suppression (in case of antagonists) of ERα 
and ERβ. Exposure to environmental xenoestrogens was shown to be potentially associated 
with various developmental abnormalities both in wildlife and in humans, including 
precocious puberty and feminization of the male reproductive tract (Fucic et al. 2012; Massart 
et al. 2008; Nikaido et al. 2004; Toppari et al. 1996). 
In a similar manner, many chemicals may interfere with the androgen signaling 
pathway via AR binding, further disturbing the sensitive balance between estrogens and 
androgens levels (Kelce et al. 1998; Kelce and Wilson 1997). Various pesticides were also found 
to possess antagonistic (anti-) properties towards androgen action, e.g. linuron, fenarimol, 
procymidone, methoxychlor and prochloraz (Hotchkiss et al. 2004; Kelce et al. 1998; Van der 
Burg et al. 2010; Vinggaard et al. 2002, 2005b; Wilson et al. 2008). Furthermore, studies 
reported that natural estrogens as well as xenoestrogens may also act as potent anti-androgens 
(Sohoni and Sumpter 1998; Sultan et al. 2001; Vinggaard et al. 2005a). A multitude of in vitro 
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and in vivo evidence suggested that early exposure to those anti-androgenic substances may 
result in reproductive deformities including cryptorchidism and hypospadias as well as 
impaired fertility (Bai et al. 2017; Borch et al. 2006; Fisher 2004; Schreiber et al. 2020; 
Toppari et al. 1996; Tyl et al. 2004; Vinggaard et al. 2005a; Welsh et al. 2008).  
As detailed earlier, there are numerous pieces of evidence demonstrating the critical 
role of estrogens and androgens in modulating the reproductive development, from fetal 
organs to full post-natal maturation. Hence, sex steroid signaling pathways, including AR and 
ERα/ERβ and their natural ligands, are key targets for studying potential reproductive 
impairments originating from perinatal EDC exposure. 
EDC interferences with thyroid hormone transport: a direct access to 
the growing child   
The thyroid signaling pathway relies on proper TH transportation from the thyroid 
gland to target cells where they can bind to nuclear thyroid receptor alpha (TRα) and thyroid 
receptor beta (TRβ) (Kim and Cheng 2013; Ortiga-Carvalho et al. 2014). THs are commonly 
transported by three major serum carrier proteins, thyroxine-binding globulin (TBG), 
transthyretin (TTR) and human serum albumin (HSA) (Pappa et al. 2015). Although it is well-
known that THs major transporter is TBG, TTR is the only carrier capable to mediate in 
passage of THs over the blood-brain barrier and the uterine-placental wall making this protein 
the main carrier of THs in the cerebrospinal fluid and the developing fetus (Landers et al. 
2013). 5′,3′,5,3-tetraiodo-[L]-thyronine (thyroxine; T4) and its bioactive form 3′,5,3-triiodo-
[L]-thyronine (triiodothyronine, T3) are natural ligands capable of activating TRα/TRβ mono- 
or dimerization inducing their translocation to hormonal response elements, regulating 
thyroid-associated gene expression (Brent 2012). Moreover, thyroid receptors often interact 
with retinoid X receptor (RXR), a retinoic acid receptor, to form heterodimers (Hsu et al. 1995; 
Zhang et al. 1992).  
In the past years, an increasing concern was raised regarding thyroid-disrupting effects 
of environmental toxicants. Highly persistent chemicals such as dioxins, PCBs and PFAS, were 
found to interfere with thyroid hormone metabolism at different biological levels e.g. decrease 
in THs circulating levels and/or interactions with TTR (Boas et al. 2012; Calsolaro et al. 2017). 
Rodent studies suggested that pollutants can transfer from the mother to the fetus 
compartment through the placenta by making use of TTR-binding to facilitate its transport, 
resulting in the reduction of T4 levels in the offspring (Lau et al. 2003; Meerts et al. 2002; 
Thibodeaux et al. 2003). In 2009, Weiss et al., demonstrated the competitive binding 
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inhibition potency of PFAS compounds towards T4 on TTR, contributing to the understanding 
of potential environmental toxicants’ route of exposure from mother to child.  
To this date, there is a real lack of more extensive studies investigating EDCs’ placental 
transfer. Although this source of exposure mainly concerns the prenatal period, the lipophilic 
characteristic of most of thyroid-disrupting pollutants suggest that breast milk could represent 
a suitable proxy for further investigating early mother-child exposure.  
Effect-based bioassays for the detection of hormone-disrupting 
activities 
            Mammalian reproduction and development, while being extremely complex, reuses a 
limited set of conserved pathways for different developmental processes. Therefore, it has 
been established that single specific in vitro effect-based bioassays covering only a few 
endpoints of these pathways may provide good predictions with regard to developmental and 
reproductive toxicity landmarks, such as sex organ deformities (Van der Burg et al. 2013). 
During the past decades, BioDetection Systems b.v. developed a large panel of highly specific 
and sensitive effect-based in vitro tests: the CALUX® (Chemically Activated LUciferase 
eXpression) reporter gene assays. These assays consist of mammalian cells, which are stably 
transfected to express a receptor of interest, e.g. ERα or AR, which upon ligand-binding 
transactivates receptor-specific gene expression, including the reporter gene luciferase 
derived from the firefly (Figure 1). In practice, cells are exposed to a dilution series of the test 
compound (pure chemical or sample extract) and incubated for about 24 hours. The next day, 
the substrate luciferin is added to the luciferase produced by the triggered cells resulting in 
light production. The produced light signal is proportional to the amount of ligand causing 
receptor activation and is quantified using a luminometer. The method is performed in both 
96- to 384-well plate formats either by hand or using a robot-based automated setup, allowing 




Figure 1. Schematic representation of Chemically Activated LUciferase gene eXpression 
(CALUX) reporter assay. 
            The CALUX panel consists of a range of assays, including those for major sex steroids 
(AR, ERα, ERβ, progesterone receptor CALUX assays), and other endocrine pathways (TRβ, 
glucocorticoid receptor, aryl hydrocarbon receptor CALUX assays etc.) (Piersma et al. 2013; 
Sonneveld et al. 2005; Van der Burg et al. 2013; Van der Linden et al. 2014). In 2015, the ERα 
CALUX bioassay was validated and approved according to the Organization for Economic Co-
operation and Development (OECD) Test No.455: Performance-Based Test Guideline for 
stably transfected transactivation in vitro assays to detect estrogen receptor agonists and 
antagonists (Besselink 2015). Recently, the AR CALUX cell line was also validated and 
approved by the OECD: “Test no 458: Stably transfected human androgen receptor 
transcriptional activation assay for detection of androgenic agonist and antagonist activity of 
chemicals”. The AR and ERα CALUX bioassays are particularly interesting for studying 
disruptions of the androgen-estrogen balance. Both bioassays were used in a pilot study 
involving ten breast milk samples, as detailed in Chapter Two. The AR CALUX bioassay was 
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further employed on 199 human milk samples, as we performed a case-study evaluating the 
possible association between anti-androgenic activity in breast milk and cryptorchidism 
occurrence in the offspring (Chapter Three).   
            During this PhD study, we also developed and validated CALUX reporters for THs, the 
TRβ CALUX, as well as a combination of TH plasma transport and TH receptor (TTR-TRβ-
CALUX). For further description of these methods, we refer to Chapter Four of this thesis. 
Effect-directed fractionation and identification of endocrine active 
compounds, including possible natural hormones  
Bioassay-based analysis can provide excellent measurements regarding total hormonal 
activity in a sample, however, due to their structural similarities with natural hormones, EDCs 
are expected to be extracted along with endogenous compounds. Although natural hormones 
may play a critical role in EDC toxicity and therefore, cannot be excluded from the analysis, it 
is important to be able to discriminate the effects caused by EDCs actions from the endogenous 
nature hormone on CALUX-based measurements.  
In order to isolate the active EDC fraction, a series of high-performance liquid 
chromatography (HPLC) fractionations was performed on a pooled breast milk sample. 
Following each separation, several extracts were collected and tested in a CALUX bioassay to 
identify the active fraction(s). The process of fractionation was continued until the active 
extract was pure enough to allow further chemical target analysis.   
The purified active fraction was analyzed on HPLC high resolution quadrupole time-
of-flight mass spectrometry (HPLC-Q-TOF-MS/MS). A set of seven human natural steroid 
hormones (E1, E2, androstenedione, DHEA, testosterone, pregnenolone and progesterone) 
and 248 of their potential metabolites were selected for target analysis. The potential presence 
of these naturally occurring compounds in the active fraction was assessed and detailed in 
Chapter Two.  




Scope of the thesis 
The research described in this thesis investigated the amount and potential effects of 
EDCs present in human milk using samples derived from the Norwegian HUMIS cohort. This 
work focused on three main actors of the endocrine system, the estrogens, androgens, and 
thyroid hormones. 
The first aim of the thesis was to develop a suitable method to properly extract EDCs 
from human milk samples, focusing on both polar and apolar endocrine active contaminants.  
The second aim was to perform a pilot study on a limited number of breast milk 
samples, using the existing ERα and AR CALUX bioassays, in agonistic and antagonistic mode. 
This phase was also used to evaluate the nature and origin of the observed EDC activity, as 
well as the contribution of endogenous hormones to the measurements. 
The third goal was to measure the EDC activity in a larger set of human milk samples 
to evaluate the potential association between anti-androgenic EDCs and an androgen-
dependent deformity: cryptorchidism. 
The last objective was the development and application of novel thyroid hormone-
based bioassays, TRβ CALUX and TTR-TRβ CALUX assays. These bioassays were used to 
evaluate the impact of breast milk contaminants, including well-known PFAS 





Outline of the thesis 
                  The thesis is divided in two distinct parts: Chapter Two and Chapter Three focusing 
on sex steroid disruption, and Chapter Four and Chapter Five covering thyroid system 
interferences, respectively. 
 
In Chapter Two, the method developed to extract EDCs from breast milk samples, used 
throughout the thesis, is described. In this chapter, estrogenic, anti-estrogenic, androgenic, 
and anti-androgenic activities derived from ten human milk extracts were analyzed on the 
(anti-)ERα and (anti-)AR CALUX bioassays. To rule out the impact of endogenous hormones 
in the measured activity, a pooled breast milk sample presenting anti-androgenic activity was 
fractionated and screened for natural hormones and metabolites by means of non-target 
screening using time-of-flight mass spectrometry UHPLC-Q-TOF-MS/MS.  
 
            Chapter Three describes a larger-scale study involving 199 participants and presents 
results of anti-androgenic EDC activity in breast milk samples. In this chapter, we investigated 
the potential association between anti-androgenic activity in mothers’ milk and the occurrence 
of cryptorchidism, an androgen-dependent deformity, in the offspring. Moreover, we 
estimated the overall extent of exposure of a nursing child to anti-androgenic EDCs via 
breastfeeding. 
 
            In Chapter Four, the TRβ CALUX bioassay, allowing screening of TRβ disrupting 
activity, and the TTR-TRβ CALUX assay, designed to detect competing properties towards T4 
for TTR binding, were evaluated using well-known reference compounds. The performance of 
the TTR-TRβ CALUX assay was also evaluated during a short pilot study involving water 
samples. 
 
In Chapter Five the newly validated TRβ and TTR-TRβ CALUX bioassays were further 
used to assess a set of thirteen PFAS, known to affect the TH system (Chang et al. 2008; 
Thibodeaux et al. 2003) for thyroid-disrupting activities. Subsequently, ten breast milk 
extracts, with known PFOS and PFOA concentrations, were analyzed on the same assays. In 
this chapter, the impact of PFOS and PFOA levels was weighed in respect to thyroid-disrupting 
activity in breast milk. Furthermore, the average exposure to thyroid-disrupting EDCs during 
the first year of life of a nursing infant through breastfeeding was estimated. 
 
Finally, Chapter Six reviews and discusses the most important outcomes of the studies 
regarding hormonal-disruption derived from the presence of EDCs in Norwegian breast milk 
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In this paper, we investigated the possible presence of endocrine disrupting chemicals 
(EDCs) based on measuring the total estrogenic and androgenic activity in human milk 
samples. We used specific bioassays for analysis of the endocrine activity of estrogens and 
estrogen-like EDCs and androgens and androgen-like EDCs and developed a separation 
method to evaluate the contribution from natural hormones in comparison to that of EDCs to 
total endocrine activities. We extracted ten random samples originating from the Norwegian 
HUMIS biobank of human milk and analyzed their agonistic or antagonistic activity using the 
ERα- and AR CALUX® bioassays. The study showed antagonistic activity towards the 
androgen receptor in 8 out of 10 of the assessed human milk samples, while 2 out of 10 samples 
showed agonistic activity for the ERα. Further investigations demonstrated anti-androgenic 
activity in the polar fraction of 9 out of 10 samples while no apolar extracts scored positive. 
The culprit chemicals causing the measured antagonistic activity in AR CALUX was 
investigated through liquid chromatography fractionation coupled to bioanalysis and non-
target screening involving UHPLC-Q-TOF-MS/MS, using a pooled polar extract. The analysis 
revealed that the measured anti-androgenic biological activity could not be explained by the 
presence of endogenous hormones nor their metabolites. We have demonstrated that human 
milk of Norwegian mothers contained anti-androgenic activity which is most likely associated 
with the presence of anthropogenic polar EDCs without direct interferences from natural sex 
hormones. These findings warrant a larger scale investigation into endocrine biological 
activity in human milk, as well as exploring the chemical sources of the activity and their 





Breast milk contains a complex mixture of proteins, lipids, carbohydrates as well as a 
high concentration of bioactive components, and is acknowledged to be important to the 
infant’s post-natal growth and development. Beside its valuable properties, this biofluid also 
constitutes an important non-invasive source of information about the quality of the perinatal 
environment and its potential contamination (Esteban and Castaño 2009). Evaluation of 
toxicant levels in breast milk is an area of major interest, revealing the presence of diverse 
environmental contaminants such as persistent organic pollutants (POPs) and chemicals with 
estrogen-like properties (xenoestrogens) (Criswell et al. 2017; Massart et al. 2005; Thomsen 
et al. 2010). Xenoestrogens and several POPs are endocrine active and therefore referred to as 
endocrine active compounds (EACs). Usually at relatively high dosage levels, several EACs 
have been shown to lead to adverse effects, and these chemicals are referred to as endocrine 
disrupting chemicals (EDCs) (Bergman et al. 2012b). EACs and EDCs have been identified in 
a myriad of sources like contaminated food, indoor dust and daily-life products representing 
a challenge in their proper assessment and management. Their dose- and time-dependent 
effects can be particularly strong during vulnerable windows of development, from fetal life to 
the post-natal period up until puberty. Androgen- and estrogen signaling has been found to be 
a frequent target of hormonally active agents (Raun Andersen et al. 2002). While linked to 
adversities in wildlife and supported by circumstantial evidence, the linkage between early 
EDC exposures and human diseases is still not firmly established (Andersson et al. 2012; 
Colborn et al. 1993). Many different chemicals can interact with the estrogen- and androgen 
receptor and it has been shown that effects of EDCs can add up in mixtures (Rajapakse et al. 
2002). Various epidemiological studies focused on investigating the possible relationship 
between early-life exposure to EDCs and child health outcomes, such as infant growth and 
impaired sexual development (Andersen et al. 2008; Iszatt et al. 2016a; Nørgaard et al. 2008). 
Exposure of Danish women workers to pesticides used in greenhouses has been associated 
with a rise in impaired reproductive development in their sons suggesting a link between EDC 
exposure and congenital deformity (Andersen et al. 2008). Although monitoring of selected 
chemicals provides precious information regarding biofluids’ contamination, data considering 
the totality of these exogenous toxicants as well as the combined biological activities resulting 
from mixture effects are still limited. 
Over the past decades, new biological, non-targeted testing procedures have been 
developed to supplement the targeted chemical-analytical techniques. Interestingly, it has 
been shown that single specific in vitro tests covering only a limited set of conserved pathways 
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can also provide very good predictions with respect to developmental and reproductive toxicity 
landmarks such as sex organ deformities (Van der Burg et al. 2014). These highly selective 
reporter gene methods to assess (anti-)estrogenic and androgenic activity, were also shown to 
be excellent alternatives to the traditional in vivo techniques in rodents and extremely suitable 
for measurements in complex mixtures such as body fluids (Pedersen et al. 2010; Sonneveld 
et al. 2006). Estrogen Receptor alpha (ERα) and Androgen Receptor (AR) mediated bioassays 
are based on two human U2-OS osteoblastic osteosarcoma cell lines stably transfected to 
endogenously express the ERα or AR, respectively. The activation of these specific receptors 
upon ligand stimulation triggers their binding to hormone-responsive elements (HRE), which 
is linked to a luciferase (“reporter”) gene, leading to luciferase expression. By measuring the 
subsequent light production by luciferase, this bioassay can quantify hormonal activity of any 
chemical or sample. To ensure the robustness of the in vitro method, the ERα CALUX® 
bioassay was validated in 2015 according to the Organization for Economic Cooperation and 
Development (OECD) Test No.455: Performance-Based Test Guideline for stably transfected 
transactivation in vitro assays to detect estrogen receptor agonists and antagonists (Besselink 
2015). 
This study confirmed that the (anti-)ERα CALUX reporter gene bioassay is suitable for 
accurately predicting estrogen-disrupting activities. In turn, the (anti-)AR CALUX assay was 
recently implemented in the EU-NETVAL (European Union Network of Laboratories for the 
Validation of Alternative Methods) validation project, following the OECD Test Guideline 
Androgen Receptor Transactivation Assays and is currently in the process of an inter-
laboratory evaluation. Over the years CALUX bioassays have been proven to be quick, specific 
methods able to measure the total effect of ligands on a receptor of interest using a limited 
volume of samples (Houtman et al. 2009; Kraus et al. 1995; Sonneveld et al. 2005).  
Being the primary source of nutrition for most infants, breast milk contamination by 
exogenous chemicals could affect hormone-dependent mechanisms compromising post-natal 
growth. In that way, it is of major interest to assess the potential presence of EDCs in human 
milk as well as its short- and long-term impact on the developing child. In this paper we 
perform a pilot study aiming to extract EDCs from breast milk samples to further evaluate 
their impact on the endocrine system using the ERα and AR as endpoints. As a first step we 
demonstrate the performance of the AR CALUX bioassay, both in agonistic and antagonistic 
mode, by comparing our internal database to the in vivo Hershberger database recently 
established by Browne et al. (2018), as has been done to evaluate the ToxCast/Tox 21 AR model 
conducted by Kleinstreuer et al. (2017). As a second part, a set of ten breast milk samples 
derived from the “Norwegian Human Milk Study” (HUMIS), a birth cohort of mother-child 
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pairs, was analyzed. Due to the various biochemical properties of human milk contaminants, 
ensuring their total extraction from breast milk using one universal method appeared to be 
challenging. Therefore, we developed a two-step method capable of extracting apolar EDCs 
fraction and polar components, including endogenous hormones, separately. Both fractions 
along with a reconstituted mixture, consisting of the combination of both apolar and polar 
extracts, were analyzed following the workflow detailed in Fig.1. In addition to analysing the 
polar and apolar extracts, we also analysed a reconstituted mixture of the two fractions derived 
from each sample. 
 
Figure 1. Study design of the extraction procedure and pilot analysis of ten breast milk 
samples on the (anti-)ERα and (anti-)AR CALUX bioassay 
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Materials & methods 
Chemicals 
17α-methyltestosterone (CAS: 58-18-4), 17β-estradiol (E2) (CAS: 50-28-2), 4-
nonylphenol (CAS: 104-40-5), 5α-dihydrotestosterone (DHT) (CAS: 521-18-6), amitrol (CAS: 
69182-5), bis-(2-ethylhexyl)phthalate (DEHP) (CAS: 117-81-7), bisphenol A (BPA) (CAS: 80-
05-7), chlorothalonil (CAS: 1897-45-6), chlorpyrifos (CAS: 2921-88-2), dibutyl-phthalate 
(DBP) (CAS: 84-74-2), estrone (E1) (CAS: 53-16-7), fenarimol (CAS: 60168-88-9), flutamide 
(CAS: 13311-84-7), flutolanil (CAS: 66332-96-5), glyphosate (CAS: 1071-83-6), linuron (CAS: 
330-55-2), p,p'-dichlorodiphenyldichloroethylene (p,p’-DDE) (CAS: 72-55-9), pregnenolone 
(CAS: 145-13-1), procymidone (CAS: 32809-16-8), progesterone (CAS: 57-83-0), tamoxifen 
(CAS: 10540-29-1), testosterone (CAS: 58-22-0) and vinclozolin (CAS: 50471-44-8) were 
obtained from Sigma-Aldrich (The Netherlands). 4-androstan-17b-ol-3-one 
(androstenedione) (CAS: 63-05-8) and 5-androstan-3b-ol-17-one (DHEA) (CAS: 53-43-0) 
were purchased from Steraloids Inc. (USA). Tributyltin acetate (CAS: 56-36-0) was obtained 
from Merck Chemicals B.V. (The Netherlands). 
Cell lines 
The AR CALUX, ERα CALUX and Cytotox CALUX bioassays (Sonneveld et al. 2005; 
Van der Linden et al. 2014) are based on a stably transfected human osteoblastic osteosarcoma 
U2-OS cell-line (American Type Culture Collection). The highly selective cell line used in the 
(anti-)AR CALUX contains a full-length human AR expression vector stably co-transfected 
with a reporter construct containing  a minimal promoter element, the TATA box,  coupled to 
a luciferase reporter construct containing three androgen responsive elements (Sonneveld et 
al. 2005). The (anti-)ERα CALUX contains a similar expression vector expressing human ERα 
and a reporter construct 3xpERE-TATA-Luc, as described earlier (Sonneveld et al. 2005). Both 
cell lines were also used to perform the antagonistic (anti-) AR and ERα CALUX bioassays. As 
a control to detect non-specific activities (e.g. cellular death), each antagonistic measurement 
was performed along with the Cytotox CALUX, consisting of U2-OS cells constitutively 
expressing the luciferase gene (Van der Linden et al. 2014). The threshold was set at 
cytotoxicity ≤ 20%. For evaluation of analysis data, concentrations surpassing this value were 






Reference compound data selection  
The Hershberger in vivo androgenicity assay database established by Browne et al. 
(2018) was browsed to establish a set of reference chemicals for the evaluation of the 
performance of the (anti)AR CALUX. Chemicals with consistent effects in Hershberger study 
were pre-selected. Compounds present in both in vivo database and internal CALUX dataset 
were chosen for the final list. A total of sixteen reference compounds including six non-active 
chemicals (4-nonylphenol, amitrol, chlorothalonil, chlorpyrifos, flutolanil and glyphosate), 
eight AR antagonists (DBP, DEHP, fenarimol, flutamide, linuron p,p’-DDE, procymidone and 
vinclozolin) and two steroidal androgens (17α-methyltestosterone and testosterone) were 
selected on that basis. The internal (anti-)AR CALUX database gathers more than 200 pure 
compounds individually analyzed using an automated version of the (anti-)AR CALUX.   
Human milk samples 
Samples were derived from the mother-child cohort study HUMIS (Human Milk 
Study), cooperatively conducted by the Norwegian Institute of Public Health between 2002 
and 2009 (Eggesbø et al. 2004). Between the first two weeks and months after delivery, 
women enrolled in the study were asked to collect 25 mL of breast milk every morning for 
eight consecutive days, preferably by hand. Milk aliquots were collected in 250 mL natural 
HDPE Packaging Bottles (Cat. No.: 967-21244, Thermo Scientific Nalgene®) made from high-
purity resins, a food-grade material free of plasticizers. Aliquots were sent by the mothers 
along with a questionnaire gathering the following information: maternal age, weight, height, 
residence, smoking habits, parity, nationality, education, work and dietary habits. Samples 
were stored upon arrival at -20 °C in a Biobank of the Norwegian Institute of Public Health. 
The study was approved by the Norwegian Data Inspectorate (ref. 2002/1398) and Regional 
Ethics Committee for Medical Research (ref. S-02122). Mothers were included after oral and 
written informed consent had been obtained.  
Sample preparation 
For this study, ten aliquots were used to extract apolar and polar components, 
following the methods described below.  
For apolar compounds, 5 mL of homogenized milk sample was transferred to a 60 ml 
glass tube. The same amount of 2-propanol (CAS: 67-63-0, BioSolve) was added prior to the 
extraction to optimize the penetration of n-hexane into the sample material during the next 
stage. Tubes were shaken for 10 min on a shaker at 200±20 strokes per minute. 14 mL of n-
Chapter Two 
36 
hexane (CAS: 110-54-3, BioSolve) was added and the tubes were shaken for an extra hour. The 
upper layers were transferred to clean collection tube and the procedure was repeated twice 
with a shaking time reduced to 30 min. The collected fractions were evaporated to dryness and 
reconstituted in 1 mL of n-hexane. The extracts were cleaned (including fat removal) using 
glass columns filled with 5 g of 2% deactivated silica, previously conditioned with 12 mL of n-
hexane. The samples were eluted with 30 mL of a 3:1 n-hexane and dichloromethane mixture 
(CAS: 75-09-2, BioSolve). The eluate obtained was evaporated to dryness and reconstituted in 
30 µL of DMSO. 
The efficiency of the apolar extraction was assessed by including four procedural 
controls extracted along the set of breast milk samples, using gas chromatograph coupled with 
tandem mass spectrometer (GC-MS/MS) as the detection technique. The controls consisted 
of 5 mL of a pooled breast milk sample spiked with 50 µL of 13C-labeled internal standard 
solution containing PCB153 (2,2',4,4',5,5'-hexachlorobiphenyl) and PCB180 (2,2',3,4,4',5,5'-
heptachlorobiphenyl) (200 ng/mL, diluted from MBP-D7, Wellington Laboratories). Due to 
their apolar properties and their known presence in breast milk, PCB153 and PCB180 were 
suitable contaminants to evaluate the performance of the extraction method (IARC Working 
Group on the Evaluation of Carcinogenic Risk to Humans. 2016). Controls were extracted 
following the same procedure as used for samples with the exception that they were dissolved 
in 1 mL of isooctane (CAS: 540-84-1, BioSolve), which is a more suitable and common solvent 
for chemical analysis with GC-MS/MS. A recovery standard containing PCB112 (10 ng/mL, 
diluted from C-112S-TP, AccuStandard) was added to each control extract just prior to the 
injection. This extra step was included to correct for response variations due to internal matrix 
effects during GC-MS/MS measurement, and is independent from the extraction 
performance. Internal standard recoveries were evaluated on a GC-MS/MS system, consisting 
of a gas chromatograph (GC-2010 Plus, Shimadzu) and a gas chromatograph mass detector 
(GCMS-TQ8050, Shimadzu), both controlled by the GCMS Real Time Analysis software 
program (available at: https://www.ssi.shimadzu.com/products/gas-chromatography-mass-
spectrometry/gcmssolution-software.html). The injection was carried out using a CTC 
CombiPal autosampler controlled by the Cycle Composer software program (CTC Analytics 
AG). The system equipped with a DB-5MS column (60m x 0.25mm x 0.25µm) (Cat. No.: 122-
5562, Agilent Technologies), operated using the following parameters: carrier gas Helium 6.0 
(BIPX10S, Air Products), constant flow rate of 1.00 mL/min (electronically controlled), 
injection temperature 280.0 °C, injection volume 1 µL, splitless mode, ion source temperature 
230.0 °C, interface temperature 300.0 °C. The analysis was performed using the parameters 
and settings described in Tables 1,2. After PCB112 correction, recovery values were evaluated 
to 92±5.4 and 91±4.1% for PCB153 and PCB180, respectively. 
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Note: m/z: mass-to-charge ratio. 
QuEChERS (Quick Easy Cheap Effective Rugged and Safe) was used to extract polar 
compounds. It is a simplified sample extraction technique developed to assess multiple 
pesticide residues in food (Anastassiades et al. 2003). We used a protocol derived and adapted 
from the original method, as described below. Samples were homogenized and 5 mL was 
transferred to a 50 mL Greiner tube. 15 mL of acetonitrile (ACN) (CAS: 75-05-8, BioSolve) was 
added as the extraction solvent and the mixture was shaken vigorously manually for 30 
seconds. One QuEChERS EN 15662 extraction packet (Cat. No.: 5982-5650, Agilent) 
containing 4 g of magnesium sulfate, 1 g of sodium chloride, 1 g of sodium citrate dehydrate 
and 0.5 g of sodium hydrogen citrate sesquihydrate was added directly into the tube and 
shaken strongly for 15 min. The tubes were centrifuged for 5 min at 4000 rpm at 4 °C and the 
upper layers were transfer into a clean collection tube. The same procedure, including ACN 
and addition of salts, was repeated once and the resulting layers were combined. Each 
combined extract was loaded to a 15 mL QuEChERS dispersive solid phase extraction (d-SPE) 
column (Cat. No.: 5982-5158, Agilent) for clean-up and vortexed for 1 min. The tubes were 
centrifuged for 5 min at 4000 rpm at 4 °C. The upper layer was transferred to a clean collecting 
Rate Temperature (°C) Hold Time (min) 
- 80.0 2.0 
20.00 180.0 0.0 
5.00 200.0 0.0 
2.00 240.0 10.0 
20.00 320.0 10.0 
Internal Standard Precursor Product 
PCB153L (m/z) 371.80 301.90 
PCB180L (m/z) 405.80 335.90 
   
Recovery Standard Precursor Product 
PCB112 (m/z) 323.90 253.90 
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tube and evaporate until dryness. The samples were reconstituted in 30 µL of DMSO and 
stored at -20 °C until analysis. 
Reproducibility and efficiency of the polar extraction was assessed by adding four 
controls to the analysis series. The controls consisted of 5 mL of breast milk spiked with 100 
µL of a mixture of BPA, E2 and testosterone as internal standards (100 µg of each 
compound/mL). Due to their polarity and their known presence in breast milk, BPA (logP = 
4.0), E2 (logP = 3.7) and testosterone (logP = 3.4) were three appropriate compounds to assess 
the efficiency of the polar extraction method (Mendonca et al. 2014). Controls and samples 
were processed following the same extraction procedure, except that controls were redissolved 
in 30 µL ACN, a suitable and common solvent for the liquid chromatography (LC) analysis of 
these components. Chemical analysis was performed by LC using a modular system from 
Agilent consisting of 1260 Infinity High Performance Degasser (G4225-64000), a 1260 
Infinity Binary pump (specified up to 600 bar - G1312B), Multisampler (G7167-64000, 
Agilent), Diode array detector (G1315b-64050, Agilent) and a thermostatted column 
compartment (G1316-64050, Agilent). The samples were analyzed on a Phenomenex Kinetex 
Biphenyl column (150x4.6mm 2.6µ particle size) (00F-4622-E0, Phenomenex) using the 
following parameters: injection volume 20 µL; flow rate of 0.8 mL/min; detection (UV) 254, 
272 nm; column temperature 40 °C. The system was controlled by Agilent OpenLAB CDS (EZ 
ChromEdition) software program. This program was also used to process the data. Water and 
ACN were used as solvents according to the scheme described in Table 3. Recovery values were 
calculated by means of comparison of the peak height in the control samples with a standard 
solution. BPA, E2 and testosterone were recovered to a rate of 36±13, 50±7.1 and 61±2.9 %, 
respectively. On average, 49% of spiked polar chemicals were recovered after extraction. This 
result was used to compensate for loss of signal during the CALUX analysis, i.e. polar 
measurements were adjusted to apolar results using a factor of 2. Moreover, polar and apolar 
ratio to reconstitute the mixture (originally 1:1) was adapted to insure the correctness of the 
study (2:1). All extracts were kept at -20 °C until analysis.  
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Note: ACN: Acetonitrile. 
CALUX assay procedures 
Human milk samples were extracted, and bioactivities were evaluated with the (anti-
)ERα and (anti-)AR reporter gene CALUX (Chemically Activated Luciferase eXpression) 
bioassays at different concentrations (dilution series 1-3-10-30-100x). The (anti-)ERα and 
(anti-)AR CALUX bioassays were carried out typically as described by Sonneveld et al. (2005). 
In short, cultured U2-OS cells were re-suspended in DMEM/F12 medium without phenol red 
indicator (Fisher, product no.: VX1041025) with 10 U/mL penicillin and 10 µg/mL 
streptomycin (P/S), non-essential amino acids (NEAA) (Cat No.: 11140-03, Gibco) and 5% 
charcoal-stripped fetal calf serum (DCC) supplemented. Cells were re-suspended in assay 
medium to a final concentration of 1x105 cells/mL, subsequently 100 µl were seeded in clear 
96-well plates. Plates were incubated for a minimum of 16 hours and maintained in a 
humidified atmosphere at 37 °C and 5% CO2. After a maximum of 24 hours, the medium was 
replaced with 200 µL/well of medium including the sample to a final DMSO concentration of 
0.1%. To perform the antagonistic mode, the medium was supplemented with a fixed 
concentration of E2 (EC50: 6.0E-12 M) or dihydrotestosterone (DHT; EC50: 3.0E-10 M), for the 
anti-ERα and anti-AR CALUX, respectively. After 22±2-hour incubation, the medium was 
removed and 30 µL/well of Triton-lysis buffer was added and luciferase activity was measured 
using a Tristar luminometer (Berthold).  
Analysis of pure compounds using the AR CALUX was essentially performed as above 
with the exception that the dilution (0.5 log unit increments) and the exposure was automated 
and performed in a 384-well plate according to a validated method as to increase the efficiency 
of the procedure (Van Vugt-Lussenburg et al. 2018).  
Time (min) Water (%) ACN (%) 
0.00 30.0 70.0 
1.00 30.0 70.0 
10.00 0.0 100.0 
12.00 0.0 100.0 
12.50 50.0 50.0 
17.50 50.0 50.0 
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All dilutions including the ones from the samples were analyzed in triplicate on the 
same 96-well plate. A solvent control (DMSO) was included to each plate to assess the 
background luciferase activity. Moreover, a full dose response curve of the reference 
compound E2 (ERα CALUX), DHT (AR CALUX) or tributyltin acetate (Cytotox CALUX) was 
included to each plate. The reference compounds tamoxifen and flutamide were used as 
reference for the anti-ERα and anti-AR CALUX assays, respectively. Antagonistic 
measurements were double-checked for non-specific interactions by assessing test 
compounds with a saturating excess amount of agonist i.e. 1000-times the EC50 concentration 
of the agonistic reference compound (Van der Burg et al. 2010). The quality and validity of the 
measurements were evaluated according to the following criteria: R2 of standard curve > 0.98, 
EC50 of the reference compound should fit between assay-specific predetermined limit values, 
z-factor of standard curve > 0.6 and overall SD of triplicate < 15%.  
Data analysis 
Luciferase activity was expressed as Relative Light Units (RLUs). The average of each 
triplicate was calculated and corrected for background using solvent control measurements. 
The maximum signal response induced by the reference compound was set to 100% for 
agonistic assay (complete activation of the receptors) and 0% for antagonistic mode (complete 
inhibition of the signal). Subsequently, all RLUs produced by the test compounds or samples 
were expressed as a % of this maximum response. The statistical software package GraphPad 
Prism 5.0 was used to fit transformed data (non-linear regression, variable slope, four 
parameters and robust fit). The lowest observed effect concentrations (LOECs) were 
determined; for agonist assays, the LOEC was defined as the PC10 value, while for antagonist 
assays a PC20 value was used. The PC10 concentration was defined as the concentration where 
the response elicited by the test substance equals 10% of the maximum response of the 
reference substance. PC20 values were defined as the concentration where the test substance 
causes 20% inhibition of the basal signal elicited by the receptor agonist. In this case, the 
maximum inhibition achieved by the reference antagonist was set at 100%. Compounds 
without a calculable PC10/PC20 value were defined as non-active (NA). For quantification of 
the (anti-)estrogenic and (anti-)androgenic potency of breast milk extracts, RLUs derived 
from CALUX analysis were plotted to the dose-response curve of the associated reference 
compound. A sample was reported as ‘active’ if its overall activity was above the limit of 
quantification (LOQ) value of the bioassay, i.e. lowest concentration that can be quantified 
with acceptable relative standard deviation. A non-active sample i.e. activity ≤ LOQ, was 
replaced by half of the LOQ value to give an estimation of the activity. The calculated 
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concentrations per well (M) were converted and expressed as equivalence of the reference 
compound per gram of processed sample.   
Instrumentation and analytical methods for fractionation  
Seven natural steroid hormones, E1, E2, testosterone and their precursor 
androstenedione plus pregnenolone, progesterone and their product DHEA and 
androstenedione were targeted during an exclusion by fractionation using liquid 
chromatography. Androstenedione, DHEA and testosterone were selected based on their 
androgenic properties that could create interferences with AR, possibly counteracting anti-AR 
activity measured in the CALUX bioassay (Burger 2002; Houtman et al. 2009). On the other 
hand, E1, E2, progesterone and pregnenolone were chosen for their estrogenic characteristics. 
This type of activity was earlier reported to be anti-androgenic and androgenic, depending on 
the concentration, which could also bias the measurements (Kelce and Wilson 1997; Sohoni 
and Sumpter 1998; Van der Burg et al. 2010).  
The outlet of the high-performance liquid chromatography (HPLC) setup described 
earlier was connected to a Fraction collector III (WFCIII, Waters) remotely triggered by the 
Agilent system. In the fractionation process we used two types of columns, Phenomenex 
Kinetex Biphenyl 150x4.6mm 2.6u particle size (00F-4622-E0, Phenomenex) and 
Phenomenex Kinetex Fluor 5 100x2.1mm 1.7u particle size (00D-4722-AN, Phenomenex) 
(pentafluorophenyl stationary phase bonded to a solid silica core). We operated the described 
system with a combination of methanol absolute HPLC Supra-gradient (CAS: 67-56-1, 
BioSolve) and ultra clean water from an ELGA filtration station as solvent. For all experiments 
the columns were maintained at 40 °C. Data were analyzed using the Agilent OpenLAB CDS 
(EZ ChromEdition) software program. Parameters including column, solvents and gradients 
used for each fractionation are referred to as ‘protocol n°1’ and ‘protocol n°2’ (Table 4.).  
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Table 4. Liquid chromatography conditions, column and gradient used for fractionation.  
 
 
Instrumental settings for chemical analysis followed by non-target screening  
The active fractions along with non-active ones, collected adjacent to the active eluates, 
were obtained through fractionation and were analyzed in triplicate with an Nexera UHPLC 
system (Shimadzu, Den Bosch, the Netherlands), coupled to a maXis 4G high resolution 
quadrupole time-of-flight HRMS (UHPLC-Q-TOF-MS/MS) upgraded with a HD collision cell 
and equipped with an electrospray ionisation source (ESI) (Bruker, Leiderdorp, the 
Netherlands) (Appendix A.1). Liquid chromatography analysis was performed according to 
protocol n°2, described earlier (Table 4). 2 mM of sodium formate in 1:1 water/MeOH solution 
was used for automatic internal calibration of the system. Positive and negative ESI was used 
to acquire MS- and MS/MS data in the range of 80 - 1200 m/z. Simultaneously an UV 
chromatogram (254 nm) was acquired using an UV detector placed in line between the UHPLC 
and the Q-TOF-MS/MS. The peak retention times in the UV chromatogram were compared to 
those found during the fractionation to compensate for differences between both LC systems.  
The data acquired from the non-target analysis (NTA) was processed using an in-house 
developed R package ‘patRoon’ (Helmus et al. 2018) which is an open-source platform that 












0.00 50.0 50.0 
150x4.6mm 2.6u 
particle size 
0.01 50.0 50.0 
0.8mL/min 10.00 5.0 95.0 
Injection vol. 30µL 16.00 5.0 95.0 
 16.50 50.0 50.0 
 25.00 50.0 50.0 












0.00 80.0 20.0 
100x2.1mm 1.7u 
particle size 
0.01 80.0 20.0 
0.250mL/min 25.00 0.0 100.0 
Injection vol. 20 µL 28.00 0.0 100.0 
 28.50 80.0 20.0 
 48.00 80.0 20.0 
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harmonizes various commonly used software tools employed in NTA. More information is 
available at https://github.com/rickhelmus/patRoon (Patroon: Open Source Software 
Platform for Environmental Mass Spectrometry Based Non-target Screening 2020). The 
first step of the patRoon workflow consisted of converting the manufacturer specific data to 
open mzML format. Second, features (single peaks within the extracted ion chromatogram) 
were extracted from all analysed fractions and grouped according to retention time and m/z 
(mass to charge ratio). Third, the features were filtered by employing different constraints and 
thresholds. The feature data were filtered following these steps: 
- Removing any features below an intensity threshold (10000). 
- Removing features that are not at least 5 times higher in intensity compared to the 
blank. 
- Remove features that are not present in all triplicate injections and with intensity 
variations amongst triplicates of >75% RSD. 
- Only unique features that are present in active fractions were kept, features from non-
active fractions were removed. 
Next, possible human metabolites of the seven endogenous hormones were predicted 
using BioTransformer (http://biotransformer.ca/) and the software R. Based on all known 
reaction pathways from BioTransformer, a list of 248 metabolites was generated (Appendix 
A.1). The presence of these metabolites in the active fractions was determined by comparing 





Evaluation of the CALUX assay performance 
In order to test the performance of the (anti-)AR CALUX assays relative to reference 
methods we used a similar approach as has been used for the ERα CALUX assay (Vugt-
Lussenburg et al. 2018). A set of sixteen reference compounds including six non-active 
chemicals, eight AR antagonists and two steroidal androgens were selected based on the 
Hershberger in vivo androgenicity assay database developed by Browne et al. (2018) (Table 
5). In the agonistic mode, only two steroids, 17α-methyl testosterone and testosterone, had 
sufficient reference data. They were evaluated and found to be strong agonists with a PC10 of 
-9.6. This is consistent with earlier findings that this assay can predict androgenicity of 
chemicals, including steroids, and is predictive for androgenicity as determined in the 
Hershberger assay (Houtman et al. 2009; Sonneveld et al. 2006). Expectedly, none of these 
agonists were active in the anti-AR CALUX assay. A larger set of eight reference anti-
androgens with consistent effects in the in vivo Hershberger assay was assessed in the anti-
AR CALUX assay. All chemicals showed anti-androgenic activity, with the exception of DEHP 
which showed no response at the highest tested concentration (-4). This is consistent with the 
fact that DEHP is not a receptor antagonist but rather decreases circulating levels of androgens 
(Borch et al. 2006). Six chemicals (4-nonyphenol, amitrol, chlorothalonil, chlorpyrifos, 
flutolanil, glyphosate), which demonstrated no effect in the in vivo Hershberger model, scored 
negative in both the agonist and antagonistic modes of the AR CALUX assay. Overall, the AR 
CALUX assay demonstrated a very satisfying predictivity suggesting that this assay is suitable 
to assess androgen receptor-mediated effects of chemicals.   
Chapter Two 
45 
Table 5. Summary of the comparison between (anti-)AR CALUX results and in vivo reference 
classification. 
Note: *PC10 (agonistic mode) or PC20 (antagonistic mode), i.e., the concentration where the response 
elicited by the test compound equals 10 or 20% of the maximum response were calculated. 
Abbreviations: DHT: 5α-dihydrotestosterone; DEHP: bis-(2-ethylhexyl)phthalate (DEHP) (CAS: 117-
81-7); p,p’-DDE: p,p'-dichlorodiphenyldichloroethylene. NA: no activity observed at the highest 
concentration tested; value in between brackets is the highest concentration tested. 
 











androgenic -9.6 NA (>-4) 
58-22-0 testosterone androgenic -9.6 NA (>-4) 
84-74-2 DBP anti-androgenic NA (>-4) -4.7 
117-81-7 DEHP anti-androgenic NA (>-4) NA (>-4) 
60168-88-9 fenarimol anti-androgenic NA (>-4) -6 
13311-84-7 flutamide anti-androgenic NA (>-4) -6.5 
330-55-2 linuron anti-androgenic NA (>-4) -6.3 
72-55-9 p,p'-DDE anti-androgenic NA (>-4) -7.5 
32809-16-8 procymidone anti-androgenic NA (>-4.5) -7.3 
50471-44-8 vinclozolin anti-androgenic NA (>-4) -6.7 
104-40-5 4-nonylphenol negative NA (>-4) NA (>-4) 
61-82-5 amitrol negative NA (>-4) NA (>-4) 
1897-45-6 chlorothalonil negative NA (>-4) NA (>-4) 
2921-88-2 chlorpyrifos negative NA (>-6) NA (>-6) 
66332-96-5 flutolanil negative NA (>-4) NA (>-4) 
1071-83-6 glyphosate negative NA (>-4.3) NA (>-4.3) 
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Determination of hormone-related activity in breast milk samples 
Next, we used the AR CALUX along with the ERα CALUX assay to assess the hormonal 
activity in ten breast milk samples. To optimally extract chemicals from the breast milk, apolar 
and polar analytes derived from each sample were extracted using two separate methods and 
combined subsequently to form reconstituted extracts. These mixtures were analyzed in the 
ERα and AR CALUX bioassays, both in the agonistic- and antagonistic mode (Table 6). All 
samples were first tested and corrected for cytotoxicity to exclude non-specific effects. No 
antagonistic activity towards ERα was observed and only two samples scored positive in the 
agonistic ERα CALUX bioassay. All samples demonstrated anti-AR activity except number 1 
and 8 which did not reach the limit of quantification (LOQ) of the AR CALUX bioassay.  
Considering that 80% of breast milk samples were positive for anti-androgenic testing, 
a migration experiment was performed according to European Commission Regulation No 
10/2011 and EN1186, described by Kirchnawy et al. (2014) to assess possible artificial activities 
derived from plastic HDPE bottles. Results demonstrated that an anti-androgenic activity 
equals to 0.18±0.04 µg flutamide eq./g of material could be attributed to the containers. These 
findings showed that only a small proportion of the activity present in human milk samples 
could be explained by storage conditions, however all active samples were well above this value 
suggesting that they contain biologically active components with anti-androgenic activity. As 
a first step towards understanding the nature of the anti-AR activities, the same ten human 
milk samples were analyzed as two distinct fractions. 
In all apolar fractions the antagonistic activities detected were below LOQ (Table 7). 
All polar fractions scored positive ranging from 1.8 to 9.0 µg flutamide eq./g with the exception 
of sample n°1 which was classified as <LOQ due to its extremely low signal. Anti-androgenic 
activity in polar fractions were found to be significantly higher than the average background 
levels from leachable components. All activities measured in the polar extracts were 
considerably higher when assessed alone rather than in combination with the apolar fraction 
as a reconstituted mixture. These results suggest an accumulation of polar compounds, 
possibly EACs with AR antagonistic properties in breast milk of the HUMIS cohort. However 
further investigation is required to determine whether the anti-AR activity is caused by 
endogenous compounds in human milk i.e., natural hormones, or is of anthropogenic nature.  
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Table 6. Hormonal activity of ten reconstituted human milk samples assessed in the (anti-
)AR and (anti-)ERα CALUX bioassays. 
Number 
ERα CALUX 
(ng E2 eq./g) 
Anti-ERα CALUX 
(µg tamoxifen eq./g) 
AR CALUX 
(ng DHT eq./g) 
Anti-AR CALUX 
(µg flutamide eq./g) 
1 0.15 0.15 (<LOQ) 4.0 0.22 (<LOQ) 
2 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.73 
3 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.53 
4 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.58 
5 0.14 0.15 (<LOQ) 0.02 (<LOQ) 0.61 
6 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.85 
7 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.64 
8 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.23 (<LOQ) 
9 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.61 
10 0.002 (<LOQ) 0.15 (<LOQ) 0.02 (<LOQ) 0.8 
Note: Each human milk sample was individually reconstituted from apolar and polar extracts. Samples 
are arbitrarily numbered from 1 to 10. Results are expressed as equivalent per gram of material using 
the reference compound of the assay as reference. Abbreviations: AR: androgen receptor; ERα: estrogen 
receptor α; E2: 17β-estradiol; DHT: 5α-dihydrotestosterone; LOQ: Limit of quantification. 
Table 7. AR antagonistic activities of breast milk sample extracts measured using the 
antagonistic mode of the AR CALUX bioassay. 
Number 
Apolar 
(µg flutamide eq./g) 
Polar 
(µg flutamide eq./g) 
Combined extract 
(µg flutamide eq./g) 
1 0.22 (<LOQ) 0.05 (<LOQ) 0.22 (<LOQ) 
2 0.15 (<LOQ) 2.82 0.73 
3 0.13 (<LOQ) 1.8 0.53 
4 0.18 (<LOQ) 3.0 0.58 
5 0.2 (<LOQ) 9.0 0.61 
6 0.22 (<LOQ) 4.8 0.85 
7 0.22 (<LOQ) 5.7 0.64 
8 0.23 (<LOQ) 6.3 0.23 (<LOQ) 
9 0.17 (<LOQ) 1.9 0.61 
10 0.22 (<LOQ) 4.2 0.8 
Average <LOQ 4.0 0.58 
Note: Apolar and polar endocrine active compounds derived from nine human milk sample were 
extracted and analyzed as two distinct fractions on the anti-AR CALUX. Both extracts were mixed and 
analyzed together to evaluate the effects of the combined fractions. Results are expressed as flutamide 




Chemical evaluation of the anti-androgenic activity in human milk samples 
Human naturally occurring steroid hormones (e.g. DHEA, E2, E1, pregnenolone, 
progesterone and testosterone) could potentially interact with the androgen receptor. Using a 
pooled breast milk sample as a basis, we evaluated if this set of hormones is related to the AR 
antagonistic activity as measured in the polar fraction. For this, we used effect-directed 
analysis to see if the biological effect (AR antagonism) coelutes with these steroids using a 
chromatographic separation step based on a Biphenyl column. Four distinct fractions, A.1 to 
A.4, were collected using HPLC following a five-minute time-interval scheme (Figure 2). 
Clearly, the steroids co-eluted with the bioactivity as an activity of 0.88 µg flutamide eq./g was 
measured in fraction number 3 (A.3) while no activity was present in the other fractions. 











Figure 2. Chromatographic overlay of elution patterns of the seven endogenous hormones 
with the pooled human milk extract. 
Note: Chromatogram derived from each individual internal standard was overlapped to the 
chromatogram of the polar fraction of a pooled breast milk sample (blue). All endogenous hormones 





A.3 was further fractionated using a Fluor 5 column. With the exception of 
pregnenolone and progesterone, all the hormones co-eluted within fraction B.2, while only 
fraction B.3 showed an AR antagonistic activity (1.7 µg flutamide eq./g) (Figure 3). Due to their 
co-elution with the active fraction B.3, pregnenolone and progesterone could still play a role 
in the observed anti-androgenic activity in human milk samples. 
Figure 3. Chromatographic overlay of elution profiles of endogenous hormones and anti-AR 
bioactivity in human milk fraction A.3 on a Phenomenex Kinetex Fluor 5 column. 
Note: Chromatogram derived from each individual internal standard was overlapped to the 
chromatogram of the polar fraction of a pooled breast milk sample (blue). All endogenous hormones 
except for pregnenolone and progesterone (b.3) co-eluted with fraction B.2. Abbreviations: E1: estrone; 
DHEA: 5-androstan-3b-ol-17-one. 
The Fluor 5 chromatographic separation procedure was repeated, using smaller time 
window collection points. As the anti-AR activity was positioned in fraction B.3 (20 to 30 min), 
this 20-30 min time frame was further divided in five two-minute fractions, labelled C.1 to C.5, 
which were collected and analyzed separately in the anti-AR CALUX (Figure 4). Fractions C.3 
and C.4 were found to contain anti-androgenic activity with a total activity of the combined 
fractions equivalent to 1.1 µg flutamide eq./g. Pregnenolone and progesterone co-eluted with 
fractions C.1 and C.2 implying that none of the studied endogenous hormones were in the 
extract containing the anti-AR activity.  
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Figure 4. Further refined sub-fractionation of the anti-AR activity containing B.3 fraction on 
the Phenomenex Kinetex Fluor 5 column, with elution pattern overlay of pregnenolone and 
progesterone. 
Subsequently, a suspect list of 248 human metabolites was generated based on the 
seven endogenous hormones, set as parent compounds, using a combination of the 
BioTransformer website and the software R (Appendix A.2). This list was used for the 
identification of metabolites in C.3 and C.4 fractions after UHPLC-Q-TOF-MS/MS-based non-
targeted analysis. After comparison between the predicted masses and the analyzed unique 
features, none of the metabolites were detected in the fractions of interest showing that neither 
these compounds nor their parent hormones (androstenedione, DHEA, E1, E2, pregnenolone, 






In this manuscript, we identified anti-androgenic activity in human milk samples 
derived from the Norwegian HUMIS cohort. Through a chemico-biological analysis, we could 
exclude that androstenedione, DHEA, E1, E2, pregnenolone, progesterone, testosterone and 
their metabolites were responsible for the observed anti-androgenic activity measured using 
the AR CALUX bioassay. While it is not excluded that endogenous hormones might contribute 
to the anti-androgenic activity observed by the as yet unidentified EDCs, the findings suggest 
that breastfeeding might constitute a potential route of early human exposure to mixtures of 
anthropogenic contaminants with anti-androgenic properties. 
Excellent correlations were observed between the in vivo Hershberger classifications 
and the AR CALUX results for the sixteen reference compounds selected. Similar to the highly 
selective ERα CALUX bioassay, the (anti-)AR CALUX reporter gene bioassay may provide a 
reliable alternative test method to the traditional in vivo methods in rodents  (Sonneveld et al. 
2006). Indeed, the six chemicals, reported as non-active in the Hershberger database 
established by Browne et al. (2018), scored negative on both AR-based CALUX assays. 
Testosterone and 17α-methyl testosterone, two natural androgens, shown strong agonistic 
properties in the AR CALUX bioassay, matching our expectations. These results are consistent 
with Sonneveld et al. (2006) demonstrating the abilities of the AR CALUX in detecting 
agonistic activities using a wide array of mainly steroidal compounds, also showing a parallel 
between in vitro and in vivo predictions. Moreover, previous studies showed that the assay 
also responds to all bioactive androgens present on the prohibited list of the World Anti 
Doping Authority (Houtman et al. 2009). The AR CALUX in its antagonistic mode was, 
however, never compared to in vivo studies. Consequently, a larger set of antagonists was 
selected. Predictivity of the anti-AR CALUX bioassays was very satisfying and in line with 
earlier work by Van der Burg et al. (2010). However, one compound, DEHP, scored differently 
than reported in the Hershberger database. This phthalate was inactive in the in vitro anti-AR 
CALUX assay, which is in line with the results from the ToxCast AR model described by 
Kleinstreuer et al. (2018) also scoring DEHP negative. In the ToxCast study the highest 
concentration tested was equal to 100 µM, similar to the concentration used in the anti-AR 
CALUX. By extrapolating the estimated administered dose, Kleinstreuer et al. showed that this 
concentration was similar to the lowest observed effect level (LOEL) values derived from the 
Hershberger method, ranging from 100-200 mg/kg body weight per day, suggesting that the 
discrepancy in classification between the methods could not be explained by a difference in 
concentration (Kleinstreuer et al. 2018). The mismatch is very likely caused by the fact that 
DEHP antagonizes steroid production, which will be measured in vivo as an antagonistic 
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effect, while this is not picked up in vitro in a receptor-based assay, but rather in a 
steroidogenesis assay as present in an EATS panel of assays (Borch et al. 2006). Both ERα- 
and AR- in vitro bioassays showed a good performance and applicability in detecting 
developmental and reproductive toxicity of chemicals and were found to be powerful tools in 
predicting the effects of EDCs on the endocrine system (Piersma et al. 2013; Van der Burg et 
al. 2014).  
The pilot epidemiological study including ten breast milk samples revealed an 
activation of the estrogen receptor α in two extracts only. However, an antagonistic activity 
towards the androgen receptor was measured in most of the assessed samples. The findings 
regarding ERα activation are crucial to understand the origins of the measured anti-
androgenic activity. Indeed, diverse estrogens such as E1 and E2 were earlier reported to be 
both androgenic and anti-androgenic, albeit at much higher dosages (more than 1000-fold), 
levels not reached in normal physiology. The absence of estrogenic activity in most of breast 
milk extracts could be explained by the typical drop in estrogens levels immediately in the 
postpartum period, programmed to induce and maintain lactation during the first months 
after delivery (Lu et al. 2017). This hypothesis is in line with the sampling time of the present 
samples, ranging from two weeks to two months after birth. Conversely, high levels of 
estrogens can lead to a reduced milk production resulting in difficulties to breastfeed, which 
is obviously not relevant for our study group. Further investigations on the anti-AR CALUX 
showed that the antagonistic activity could be fully attributed to the polar fraction with an 
average of 4.0 µg flutamide eq./g. On the contrary, all measurements of the apolar fraction 
were found to be below the limit of quantification. No indication of synergy between the two 
fractions was noticed. However, it appears that the presence of the apolar fraction, although 
having a limited response, induces the repression of the activity of the polar extracts when 
assessed as a mixture (0.58 µg flutamide eq./g on average). Interestingly, this response 
contrasts with the additive or synergistic effects usually expected from EDCs mixing cocktails 
(Bergman et al. 2012b; Kortenkamp 2014). While the presence of polar anti-androgenic EDCs 
could be linked to the activity measured on the anti-AR CALUX bioassay, we cannot exclude 
the fact that a mixture effect could lead to an enhanced anti-AR activity in the samples. Indeed, 
studies showed that chemicals with similar anti-androgenic properties may induce strong 
adverse outcome in male rats, in comparison, only showing small effects were noticed during 
individual chemical analysis (Hass et al. 2007). Therefore, it is unlikely that the activity 
measured in breast milk samples could be solely attributed to the presence of certain highly 
anti-androgenic EDCs whereas, a more complex combination of different type of chemicals is 
more plausible. Total activity measurements such as the CALUX method gives an overview of 
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the activity considering all chemicals present in the sample however, further analysis is 
required to identify a specific chemical to be avoided. 
In our samples, we expected natural estrogens and androgens to be extracted along 
with polar chemicals, thus their potential presence and activity had to be assessed. Using a 
pooled human milk sample as a basis, we investigated the possible contribution of seven 
relevant steroids to the measured anti-androgenic activity (Barreiro et al. 2015; Burger 2002). 
E1, E2, androstenedione, DHEA and testosterone were eluted together as may be expected due 
to their structural similarities and comparable physico-chemical properties. Elimination of the 
natural AR agonists, androstenedione, DHEA and testosterone from the extract might explain 
the observed increase in antagonistic activity, from 0.88 to 1.7 µg flutamide eq./g (Houtman 
et al. 2009). On the contrary, pregnenolone and progesterone’s removal coincided with a drop 
of about 30% of the activity. Overall an antagonistic activity of 1.1 µg flutamide eq./g was still 
noticeable after exclusion of the seven endogenous steroid hormones. The remaining anti-AR 
activity in human milk samples after removal of the sex hormones indicates that other 
compounds than these natural sex hormones are causative for the observed anti-androgenic 
activity. It is important to note that, steroid metabolites might also exert an influence on the 
anti-AR activity, although this seems unlikely since steroidal metabolites do hardly show any 
remaining receptor-based bioactivities (Houtman et al. 2009). In addition, UHPLC-Q-TOF-
MS/MS-based screening of a pooled breast milk sample indicated the absence of 248 potential 
metabolites derived from our initial set of hormones, which further excluded the hypothesis 
of involvement of natural hormones or their metabolites in the observed anti-androgenic 
activity in human milk. Thus, it is more likely that the observed anti-AR activity in human milk 
samples is caused by yet unidentified anthropogenic, exogenous chemicals which may be 
present as contaminants. Over the past decades, many studies reported breast milk 
contamination by various EDC classes. In 1998, Sonawane (1995) established an extensive list 
of these groups of contaminants describing pesticides (DDT, DDE, dieldrin, aldrin and 
endrin), polychlorinated biphenyls (PCBs) and dioxins as the most preeminent compounds. 
The physico-chemical properties of aldrin, dieldrin and endrin imply that these particular 
pesticides might be present in the polar fraction of breast milk. For o,p’-DDT and p,p’-DDE 
which turned out to be potent anti-androgens in the anti-AR CALUX, it is unlikely that they 
may have contributed to the anti-AR activity in human milk, due to their apolar nature, and 
therefore they would not likely elute in the polar fraction of our samples where the anti-AR 
activity was observed (Van der Burg et al. 2010). The same argument goes for dioxins, dioxin-
like PCBs and PCBs which can be expected in the apolar extract rather than the polar fractions. 
While these pollutants are not in the fraction of current interest, their role in the activity 
measured in the human milk samples should not be excluded. As demonstrated in the previous 
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section, the apolar fraction, while remaining quite low in anti-AR activity, might still play a 
role in diminishing the overall activity when measured as a reconstituted sample. Over the 
years, studies focusing on human milk have identified brominated flame retardants 
(polybrominated diphenyl ethers (PBDEs) and hexabrominated cyclododecane (HBCD)), 
dibenzo-p-dioxins (PCDDs), phthalates esters along with other organochlorine pesticides 
(aldrin, chlordane, α-endosulfan, metoxychlor, etcetera), constituting an non-exhaustive list 
of potential actors in the measured anti-AR activity (Damgaard et al. 2006; Main et al. 2006, 
2007; Norén and Meironyté 2000).  
Conclusion 
The present manuscript describes a first attempt in understanding the observed anti-
androgenic activity in breast milk samples. We found that the anti-AR activity could be 
distinguished from the major natural steroid hormones, and their metabolites, present in 
human milk and therefore suggests that the observed anti-AR activity might be associated with 
yet unidentified contaminants of anthropogenic origin. In future studies, further targeted and 
untargeted analysis are required to precisely identify their chemical nature. In addition, the 
possible role of this anti-AR activity in the observed increase in adverse health outcome e.g., 
frequency of cryptorchidism in offspring from the Norwegian HUMIS cohort will be studied 
in more detail as well. 
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Background The prevalence of cryptorchidism has increased over the past decades, yet its 
origins remain poorly understood. Testis descent is dependent on androgens and likely 
affected by endocrine disrupting compounds (EDCs), targeting the androgen receptor (AR).  
Objective We investigated the association between anti-androgenic activity, not derived from 
natural hormones, in maternal breast milk and impaired testis descent among boys.  
Methods We performed a case-control study based on 199 breast milk samples from 94 
mothers of cryptorchid boys and 105 random non-cryptorchid boys participating in the 
Norwegian HUMIS (Human Milk Study) cohort. For each participant, apolar, and polar 
fractions were extracted, and combined to reconstitute a mixture. Anti-androgenic activity was 
measured in all three fractions using the human cell-based in vitro anti-AR CALUX® assay 
and expressed in µg of flutamide equivalent, a well-known anti-androgen. Results from 
fraction analyses were compared among boys with cryptorchidism and controls using multiple 
logistic regression, controlling for appropriate confounders identified using a directed acyclic 
graph.  
Results Children’s daily exposure to anti-androgenic EDCs through breastfeeding was 
estimated to 78 µg flutamide eq./kg of body weigh/day. The activity was higher in the polar 
fraction (1.48±1.37 µg flutamide eq./g of milk) representing non-persistent chemicals, in 
contrast to other fractions. However, the activity in the polar extracts was decreased when in 
mixtures with the apolar fraction, indicating synergistic interaction. No significant difference 
in the activity was observed according to cryptorchid status, but we observed a non-significant 
positive association between anti-androgenic activity in the apolar fraction and cryptorchidism 
(Odd Ratio = 2.2, 95% CI (0.4, 13.3)).  
Discussion The study showed anti-androgenic activity in nearly all human milk samples, and 
at levels higher than the advisory threshold. A non-significant association between the apolar 
fraction which represents non-persistent chemicals and cryptorchidism was observed 




During the last few decades, an alarming increase in the prevalence of undescended 
testis in male newborns has been reported (Boisen et al. 2004; Toppari et al. 1996). 
Cryptorchidism is a risk factor for developing testicular germ cell cancer and impaired fertility, 
but its etiology is to this date still not fully understood (Mieusset et al. 1995). Over the years, it 
has been hypothesized that exposure to environmental factors such as endocrine disrupting 
chemicals (EDCs) could potentially add up to cause uncomplete masculinization in boys 
exposed during pregnancy (Sharpe and Skakkebaek 1993, 2003; Toppari et al. 1996).  
Many consumer products contain EDCs with either weak estrogenic (bisphenol A) or 
anti-androgenic (phthalate) properties even in relatively low dosages (Sohoni and Sumpter 
1998; Bergman et al. 2012). Exposure to EDCs has been associated with various adverse health 
effects including disruption of the proper masculinization of the gonads (Bergman et al. 2012; 
Toppari et al. 1996). In experimental animals, impact of EDCs is dependent on the level and 
period of exposure, identifying fetal and early life as a particularly vulnerable window 
(Bergman et al. 2012). In humans this window of androgen dependence of testicular decent 
occurs between 8 to 10 gestational weeks and much later around 25 to 35 gestational weeks 
(Hutson et al. 2013; Welsh et al. 2008). Some studies have reported associations between 
prenatal exposure to EDCs e.g. xenoestrogens, polychlorinated biphenyls (PCBs) and 
dichlorodiphenyltrichloroethane (DTT), and cryptorchidism at birth (Brucker-Davis et al. 
2008; Fernandez et al. 2007). However, subsequent studies on cryptorchidism reported that 
PCBs and DDT placenta levels, as well as perfluorinated compounds cord blood concentrations 
were not associated with cryptorchidism (Jensen et al. 2014; Virtanen et al. 2012).  
To date, most case-control studies associating exposure to EDCs and cryptorchidism 
are based on analysis of a limited number of chemicals. This is an important shortcoming since 
it has been shown that the effects caused by EDCs can add up in mixtures (Kortenkamp 2014; 
Rajapakse et al. 2002). Because most EDCs at realistic exposure levels only show weak binding 
to nuclear hormone receptors, a more comprehensive analysis of their combined effects is 
needed to elucidate their possible role in the increased incidence of cryptorchidism. Since the 
main nuclear receptor involved in male sexual development is the androgen receptor (AR), it 
can be used as a model to identify EDCs with the potential to be involved mechanistically in 
cryptorchidism. Breast milk is a suitable bio-fluid for assessing maternal body burden of 
persistent chemicals accumulated over life, and thus a good indicator of fetal exposure to 




In our previous pilot study, we developed a method to distinguish endogenous 
hormones from EDCs in human milk samples (Collet et al. 2020). Furthermore, we found anti-
androgenic activity in most samples and demonstrated that this activity could not be explained 
by endogenous hormones present in the milk. The present study therefore investigates the 
possible association between the disruption of androgen action, through mixtures of chemicals 
antagonizing normal AR functioning, and cryptorchidism. We extend the previous analyses 
using the anti-AR CALUX® (Chemically Activated LUciferase gene eXpression) bioassay to 
evaluate the effects of mixtures of EDCs on AR activity (Sonneveld et al. 2006).    
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Material and methods  
Study population 
The study population is a subset of participants from the multi-center birth cohort 
Norwegian Human Milk Study (HUMIS) previously described in detail (Eggesbø et al. 2009, 
2011) (Supplementary Table 1). In brief, HUMIS is a prospective mother-infant pair study 
performed at the Norwegian Institute of Public Health. Between 2002 and 2009, 2606 mothers 
were recruited by public health nurses in seven counties across Norway, except for Østfold 
county where they were recruited by a pediatrician in Østfold hospital. In the present study, 199 
mother-child pairs were selected based on the following criteria: singleton and live born. The 
cases and controls were selected based on the availability of adequate volume of banked breast 
milk samples for extraction and analysis. For each case, about one potential control was selected 
by restricting the sex to boys-mother pairs with adequate milk sample for extraction and 
analysis. Details of the selection procedure are shown in Figure 1. 
 
Figure 1. Flow chart of the study population selection for the case-control study. 
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Cryptorchidism: definition and mapping  
Mothers were asked to fill in questionnaires at 1, 6, 12 and 24 months after delivery. 
The reported number of cryptorchidism cases were 55 at 1 month (n = 55/907), 24 at 6 months 
(n = 24/986), 24 at 12 months (n = 24/1036), and 26 at 24 months (n = 26/1043). The 
cumulative reported number of cases at any time point (1, 6, 12, 24 months) was 154 (n = 
154/1262). The unique inclusion criteria of the case-study for a mother/child pair was to have 
a boy with reported cryptorchidism at any time point (1, 6, 12 or 24 months). A total of 94 out 
of 154 eligible participants fulfilled the inclusion criteria and were selected as cases having 
enough milk samples for analysis. 105 controls were selected randomly from the eligible 
dataset (n = 1262) following the same inclusion criteria. 
Mother milk collection 
Women were asked to collect 25 mL of milk every morning for eight consecutive days 
between the first two weeks and two months after giving birth. Mothers were encouraged to 
avoid electrical pumping equipment and were asked to register details on how and when the 
milk was sampled (Eggesbø et al. 2011). Milk samples were collected in 250 mL natural HDPE 
Packaging Bottles (Cat. No.: 967-21244, Thermo Scientific Nalgene®) made from food-grade 
high-purity resins, previously tested for potential migration of antiandrogenic chemicals 
(Collet et al. 2020). The milk bottles were posted by the mothers and stored at -20 °C in a 
Biobank of the Norwegian Institute of Public Health upon arrival. In this case-control study 
we selected milk samples from a subset of mothers to 94 boys with cryptorchidism (unilateral 
or bilateral) and to 105 boys with no cryptorchidism. 
Ethical approval 
The study was approved by the Norwegian Data Inspectorate (ref. 2002/1398) and 
Regional Ethics Committee for Medical Research (ref. S-02122). Mothers were included after 
oral and written informed consent had been obtained. 
Covariates 
Questionnaires filled in by the mothers were used to obtain information on potential 
confounders. Information on the child’s sex, birth weight, preterm, gestational age and 
maternal smoking during pregnancy was obtained by linkage to the Medical Birth Registry of 
Norway (Skjærven et al. 2000). Maternal age (˂ 25, 25-35, > 35 years old), pre-pregnancy body 
mass index (BMI) (under-weight, normal, overweight, obese) and birth weight (˂ 2500 g, 2500 
to 4000 g, > 4000g) were entered as continuous variables. Gestational diabetes, preeclampsia, 
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parity, preterm (child born before 259 days or 37 completed weeks), small for gestational age 
(< 10th percentile), smoking habits (no smoking, daily smoker ˂ 10 cigarettes, daily smoker > 
10 cigarettes), as well as maternal education (low, medium, high) were set as categorical 
variables. 
Sample preparation 
Analytes derived from each breast milk sample were extracted following a two-step 
extraction method previously described in (Collet et al. 2020). To extract apolar compounds, 
5 mL of homogenized breast milk per sample was transferred to a clean 60 ml glass tube with 
5 mL of 2-propanol (CAS. no.: 67-63-0, BioSolve) and shaken for 10 min on a shaker at 200±20 
strokes per minute. 14 mL of n-hexane (CAS no.: 110-54-3, BioSolve) was added and the tubes 
were shaken for an extra hour at 200±20 strokes per minute. The upper layer was collected 
into a clean collecting tube and the procedure was repeated twice with a shorter shaking time 
(30 min). Collected fractions were evaporated to dryness and reconstituted in 1 mL of n-
hexane. Glass columns were prepared with 5 g of 2% deactivated silica and conditioned with 
12 mL of n-hexane. Samples were loaded and eluted with 30 mL of a combination of n-hexane 
and dichloromethane (CAS no.: 75-09-2, BioSolve) to a ratio of 3:1. The final extract was 
evaporated until dryness, reconstituted in 30 µL of DMSO and stored at -20 °C.  
One control consisting of 5 mL of breast milk primarily spiked with 50 µL of a solution 
of 13C-labeled internal standard containing PCB153L and PCB180L (200 ng/ml) (MBP-D7, 
Wellington Laboratories) was added to every ten-sample batch. Controls were processed as 
described earlier (Collet et al. 2020). In brief, controls were extracted following the same 
procedure as the samples with the exception that the final fraction was reconstituted in 
isooctane (CAS no.: 540-84-1, BioSolve). Internal standard recoveries were assessed on a gas 
chromatograph/tandem mass spectrometer (GC-MS/MS) system using gas chromatograph 
GC-2010 Plus (Shimadzu) and gas chromatograph mass detector GCMS-TQ8050 (Shimadzu) 
controlled by the program GCMS Real Time Analysis (Shimadzu) and a CTC CombiPal 
autosampler controlled by the software Cycle Composer (CTC Analytics AG). Parameters and 
settings used for the analysis were similar to those described by (Collet et al. 2020). Overall, 
recovery values were 96±13 and 115±21% for PCB153 and PCB180, respectively. 
Polar compounds from breast milk samples were extracted according to the method 
detailed by (Collet et al. 2020). In brief, we adapted and optimized a QuEChERS (Quick Easy 
Cheap Effective Rugged and Safe) solid phase extraction and cleaning method for isolating 
polar EACs in the breast milk samples (Anastassiades et al. 2003). The 199 samples were 
homogenized prior to the procedure. In a clean 50 mL tube (Grenier Bio-One), 5 mL of sample 
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was transferred and completed with 15 mL of acetonitrile (ACN) (CAS no.: 75-05-8, BioSolve). 
After 30 secs of vigorous shaking, one QuEChERS EN 15662 extraction packet (Cat. no.: 5982-
5650, Agilent) was added. Tubes were shaken for 15 min using a circular shaker and then 
centrifuged for 5 min at 4000 rpm at 4 °C. The upper phase was collected in a clean 60 mL 
glass tube and the solid lower phase mainly constituted of salts was re-dissolved by adding 15 
mL of ACN. The complete procedure was repeated once using the same Grenier tube but 
without adding sample. The upper layers were combined and transferred to a 15 mL 
QuEChERS d-SPE (Cat. no.: 5982-5158, Agilent) clean-up tube. After 1 min vortex for 
homogenization, the d-SPE tubes were centrifuged for 5 min at 4000 rpm at 4 °C. 
Subsequently, the upper layer was collected and evaporated until dryness. All extracts were 
reconstituted in 30 µL of DMSO and stored at -20 °C until analysis.  
Samples were extracted by sets of 10. A procedure control consisting of 5 mL of spiked 
breast milk was included to each batch to assess the efficiency of the extraction. 100 µL of a 
mixture of internal standards (100 µg/mL) of bisphenol A (CAS no.: 80-05-7, Sigma-Aldrich), 
17β-estradiol (E2) (CAS no.: 50-28-2, Sigma-Aldrich) and testosterone (CAS no.: 58-22-0, 
Sigma-Aldrich) was used, similar to the pilot study (Collet et al. 2020). Controls were extracted 
following the same procedure as the samples with the exception that the final extract was 
reconstituted in pure ACN. Controls were analyzed by liquid chromatography using a Kinetex 
Biphenyl column (150x4.6mm 2.6µ particle size) (Cat. no.: 00F-4622-E0, Phenomenex). The 
system setup was the same as detailed earlier (Collet et al. 2020). After analysis, recovery 
values were calculated by comparing the peak height in the control samples with the initial 
internal standard spiking solution. BPA, E2 and testosterone were recovered to a rate of 35±13, 
50±6.8 and 59±5.9%, respectively. The polar fraction was compensated for loss i.e. 
measurements were adjusted using a factor of 2. Moreover, for the reconstituted mixture, the 
combination of polar and apolar (originally 1:1 ratio) was adapted to insure the correctness of 
the study (2:1).  
Anti-AR CALUX bioassay 
Apolar, polar and mixed fractions derived from each sample were individually analyzed 
on the anti-AR CALUX reporter gene assay (Sonneveld et al. 2005). The anti-AR CALUX assay 
is based on human osteoblastic osteosarcoma U2-OS cell-line (American Type Culture 
Collection), cultured as described previously (Sonneveld et al. 2005). The AR cell line is stably 
transfected with a full-length human AR expression vector and a minimal promoter element 
coupled to a luciferase reporter construct containing three androgen responsive elements 
(Sonneveld et al. 2005).  
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Blinded analysis was chosen to reduce bias. Anti-AR CALUX analysis was performed using 
a Hamilton Starlet liquid handling robot coupled to a Cytomat incubator. The procedure was 
adapted from the automated version of the CALUX bioassay described earlier in Van der Burg 
et al. (2014). For this, cultured AR CALUX cells were re-suspended in assay medium (1x105 
cells/mL) consisting of DMEM/F12 medium without phenol red indicator (Cat no.: 
VX1041025, Fisher) supplemented with 10 U/mL penicillin and 10 µg/mL streptomycin (P/S), 
non-essential amino acids (NEAA) (Cat no.: 11140-03, Gibco) and 5% charcoal-stripped fetal 
calf serum (DCC). 100 µL were transferred in 96 well plates and incubated for 20±4 hours at 
37 °C and 5% CO2. After incubation, samples were placed in the handling robot along with a 
nine-point calibration line of the reference compound flutamide ranging from 0M, consisting 
of pure DMSO, to 1.0E-05 M (stock solution). The robot was programmed to dilute each extract 
(dilution series 1-3-10-30-100x) using assay medium supplemented with 3.0E-10M of 5α-
dihydrotestosterone i.e. DHT (CAS: 521-18-6, Sigma Aldrich). The final DMSO concentration 
was set to 0.2%. The robot was programmed to fill the 96-plate with 100 µL of exposure 
medium. All dilution points including the calibration line were tested in triplicate on the same 
96-well plate. A solvent control (DMSO) was added to each plate to evaluate background 
activity. After 22±2 hours of incubation the medium was discarded and replaced by 30 µL of a 
Triton-lysis buffer. Plates were shaken for 10 minutes and the luciferase signal in cellular 
lysates was measured using a Tristar luminometer (Berthold).  
Controls 
All anti-androgenic measurements were performed along with the Cytotox CALUX® 
assay. Used as a control, the assay identifies non-specific luciferase activity repression e.g. 
caused by cellular death. The Cytotox CALUX bioassay consists of U2-OS cells constitutively 
expressing the luciferase gene (Van der Linden et al. 2014) and was essentially performed as 
described above with the exception that the analysis was done by hand with undiluted samples. 
A full dose response curve of the reference compound tributyltin acetate (CAS: 56-36-0, Merck 
Chemicals B.V.) was added to each Cytotox CALUX plate. Samples inducing a decrease in 
luminescence of more than 20% (i.e. cytotoxicity ≥ 20%) were further diluted and reanalysed. 
For further evaluation of non-specific signals, ten breast milk samples randomly selected from 
the sample set were incubated with an excess amount of DHT (i.e. 1000-times the EC50 
concentration). DHT saturating concentration is set to maintain receptor activation through 
competing with anti-androgenic compounds. In this way, a remaining decrease in 
luminescence demonstrates a non-specific repression, independent from AR inhibition. As 
none of the tested samples showed such repression of the signal, further measurements were 
considered as true antagonistic activity. 
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 Data handling 
For each plate, the EC50 DHT agonistic signal was set to 100% and the maximum signal 
response induced by the antagonist flutamide was defined as 0% (Figure 2). Relative Light 
Units (RLUs) measurements were corrected for background using DMSO. The average of each 
triplicate was plotted to the reference dose-response curve. Subsequently, all results were 
transformed using the statistical software package GraphPad Prism 5.0 (non-linear regression, 
variable slope, 4 parameters, robust fit), and expressed as a percentage of the maximum signal 
(relative induction). The relative induction was used to quantify the anti-androgenic activity in 
each sample expressed as µg equivalent of flutamide per gram of milk (µg flutamide eq./g of 
milk).  
A sample is considered active if its activity surpasses the limit of quantification (LOQ) 
of the anti-AR CALUX bioassay, set to ≥ 0.40 µg flutamide eq./g of milk. A non-active sample 
i.e. activity ≤ LOQ, was replaced by an estimation of the activity equal to half the LOQ value. 
CALUX measurements were evaluated according to the following criteria: EC50 of the 
reference compound between assay-specific predetermined limit values; R2 of standard curve 
> 0.98; z-factor of standard curve > 0.6.     
Figure 2.  Example of the antagonistic evaluation method for three breast milk samples using 
flutamide as a reference compound. 
 
Statistical analysis 
Differences in maternal and child characteristics between cryptorchidism cases and 
controls in our study were tested in a univariate analysis using Pearson’s chi-square test for 
Chapter Three 
69 
binary or categorical variables, and the Wilcoxon rank-sum test for the continuous variable 
(gestational age).  
Adjustment models. To estimate the association between anti-AR activity in human milk 
samples and the risk of cryptorchidism, appropriate confounders were first identified using a 
Direct Acyclic Graph (DAG) (DAGitty v3.0) (Figure 3). Multiple logistic regression models 
were used to estimate adjusted Odds Ratio (OR) and 95% Confidence Interval (95% CI). Two 
sets of potential confounders were identified. Set 1 included socioeconomic status (SES), 
maternal age, pre-pregnancy BMI, preterm, gestational age and parity, in which the overall 
percentage of missing values was 7%. Set 2 included small for gestational age, gestational 
diabetes, preeclampsia, smoking during pregnancy, alcohol consumption during pregnancy, 
antibiotic use, fat content of the milk, and a selected maternal toxicant. The overall missing 
when adjusting for both set 1 and 2 was 83% (Supplementary Table 2). The high percentage of 
missing was due to the fact that information on some covariates were obtained through linkage 
with the Norwegian MoBa study, for the small set of participants who also participated in the 
MoBa study. However, the high percentage of missing values in the fully adjusted model was 
problematic, so we decided to use multiple imputation by predictive mean matching in Stata 
as a sensitivity analysis. As a result, the other set of potential confounders (alcohol use, 
smoking, antibiotics use, maternal toxicant and fat content) were dropped since they had high 
missing values, and sensitivity analysis after multiple imputation by predictive mean did not 
change the result (Supp. Fig 1-5). The final model was therefore a complete case analysis of the 
association between anti-AR activity measured in breast milk fractions (polar, apolar, mixture) 
and the risk of cryptorchidism adjusted for variables in set 1.    
Software. Stata (version 16.1; Stata Corp LP, College Station, Texas, USA) was used for all 







Figure 3. Directed acyclic graph (DAG) based on literature for the associations between anti-
AR activity measured in breast milk (exposures), covariates, and cryptorchidism among 
Norwegian sons in the HUMIS study. 
Note: The first modelling set (S1) included relationship with maternal factor marked as adjusted on the 
DAG (White circle). The second modelling set (S2) included more potential confounders and were 







The characteristics of the study population in which anti-androgenic activity was 
assessed are presented in Table 1. Of 199 mothers, 148 (74.4%) were between 25-35 years of 
age at delivery, comparable between cases and controls. Most of the participants were highly 
educated (75.4%). The study population shows a minority of overweight or obese women (31%) 
and more than 80% reported no smoking history. In both cases and controls, most boys 
weighted within 2500-4000 grams at birth. A non-significant tendency of lower education 
among mothers of cases was observed. Overall, no major difference was found between the 
mothers giving birth to a cryptorchid boy versus a healthy child. Also, the selection of the case-
control study participants is representative of the study population enrolled in the HUMIS 
cohort with respect to maternal age, maternal education, and small birthweight for gestational 
age (9.5% vs 10%). Preterm was lower in the present study compared to the study population 
(6.5% vs 9%). Detail of the profile is presented in the supplementary material (Table S1).  
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Table 1. Univariate analysis of the association between maternal and child characteristics of 
the study participants (n (%) or median (IQR)) and the occurrence of cryptorchidism in a case-









Maternal age (years)     
 <25   30 (15.1%) 15 (14.3%) 15 (16.0%) 0.94 
 25-35 148 (74.4%) 79 (75.2%) 69 (73.4%)  
 >35   21 (10.6%) 11 (10.5%) 10 (10.6%)  
SES     
 Low     19 (9.5%)     7 (6.7%) 12 (12.8%) 0.16 
 Medium   26 (13.1%) 11 (10.5%) 15 (16.0%)  
 High 150 (75.4%) 84 (80.0%) 66 (70.2%)  
 Missing       4 (2.0%)     3 (2.9%)     1 (1.1%)  
Birth weight (grams)     
 <2500       5 (2.5%)     3 (2.9%)     2 (2.1%) 0.62 
 2500-4000 146 (73.4%) 74 (70.5%) 72 (76.6%)  
 > 4000   48 (24.1%) 28 (26.7%) 20 (21.3%)  
Parity   78 (40.0%) 43 (41.7%) 35 (38.0%) 0.60 
Small for gestational age     19 (9.5%)     9 (8.6%) 10 (10.6%) 0.62 
Gestational age (days) 281.5 (273-288) 284 (272-289) 280 (273-287) 0.18 
Preterm  
(before 37 week/259 d) 
   13 (6.5%)    8 (7.6%)  5 (5.3%) 0.51 
Pre Pregnancy BMI     
 
Under weight  
(< 18.5) 
     4 (2.0%)     4 (3.8%)     0 (0.0%) 0.27 




 39 (19.6%) 19 (18.1%) 20 (21.3%)  
 Obese (≥30)  22 (11.1%) 12 (11.4%) 10 (10.6%)  
 Missing      9 (4.5%)     5 (4.8%)     4 (4.3%)  
Smoking at the end of 
pregnancy 
    
 No smoking 160 (80.4%) 83 (79.0%) 77 (81.9%) 0.55 
 Daily smoker < 10       5 (2.5%)     2 (1.9%)     3 (3.2%)  
 Daily smoker >10       1 (0.5%)     1 (1.0%)     0 (0.0%)  
 Missing    33 (16.6%) 19 (18.1%) 14 (14.9%)  
Preeclampsia       7 (3.5%)     2 (1.9%)     5 (5.3%) 0.19 
Gestational diabetes       1 (0.5%)     1 (1.0%)     0 (0.0%) 0.34 
Note: BMI: body mass index; SES: socio-economic status; IQR: interquartile range. 
 Anti-androgenic activity was evaluated in 199 breast milk samples and expressed as µg 
equivalent of the reference compound flutamide, per gram of milk. For each participant, the 
apolar and polar fractions including the endogenous hormones, and the combination of both 
have been analyzed separately using the anti-AR CALUX bioassay (Figure 4, Table 2.).  
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Figure 4 and Table 2 present the distribution of anti-androgenic activity in the apolar 
and polar fractions along with the mixtures of both. The mixtures showed antagonistic 
properties ranging from 0.40 to 2.82 µg flutamide eq./g of milk. In nine milk samples, the 
mixtures were found to be ≥ 1.0 µg flutamide eq./g. of milk while in 70 samples, the mixtures 
were below LOQ (data not shown). Polar analyte-based measurements ranged from 0.41 to 
9.25 µg flutamide eq./g of milk, and most samples (124) were above ≥ 1.0 µg flutamide eq./g 
of milk. In contrast, apolar fractions showed a smaller range of values (0.40 to 1.16 µg flutamide 
eq./g of milk) with 23 milk samples eliciting activity above the LOQ cut-off value, and only one 
sample scoring above 1.0 µg flutamide eq./g of milk. Yet, considering that more than half of 
breast milk samples showed anti-androgenic activity when the mixture was assessed, we 
estimated the potential daily exposure to anti-androgenic EDCs of a breastfed child during the 
first twelve months of life. 
 Figure 4. Distribution of anti-androgenic activity in reconstituted breast milk samples 





Table 2. Distribution of anti-AR activity in polar, apolar, and combined fractions in breast 




Note: Concentration are expressed in µg flutamide eq./g of milk. N: number of samples per category; 
Mean: average activities; SD: standard deviation; p5-95: 5th to the 95th percentile; Max: maximum 
activity measured for the category; Range: difference between minimum and maximum activity 
measured for the category; IQR: interquartile range, difference between p75 and p25. 
According to WHO guidelines on breastfeeding (WHO 2011), a child should be 
exclusively breastfed for the first six months to one year of life. During this period, an infant 
ingests about 150 mL of milk per kg of body weight (bw) per day, on average. Our previous 
results showed that breast milk from Norwegian mothers of the HUMIS cohort could be 
contaminated with anti-androgenic toxicants, equivalent to 0.52 µg flutamide eq./g of milk, on 
average. Considering these data, and the volume of daily intake of an infant, we estimated the 
average exposure to anti-androgenic EDCs during the first year of life, in µg of flutamide/kg 
bw/day (Table 3). 
Table 3. Estimation of a child’s daily intake of anti-androgenic EDCs through breastfeeding 
















Nursing child dose per 
day 
(µg flutamide eq./kg 
bw/day) 
0.52 1 525 273 3.5 78 
0.52 6 1125 585 7.5 78 
0.52 12 1380 718 9.2 78 
 
Note:  *Assuming that the child is exclusively breastfed. 
** Average body weight at 1, 6 or 12 months. 
 
 N Mean SD p5 p25 p50 p75 p95 Max Range IQR 
Mixtures            
 All 199 0.52 0.32 0.13 0.27 0.50 0.70 0.98 2.90 2.82 0.43 
 Cryptorchidism 94 0.51 0.28 0.14 0.26 0.51 0.68 0.98 1.8 1.68 0.42 
 Controls 105 0.53 0.36 0.13 0.27 0.48 0.71 0.97 2.90 2.82 0.44 
Polar fraction            
 All 199 1.48 1.37 0.18 0.64 1.24 1.80 4.20 9.30 9.25 1.16 
 Cryptorchidism 94 1.49 1.42 0.19 0.64 1.24 1.78 5.1 9.3 9.16 1.14 
 Controls 105 1.47 1.33 0.17 0.64 1.14 1.80 3.90 9.00 8.95 1.16 
Apolar fraction            
 All 199 0.22 0.16 0.10 0.14 0.17 0.23 0.55 1.23 1.16 0.09 
 Cryptorchidism 94 0.23 0.18 0.1 0.14 0.17 0.23 0.57 1.23 1.16 0.1 




The distribution of anti-androgenic activity in control and cryptorchid groups is shown 
in Table 2. The mean of the mixed fractions was 0.53±0.36 and 0.51±0.28 µg flutamide eq./g 
of milk in controls and cases, respectively. Most apolar fractions fell below the LOQ value of 
the anti-AR CALUX bioassay regardless of the studied group (p75 = 0.23 µg flutamide eq./g of 
milk). Finally, the mean activities of the polar fractions were 1.47±1.33 and 1.49±1.42 µg 
flutamide eq./g of milk. In conclusion, the anti-androgenic activity measured in breast milk 
samples from controls and cases were similar across all the tested fractions. The association 
between anti-AR activity measured in breast milk fractions (polar, apolar, mixed) and the 
occurrence of cryptorchidism was estimated using logistic regression (Figure 5, Supp. Table 2). 
The minimally adjusted model contained maternal age, maternal education, pre-pregnancy 
BMI, gestational age, and number of siblings, while the fully adjusted model also contained 
gestational diabetes and preeclampsia. The other set of variables (alcohol use, smoking, 
antibiotics use, maternal toxicant and fat content) were dropped since they had high missing, 
and sensitivity analysis after multiple imputation by predictive mean didn’t change the result 
(Supp. Fig 1-5). No statistically significant association was observed between anti-androgenic 
activity in the mixture or polar fractions and cryptorchidism in the minimal and fully adjusted 
models. Yet non-significant positive association between anti-androgenic activity in the apolar 
fraction and cryptorchidism (Odd Ratio = 2.2, 95%CI (0.4, 13.3)) was found.  
Figure 5. Forest plot showing association between cryptorchidism at one month and anti-AR 
activity from mixed, polar and apolar fraction of breast milk in HUMIS cohort. 
Note: Minimal adjusted model: Maternal age, socio economic status, pre-pregnancy BMI, and parity. 




This study shows that nearly all Norwegian babies are exposed to anti-androgenic activity 
through breast milk and at levels higher than the advisory threshold. Children’s daily exposure 
to anti-androgenic EDCs through breastfeeding was estimated to 78 µg flutamide eq./kg of 
body weigh/day. A non-significant association between the anti-androgenic activity in the 
apolar fraction and cryptorchidism was observed in this study, warranting further studies on 
EDCs and cryptorchidism. No significant association between anti-androgenicity from polar 
contaminants and cryptorchidism was found, nor from the overall reconstituted samples 
(mixtures).  
Anti-AR CALUX mother milk analysis showed that anti-androgenic activity was associated 
with the presence of polar compounds in the samples. In contrast, apolar fractions gave a lower 
anti-AR activity signal. This was unexpected, since the latter fraction is supposed to contain 
various toxicants such as DDT, DDE, brominated flame retardants, and organochlorines, 
known to exhibit anti-androgenic activity (Kelce et al. 1995; Lemaire et al. 2004; Van der Burg 
et al. 2010). Yet, the present results match our previous pilot study demonstrating less activity 
in apolar extracts in comparison with polar measurements (Collet et al. 2020). Due to their 
resistance to degradation and extended half-life, persistent toxicants are able to bioaccumulate 
throughout life in diverse fatty tissues, including breasts. Over the past decades, many studies 
highlighted EDCs presence in mother milk, demonstrating breastfeeding as an important 
source of exposure for the infant (Norén and Meironyté 2000; Sonawane 1995; Thomsen et al. 
2010). The present study provides insights regarding child’s early life exposure showing an 
almost ubiquitous anti-androgenicity in breast milk. Although generally less potent, apolar 
fraction analysis provides a better general insight of perinatal exposure in opposition to the 
polar fraction, which mainly reflects the action of non-persistent compounds i.e. less stable 
exposure. Yet, exposure may be stable if mothers have a stable consumption/use of products 
containing non-persistent chemicals. Nevertheless, reconstituted samples analysis highlighted 
the importance of studying both fractions, alone and in combination. Anti-AR CALUX analysis 
showed a decline in anti-androgenic activity from polar compounds (p50 = 1.80 µg flutamide 
eq./g of milk) when assessed along with apolar chemicals as a mixture (p50 = 0.50 µg flutamide 
eq./g of milk). These results demonstrate that the presence of apolar compounds influences 
anti-androgenicity by weakening stronger polar chemical effects. While various classes of 
lipophilic chemicals were proven to cause anti-androgenic activity, there are likely many other 
chemicals in this fraction, with unknown effect on the AR which could cause unpredicted 
mixture effects (Bergman et al. 2012; Kortenkamp 2014). Overall, these anti-AR CALUX 
measurements provide an overview of the AR activity present in human milk. A nursing child’s 
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dose exposure to anti-AR EDCs based on the AR activity levels present in human milk was 
estimated to 78 µg of flutamide eq./kg bw/day approximately. This level of anti-androgens, 
expressed as flutamide equivalent, largely exceeds the acceptable daily doses of a flutamide 
exposure for humans reported in 2017 (no adverse effects level NOAEL of 0.025 mg/kg/day) 
(Zacharia 2017). Additional studies involving targeted methods and mixture effect analysis are 
necessary to identify specific compounds and their origins in order to advice regulatory 
authorities on necessary further chemical restrictions. Nevertheless, the present extraction and 
analysis of 199 breast milk samples gave a starting point in the path of exploring anti-
androgenicity and mixture effect in human milk.  
As a first attempt to evaluate the potential risks of an early exposure to anti-androgenic 
EDCs, we investigated the potential link between anti-androgenic activity in breast milk and 
cryptorchidism occurrence in the offspring. Anti-androgenic measurements in cryptorchid and 
control groups were similar regardless of the assessed fraction. Nevertheless, statistical 
analysis suggests a non-significant tendency for a positive association between apolar anti-
androgenic activity and cryptorchidism only. Experimental studies on animals clearly 
demonstrated that cryptorchidism can be caused by the disruption of hormones involved in 
regulation of testicular descent (MacLeod et al. 2010; Welsh et al. 2008). The mechanistic 
studies investigating anti-androgenic activity and cryptorchidism in humans were mainly 
focused on the relationship between hormone (testosterone/estrogen) levels or non-persistent 
i.e. polar compounds and cryptorchidism. (Key et al. 1996; Virtanen and Adamsson 2012). Still, 
there are a few studies investigating on cryptorchidism incidence and apolar chemicals. In 
2007, a Danish-Finnish case control study among 280 boys suggested a possible association 
between flame retardants (polybrominated diphenyl ethers) levels in breast milk and 
congenital cryptorchidism (Main et al. 2007). Then, Brucker-Davis et al. (2008) showed that 
cryptorchid boys were more likely to present higher levels of DDE and polychlorinated 
biphenyls in colostrum in comparison with the control group. While these studies point 
towards the direction of our results i.e. a potential link between lipophilic compounds and 
undescended testis, we cannot exclude that the trend we observed in the present analysis could 
be influenced by the rather low activity derived from apolar anti-AR CALUX measurements, 
close to the background value of the bioassay. In this way, further investigations combining 
targeted and untargeted methods, such as CALUX reporter gene bioassays, are necessary to 
further investigate potential link between chemicals exposure and the increasing 
cryptorchidism incidence. 
 This study is the first to investigate anti-androgenic receptor activity in human breast 
milk fractions in a case-control study selected from prospective cohort. However, some 
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strengths and limitations need addressing. Firstly, the selection of the study participants in 
this case-control study compared to the entire cohort is representative with respect to maternal 
(age, education, parity, pre-pregnancy BMI) and child (gestational age, small for gestational 
age) characteristics. The HUMIS cohort is a multi-center birth cohort enrolling participants 
across Norway to represent Norwegian population. The exposure, breast milk extracts were 
collected after the outcome, however, represents real-life exposure covering both prenatal and 
postnatal windows especially for lipophilic compounds as it accumulates in lipid-rich tissues 
and represents mothers body burden. There is also a positive correlation between levels 
measured in breast milk and levels in the umbilical cord for persistent chemicals making it a 
suitable proxy for prenatal exposure (Kanja et al. 1992; Verner et al. 2013; Waliszewski et al. 
2001). Moreover, using CALUX bioassays and total EDC content, this study takes into account 
the interactions among “real” chemical mixtures in the breast milk. In addition, we had 
information on a large set of potential confounders and the outcome, cryptorchidism, was 
based on repeated questionnaire (maternal reports) at 1, 6, 12, and 24 months which enables 
to capture recurrent cryptorchidism; normally descended testis at birth that subsequently 
ascended. While self-report is prone to bias and not as robust as clinically diagnosed cases of 
cryptorchidism, high reliability has been demonstrated in maternal reports from Norwegian 
mothers (Skulstad et al. 2017). One of the major limitations was the sample size (199 samples) 
that might have underpowered the study, preventing the detection of any significant difference. 
Breast milk was used as a proxy for prenatal chemical exposure which is not suitable for polar 
chemicals. While it is well-known that apolar compounds bioaccumulate in breast tissues, 
polar chemicals, i.e. non-persistent compounds, content tends to fluctuate during life. 
Although polar activity measurements were corrected for loss during the extraction procedure, 
an underrepresentation of non-persistent EDCs cannot be ruled out. Androgen-dependent 
phases of testis descent occur during early fetal development (8-10weeks) and much later 
around 25-35 gestational weeks (Hutson et al. 2013; Welsh et al. 2008). Whereas breast milk 
appears as a suitable matrix for monitoring late fetal environmental, earlier steps of 
cryptorchidism determinism might have been overlooked. 
In conclusion, in this case-control study we found the ubiquitous anti-androgenicity 
present in breast milk samples from Norwegian mothers. We highlighted the interactions 
between chemicals of different polarity and the interest in assessing them alone and in 
combination. No association between anti-androgenic activity in mother milk and the 
occurrence of cryptorchidism in the offspring was found, however, a possible association with 
anti-AR activity from apolar compounds was suggested. Additional studies based on a larger 
sample size are needed to further explore the relationship between anti-androgenic activity in 
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We developed a thyroid testing panel to assess endocrine disrupting chemicals (EDCs) 
capacities to bind either the thyroid receptor β (TRβ) or the thyroid hormones transporter 
transthyretin (TTR). We first stably transfected a human U2OS cell line with TRβ and a 
luciferase reporter construct to develop the TRβ CALUX® reporter gene assay to assess 
chemicals’ potential to interact with TRβ. Secondly, we combined a TTR-binding assay with 
the TRβ CALUX (TTR-TRβ CALUX) and optimized the system to evaluate the competitive 
properties of EDCs towards T4 for TTR binding. Both systems were evaluated with a range of 
known thyroid-disrupting compounds. The agonistic/antagonistic TRβ CALUX successfully 
predicted 9/9 and 9/12 test compounds, respectively. The TTR-TRβ CALUX predicted 9/9 
compounds and demonstrated competitive activities when analyzing wastewater samples. We 
concluded that the proposed test battery is a promising screening method able to efficiently 




Over the course of several decades, some evidence has suggested the sensitivity of fetal 
development and adult physiology towards endocrine disrupting chemicals (EDCs) (Kabir et 
al. 2015). It has been reported that a repeated exposure to these EDCs can interfere with 
endogenous hormones leading to adverse health effects, even at very low concentrations (Kabir 
et al. 2015). The importance of the endocrine system in major physiological processes and 
disease etiology emphasizes the growing need of developing reliable high throughput tools to 
efficiently predict the disrupting activity of chemicals and their mixtures. In the past, we 
developed CALUX® (Chemically Activated LUciferase eXpression) reporter gene assays able to 
assess androgen receptor (AR) and estrogen receptor (ER) alterations by environmental 
chemicals (Sonneveld et al. 2005; Van der Burg et al. 2014). These bioassays cover a variety of 
endpoints related to EATS (Estrogens, Androgens, Thyroid, and Steroidogenesis) adverse 
outcomes. In order to further expand our current testing panel, we selected the thyroid system 
as a next step in developing a complete in vitro test battery for assessing developmental and 
reproductive toxicity (DART) effects.   
Thyroid hormones (THs) are important in numerous physiological processes such as 
regulation of metabolism, bone remodeling, cardiac function and mental status. The two main 
THs, the prohormone 5′,3′,5,3-tetraiodo-[L]-thyronine (thyroxine, T4) and its bioactive form 
the 3′,5,3-triiodo-[L]-thyronine (triiodothyronine, T3), play a major role in maintaining body 
homeostasis (Brent 2012). Thyroid hormonal output is regulated by a finely tuned feedback 
system acting at both hypothalamic and pituitary levels (Brent 2012; Mullur et al. 2014). First, 
the thyroid-releasing hormone (TRH) is secreted by the hypothalamus into blood, through the 
hypophyseal portal system. Once in the anterior pituitary, TRH induces the production of 
thyroid-stimulating hormone (TSH) which is released in the general circulation towards the 
thyroid gland. Within the thyroid gland, TSH stimulates the synthesis and secretion of THs. 
Depending on serum levels, THs can modulate their own production and release by exerting a 
retro-negative control on both TRH and TSH (Brent 2012; Mullur et al. 2014). Once in the 
bloodstream, T4, the major thyroid hormone produced, binds to transport proteins so as to be 
distributed to target cells across the body. In humans there are three major serum carrier 
proteins, thyroxine-binding globulin (TBG), transthyretin (TTR) and human serum albumin 
(HSA) (Landers et al. 2013; van der Spek et al. 2017). Although the major transporter is TBG, 
specific structural properties allow TTR to pass through the blood-brain barrier and the 
uterine-placental wall making this protein the main carrier of T4 in the cerebrospinal fluid and 
the developing fetus (Landers et al. 2013). Within the target tissues, T4 is mainly converted 
into its bioactive form T3 by deiodinase enzymes (Mullur et al. 2014; van der Spek et al. 2017). 
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Both T4 and T3 are natural ligands for the thyroid receptors α and β (TRα and TRβ) (TRs), 
with T3 having a 10-fold higher affinity (Kim and Cheng 2013; Ortiga-Carvalho et al. 2014). 
TRs primary isoforms are differentially expressed in fetal and adult tissues, TRα being 
predominant in the brain, heart ventricles, intestine and skeletal muscle while TRβ is more 
widely distributed (brain, retina, inner ear, heart, kidney, liver and lung) (Brent 2012; Ortiga-
Carvalho et al. 2014). In 2014, Ortiga-Carvalho et al. demonstrated that patients with thyroid 
hormone β (THβ) resistance presented a severe deregulation of the hypothalamic-pituitary-
thyroid (HPT) axis as well as abnormally elevated THs levels (Ortiga-Carvalho et al. 2014). On 
the contrary, patients with thyroid hormone α resistance showed nearly normal THs and TSH 
levels, implying a lower impact of the condition on the HPT axis. These results suggest that 
TRβ isoforms might play a crucial role in maintaining circulating THs levels by participating 
in the negative feedback of the HPT axis, an important target of EDCs (Ortiga-Carvalho et al. 
2014). As a response to THs stimulation, TRs enter the nucleus and bind to thyroid hormone 
response elements (TREs), triggering the transcription of T3 target genes (Boas et al. 2012; 
Kim and Cheng 2013; Sandler et al. 2004). TRs can either act as homodimers or form 
heterodimers with retinoid X receptor (RXR) able to bind to TRE, inducing the stimulation or 
inhibition of associated genes (Hsu et al. 1995; Zhang et al. 1992). The thyroid system plays a 
central role in proper fetal development as well as preserving homeostasis during life, therefore 
maintaining a normal thyroid function and hormone levels is essential.   
In recent years a link has been found between disturbed thyroid hormones’ functions 
and exposure of man and wildlife to pollutants with endocrine disrupting properties (Ortiga-
Carvalho et al. 2014). Although multiple sites of the thyroid system can be disrupted, it is 
extremely complex to assess them all as there is currently no practical battery that can cover 
all of these potential targets of EDCs. In the present paper, we designed a condensed thyroid 
hormone disruption panel aiming to evaluate both the potential agonistic and antagonistic 
aspects of chemicals towards TRβ, as well as their possible interferences with T4/TTR-binding. 
First, we developed the in vitro TRβ CALUX reporter gene assay based on the human U2OS 
cell line stably transfected to endogenously express TRβ. The cells were additionally 
transfected with a reporter construct containing a luciferase gene linked to two copies of TREs. 
In this bioassay, a TRβ activation stimulated by ligand-binding consecutively induces both the 
transcription of THs target genes and of gene coding for the luciferase protein. This method 
allows assessment of in vitro hormonal activity of agonistic chemicals by luciferase production 
quantification. Moreover, the TRβ CALUX assay can also be used to assess the activity of 
antagonistic compounds through cells pre-stimulation with the natural ligand T3. The current 
paper describes the design and operating mode of the new TRβ CALUX bioassay. In addition, 
this manuscript details the evaluation process used to assess the overall performance of both 
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agonistic and antagonistic methods. As no prior set of recommended chemicals was available 
at the time of the beginning of the study, we generated our own list of compounds selected on 
their thyroid-related activities reported in literature. 
While a limited number of chemicals are known to directly interfere with TRβ, TTR is 
a well-known target for phenolic organo-halogen EDCs which may lead to thyroid depletion of 
the fetal brain and associated disorders (Cheek et al. 1999; Lans et al. 1993; Meerts et al. 2000; 
Montaño et al. 2012). In this manner, and as a complement to the TRβ CALUX bioassay, we 
included a TTR-binding assay to our method in order to assess TTR/THs potential 
interferences by EDCs. The TTR-binding assay involves the incubation of possible T4 
competitor with a fixed amount of T4 and TTR. After separation from free remaining 
T4/compound, the fraction of T4 which bound to TTR can be measured using TRβ CALUX 
bioassay. This publication presents the detailed procedure to perform the optimized TTR-
binding assay using TRβ CALUX as read-out system, hence referred as TTR-TRβ CALUX. The 
overall combined method’s performance was evaluated by the analysis of known T4 competitor 
for TTR binding. In this report, we demonstrate that the newly developed TRβ CALUX method 
can be used as a readout of the existing TTR-binding assay, so as to assess potency of 
compounds for competing with T4 for TTR binding sites. Step by step, we detail the 
development of the TRβ CALUX and the TTR-TRβ CALUX bioassays as well as the intra-
laboratory evaluation strategy used for each method (Fig 1.). We completed this study by 
investigating the applicability of the TTR-TRβ CALUX bioassay through a short case-study. We 
analyzed waste- and HPLC-water samples on the combined assay and highlighted net T4 
competitive activities for TTR binding. This result showed a potential field application for the 
TTR-TRβ CALUX bioassay. Overall, three different CALUX-based bioassays (TRβ CALUX, 
anti- TRβ CALUX and TTR-TRβ CALUX) were developed and controlled for variance and 
reproducibility. This study shows that chemicals presenting both agonistic and antagonistic 
activities on the TRβ as well as T4 competitive properties for the thyroid transporter TTR can 





Figure 1. Study design for the evaluation of TRβ CALUX and TTR-TRβ CALUX bioassays. 
OECD: Organisation for Economic Co-operation and Development.
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Materials and methods 
TRβ CALUX reporter gene assay 
The TRβ CALUX cell line is a human osteoblastic osteosarcoma U2OS line (American 
Type Culture Collection) stably transfected with a pSG5-neo-hTRβ plasmid to express TRβ 
receptors. The plasmid contains a full-length receptor and is expected to be able to 
heterodimerize with RXR expressed endogenously. The cells were additionally transfected 
with a pGL3 (Promega)-based reporter construct containing a luciferase gene linked to two 
copies of TREs (pGL3-2xTRE-Luc) 
(5’agctt/gatatcaggtcatttcaggtcagcatgc/gagctt/gatatcaggtcatttcaggtcagcatgc/g3’ x2).  The TRβ 
CALUX bioassay assesses TREs based responses triggered by TRβ activation, or RXR when 
present in a heterodimer. Either way the thyroid system will be affected: a TRβ/RXR activation 
will induce the transcription of the TRE following the same pathway than a TRβ homo-
dimerization. This activation will consecutively induce the transcription of the T3-related 
genes and genes coding for luciferase protein.  
TRβ CALUX were cultured as described before [2]. In brief, TRβ CALUX cells were 
cultured in Dulbecco’s modified Eagle’s medium and Ham’s F12 medium (DMEM/F12) (Gibco, 
product no.: 31331-028) supplemented with 7.5% charcoal-stripped fetal calf serum (FCS), 
non-essential amino acids (NEAA) (Gibco, product no.: 11140-03) and 10U/mL penicillin and 
10µg/mL streptomycin (P/S) (culture medium). Cells were maintained at 37°C and 5% CO2 at 
all times and sub-cultured every 3-4 days. 
One day prior to the exposure, cultured TRβ CALUX cells were trypsinized and re-
suspended at a final concentration of 1x105 cells/mL in DMEM/F12 medium without phenol 
red indicator supplemented with P/S, NEAA and 5% charcoal-stripped fetal calf serum (DCC) 
(assay medium). Cell suspension was seeded in clear 96-well plates and incubated for a 
minimum of 16 hours and maximum 24 hours in a humidified atmosphere at 37°C and 5% CO2. 
The next day, the medium was removed, and cells were incubated with 200µL of exposure 
medium consisting of DMEM/F12 supplemented with P/S, NEAA and the compound to be 
assessed dissolved in DMSO. To avoid any aspecific proteins’ interference, the exposure 
medium does not contain DCC. For each chemical, 8 serial dilutions were tested to a final 
concentration of 0.1% DMSO, in exposure medium. Each dilution of the test chemicals, 
including the reference compounds, were tested in triplicate. Plates were placed back in the 
incubator at 37°C and 5% CO2 for a period of 24±2 hours. After incubation, the medium was 
discarded, and cells were lysed using 30µL/well of a Triton-lysis buffer. Plates were shaken for 
10 minutes after which luciferase activity in cellular lysates was measured for 4 seconds using 
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a luminometer (Tristar, Berthold). The described procedure is used to determine the agonistic 
potency of chemicals, reflected by light production which can be quantified. For antagonistic 
assessment, the same procedure was followed with the exception that the exposure medium 
was supplemented with a non-saturating level of T3 (1.7E-6 M). Therefore, an antagonistic 
compound is expected to compete with T3 for TRβ binding resulting in a reduction in light 
emission.  
For all measurements, a full dose response dilution series of the reference compound 
was included on each plate for response quantification. To strengthen quality control, a 
positive and a negative compound control as well as a solvent control (DMSO) were added to 
each plate. Regarding the agonistic mode of the TRβ CALUX bioassay, the selected reference 
compound was the natural ligand T3. 3,3’5-triiodothyroacetic acid (TRIAC), a T4-like 
compound was chosen as positive control, and bisphenol A (BPA), a TRs antagonist, as 
negative control. For the antagonist approach, deoxynivalenol was set as the reference, T-2 
mycotoxin (T2-toxin) as the positive control and amiodarone as a negative control. 
TTR- TRβ CALUX: the competitive binding assay and analysis 
Prior to the TTR-binding assay, all compounds including the reference 
tetrabromobisphenol A (TBBPA) were dissolved in DMSO in dark glass vials. TTR and T4 
working solutions were prepared in Tris buffer, made by mixing 12.11g of Tris base (CAS no.: 
77-86-1, Sigma Aldrich), 5.84g NaCl (CAS no.: 7647-14-5, Sigma Aldrich) and 0.372g of 
ethylenediaminetetraacetic acid (EDTA) (CAS no.: 60-00-4, Sigma Aldrich) in 1L of HPLC 
water (J.T Baker). The final Tris buffer pH was adjusted to 8.0. Expected T4 and TTR working 
solution concentrations were 0.08μM and 0.190μM, respectively. The TTR-binding assay is 
based on an incubation mixture containing 100μL of T4, 50μL TTR and 5μL of tested or model 
competitor compound, prepared in a 1.5mL Eppendorf tube (Fig. 2). In order to prevent TTR 
denaturation, it is important to handle the protein carefully and avoid mixing with a vortex at 
any point of the procedure. After one hour of incubation at room temperature, tubes were 
stored at 4°C for at least 20 minutes to overnight. As a next step, self-made Bio-Gel P-6DG 
columns were prepared to separate T4- or test compound-TTR complexes from unbound 
compounds. In short, columns were prepared in 1ml disposable Omnifix®-F Solo syringes (B. 
Braun, product no.: 9161406V). For one 96-well plate, 3g of Bio-Gel P-6DC (Bio-Rad, product 
no.: 150-0739) was dissolved in 30mL of Tris buffer and incubated at 4°C overnight. From this 
point, tubes containing mixtures were kept on ice at any time to avoid the dissociation of the 
compound-TTR complexes. Syringes were placed into 15mL Greiner tubes and approximately 
1.3mL of Bio-Gel was added, followed by a minute of centrifugation at 120g at room 
temperature. Bio-Gel P-6DG columns were transferred into clean collector 15mL Greiner tubes 
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placed on ice, whereupon incubate mixtures were immediately loaded. Columns were 
centrifuged for an additional one minute at 120g. Collected fractions can either be stored up to 
8 days at room temperature or directly tested in the TRβ CALUX bioassay.
  
Figure 2. Diagram of the TTR-TRβ CALUX bioassay. Free T4, potential competitor chemical 
and TTR are incubated as a mixture for 1h at room temperature. Unbound T4 and free chemical 
molecules are separated from TTR complexes using BioGel columns. The bound fraction 
containing T4/TTR complexes is left at room temperature for few minutes in order to allow T4 
to dissociate prior to analysis on the TRβ CALUX bioassay.  
The method of TRβ CALUX testing was carried out essentially as described in 2.1 with 
only slight variations in the exposure method. In short, exposure medium was prepared by 
adding 140µL of TTR-T4 mixture to 500µL of phenol red-free DMEM/F12 medium 
supplemented with non-essential amino acids (NEAA) and P/S. Additionally, quality control 
was included to each plate by filling one triplicate with 200µL of 8e-6M T4 at a final DMSO 
concentration of 0.1%. All data points were carried out in triplicate. After 24±2-hour 
incubation, the exposure medium was removed, and cells were lysed using 10µL/well triton-
lysis buffer. Afterwards, the luciferase activity in cellular lysates was measured with a 
luminometer (Berthold) as described above.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Each TTR-binding assay procedure included the solvent DMSO, in which the reference 
compound, competing chemicals and sample extracts were dissolved, as a solvent control. For 
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normal testing, one dilution series of the reference compound TBBPA was added to each plate 
as a quality control for the proper functioning of the assay. For each compound, a second 
negative control including TTR and the assessed competitor, without the addition of T4, was 
included to the procedure. This step allowed to evaluate potential direct interactions between 
the tested compound and TRβ. 
Compound selection and evaluation guidelines 
The evaluation of the bioassays was conducted following the Organisation for Economic 
Co-operation and Development (OECD) guidelines (OECD 2015). According to OECD 
requirements intra- and inter-laboratory studies have to be performed. In this paper, only the 
intra-laboratory phase was conducted. As in the foreseeable future, TRβ CALUX bioassays will 
be evaluated side by side with other thyroid-relevant endpoints such as thyroperoxidase (TPO), 
TBG and deiodinase activities as a part of a larger study organized by the European Union 
Reference Laboratory for alternatives to animal testing (EURL-ECVAM). The intra-laboratory 
evaluation described in this paper required the generation of three lists of compounds chosen 
for their properties to interact or not with the TRβ and/or TTR. While the selection was mainly 
built on literature review, we selected few additional chemicals from our own internal 
database. For intra-laboratory assessment of the TRβ CALUX bioassay (agonistic mode), an 
initial set of eighteen chemicals were chosen (See Annex 2, Table 1). There are very few 
compounds referred in literature for their agonistic interaction with TRβ besides the four well 
known TRb agonists (T3, T4, 3,3’5,5’-tetraidothyroacetic acid TETRAC and TRIAC). Hence, 
along with these chemicals, we decided to also include two compounds from our internal 
screening that showed a weak response on the TRβ (2-acetamidofluorene 2-AAF and all trans-
retinoic acid atRA). To complete this set we incorporated 10 non-active chemicals, 5 were 
derived from a literature review (1-850, amiodarone, bisphenol A (BPA), endosulfan and 
TBBPA) and 5 from our own database (aflatoxin B1, dieldrin, methoxyacetic acid, valproic acid 
and vinclozolin). T2-toxin and hydroquinone were also analyzed on the TRβ CALUX bioassay 
but not included in the performance calculations as no prior data were reported at the time of 
the study. 
A list of fifteen chemicals were established to test the reliability of the antagonistic TRb 
CALUX assay (See Annex 2, Table 2). Nine antagonistic compounds were selected from 
literature (1-850, 4-nonyphenol, BPA, deoxynivalenol, dibutylphthalate, endosulfan, 
pinoresinol, TBBPA and zearalenone). We also included the mycotoxin T2-toxin due to its 
antagonistic characteristics found in previous unpublished results obtained in our laboratory. 
Four chemicals were chosen for their non-active properties (aflatoxin B1, amiodarone, 
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dronedarone and T3). We decided to include the RXR ligand at-RA to our study to assess its 
potential activity on the TRβ. 
To test the TTR-TRβ CALUX bioassay, eleven compounds were assessed for their 
interference with the T4-TTR binding. Nine compounds were selected based on published 
information on their capacities to interact with either TRβ or TTR (4-nonyphenol, BPA, 
diethylstilbestrol (DES), pentabromophenol (PBP), pentachlorophenol (PCP), 
perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), TBBPA and 
tetrachlorobisphenol A (TCBPA)). Alachlor is known to be inactive and was chosen from 
literature. T2-toxin was included based on results obtained during an internal screening. 
The evaluation procedure included a pre-screen step followed by at least two independent 
comprehensive measurements (biological replicate = 3). The general objectives of a pre-screen 
are to determine the solubility of test chemicals in both DMSO and assay medium and assess 
their potential cytotoxicity towards U2OS cells. Therefore, during this pilot phase, all 
concentration tested in the (anti-)TRβ CALUX bioassays were also assessed on the Cytotox 
CALUX® bioassay that can be used to assess non-specific CALUX assay interferences, e.g. 
caused by cytotoxicity (Sonneveld et al. 2005; Van der Linden et al. 2014). In short, the Cytotox 
CALUX bioassay uses U2OS cell line which constitutively express luciferase, the addition of 
cytotoxic compound to the cells would consequently result in a reduction in light production 
quantifiable with a luminometer. For the pre-screen, 8 serial dilutions of each compound were 
made from the highest soluble concentration using 10-step dilutions. In order to obtain a 
proper full dose response curve, the highest concentration tested should not be cytotoxic 
(cytotoxicity ≤ 20%). If one or several dilutions induced cytotoxicity, the test was repeated 
using lower concentrations (Annex 1. Table 1-3). Results of the pre-screen study were used to 
refine the concentration ranges of the test compounds to be used for the comprehensive 
studies. Unlike the pre-screen phase, comprehensive measurements were based on 3-step 
dilutions prepared from the highest concentration of each chemical not showing cytotoxicity. 
In case the results of the comprehensive tests were divergent to each other, a third 
measurement was added to the study increasing the biological replicates from 3 to 4. Each 
dilution of the test chemicals including the reference compounds were tested in triplicate on 
the same 96-well plate. 
Data handling and acceptance criteria 
Luciferase activity per well was expressed as Relative Light Units (RLUs) and corrected 
for background using solvent control measurements (pure DMSO). The maximum signal 
response elicited by the reference compound was set to 100% (full receptor activation). 
Chapter Four 
94 
Subsequently, all registered RLU produced by the test compounds or samples were expressed 
in % of maximum response of the reference compound. The statistical software package 
GraphPad Prism 5.0 was used to fit transformed data (non-linear regression, variable slope, 4 
parameters and robust fit). Compounds were scored positive if a minimum of two consecutive 
concentrations showed an increase of at least 10% (PC10, agonist mode) or a decrease in TRβ 
activation of more than 20% (PC80, antagonist mode) of the maximal effect of the reference 
compound. Depending on the selected mode of the TRβ CALUX bioassay, either EC50 or IC50 
were evaluated using the same software package. EC50 refers to the maximal induced effect of 
the compound tested. For the antagonist procedure, 50% maximal inhibitory concentration 
(IC50) was evaluated for each chemical and compared with available data in literature, if 
available. EC50 and IC50 can be used to assess and rank the potencies of tested chemicals. For 
agonistic studies, the limit of detection (LOD; average (solvent blank) +3*SD (solvent blank))) 
and the limit of quantitation (LOQ; average (solvent blank) +10*SD (solvent blank))) were also 
determined for all plates based on the standard deviation of the solvent blank DMSO. Z-factor 
was systematically calculated for the reference compound according to the following formula 
(1). Z-factor values should be above 0.6 to fit the acceptance criteria. 
(1) 
 
For the evaluation of intra-laboratory assessment results, the coefficient of variance 
(%CV) and reproducibility (%VCR) were calculated. The intra-laboratory coefficient of variance 
was determined based on the average log (EC50) and log (PC10) (agonist), and log (IC50) and log 
(PC80) (antagonist) derived from both comprehensive test runs. In addition, the intra-
laboratory reproducibility variation coefficient was determined based on the log (EC50) and log 
(PC10) (agonist), and log (IC50) and log (PC80) (antagonist) derived from both comprehensive 
test runs. The reproducibility is the variation in measurements taken by a single/multiple 
persons or instruments on the same item at different time-points. Reproducibility was 
calculated according to formula (2).  






× 100%  
%VCR = reproducibility variation coefficient 
       xi1 = measuring result ith determination first observation 
 




      n = number of determinations 
 
The qualitative intra-laboratory concordance of classifications (active/non-active) was 
determined based on the results of two independent comprehensive tests under reproducibility 
conditions. From these results, overall accuracy, sensitivity, and predictability of the methods 
were calculated and expressed as a percentage.  
Demonstration study using water samples   
Spiked water sample 
In order to assess the TTR-TRβ CALUX assay applicability for environmental studies, 
HPLC-grade water was spiked with three pure compounds: DES, TCBPA and PBP, under 
controlled conditions. These three chemicals were defined as T4-competitors in the previous 
TTR-TRβ CALUX evaluation, allowing us to further calculate the relative potency resulting 
from their mixture. All compounds were dissolved in methanol (MeOH) to a stock 
concentration of 2.5E-3M. 120µL of this mixture was added to 250mL HPLC-grade water, 
resulting in a final concentration of 4.1E-7M for each of the spike-compounds. A procedure 
blank, consisting of 250mL of water with MeOH, was also included into the experiment. 
Samples were extracted using Solid Phase Extraction (SPE) columns (OASIS HLB SPE 
cartridges 500mg 6 cc, Waters product no.: 186000115) conditioned with approximately 
500ml of water and eluted with 10ml of MeOH followed by 10ml of acetonitrile. Fractions were 
pooled and evaporated until dryness under a gentle stream of nitrogen at 40°C. The final 
extracts were dissolved in 100µL of DMSO in order to keep the concentration of the spiking 
mixture and extract equal. The diluted extracts (dilution series 1-3-10-30-100-300-1000-
3000-10000-30000x) as well as the neat spiking mixture were tested on the TTR-TRβ CALUX 
assay and analyzed following the procedure previously described in section 2.2. 
Environmental water samples 
Two effluent samples collected from a wastewater treatment plant and one HPLC-water 
blank were extracted and analyzed following the previously described method (2.5.1). In short, 
1L of each sample were extracted through SPE columns eluted with 10ml of MeOH and 10ml 
of acetonitrile. After evaporation, the final extracts were dissolved in 150µl of DMSO and used 
to prepare serial dilution (1-3-10-30-100x). A first range finding analysis was performed in the 
TTR-TRβ CALUX bioassay to obtain the appropriate dose-response range of the sample 
extracts. Based on which the dilution series was adjusted (1-1.5-2-2.5-3-10x) and extracts were 




Determination of thyroid receptor agonistic activity of compounds using 
TRβ CALUX bioassay 
 
The sensitivity and responsiveness of the TRβ CALUX assay were assessed by 
measuring the signal of the reference compound T3 along with eighteen chemicals (see Annex 
2. Table 1.). This set contained known TRβ agonists and chemicals that showed no affinity 
towards the TRβ receptor, also referred to as “non-responders”. As a start, the performance 
and stability of the agonist test were determined by comparing EC50 values of the reference 
compound, T3 from the different measurements (Table 1; Fig. 3). The range in EC50 values was 
small, reflected by a %CV of 0.8%. Additionally, the LOD and LOQ were calculated for each 
measurement and compared. The variations in LOD and LOQ values were low (%CV≤1%) 
clearly indicating that the TRβ CALUX bioassay is a stable bioassay producing repeatable 
results. 
 
Table 1. Log EC50, PC10, PC50, LOD and LOQ values for the reference agonistic compound T3 
on the TRβ CALUX bioassay. 
 
Run log EC50 (M) log PC10 (M) log PC50 (M) log LOD (M) log LOQ (M) 
Pre-screen -9.77 -10.28 -9.74 -10.99 -10.51 
Comprehensive 1 -9.88 -10.37 -9.85 -10.84 -10.36 
Comprehensive 2 -9.92 -10.43 -9.92 -10.80 -10.32 
Average -9.86 -10.36 -9.83 -10.88 -10.40 
%CV 0.8% 0.7% 0.9% 0.9% 1.0% 
Note: Average represents the average values and %CV corresponds to the calculated coefficient of 




Figure 3. Dose-response curves obtained with the reference compound T3, analyzed at least 
twice for the prescreen and each comprehensive. Each point represents the average of these 
measurements. 
Next, the panel of test compounds was tested on the TRβ CALUX assay by two different 
technicians. Out of these eighteen chemicals, six scored positive on the agonistic bioassay 
(Table 2). The TRβ CALUX bioassay gave a general z-factor of 0.89. Whereas T3, T4, TRIAC 
and TETRAC provided similar full dose-response curves, both at-RA and 2-AAF showed 
differences in shape and lower activity resulting in an absence of PC50 value (Fig. 4). All the 
natural THs, as well as their analogues TRIAC and TETRAC (T3 and T4-like, respectively), 
showed agonistic activities. Regarding this valuation, 2-AAF scored positive due to the fact of 
its low but still noticeable activity (Fig 4). Indeed, this compound showed a slight partial 
agonistic response on the TRβ CALUX bioassay matching preset OECD scoring criteria of at 
least two consecutive points above 10% T3’s activity to be considered as an active chemical. 
Following the same criteria, at-RA was also scored positive in the bioassay. Whereas 2-AAF 
showed no cytotoxicity at high concentration, at-RA was reported as cytotoxic at the highest 
concentration tested (i.e. 3.E-5M and higher) (data not shown). Although the activity was quite 
low both 2-AAF and at-RA were defined as activators of the TRβ. From the initial list, twelve 
compounds (1-850, aflatoxin B1, amiodarone, methoxyacetic acid, BPA, dieldrin, endosulfan, 
hydroquinone, T2-toxin, TBBPA, valproic acid and vinclozolin) scored negative on the agonist 
TRβ CALUX bioassay (data not shown).  



























Table 2. Log EC50, PC10 and PC50 values for positive expected and tested compounds in agonist 
















avg -9.44 -10.13 -9.48 
1.0 active active 
%CV 0.80% 1.60% 0.80% 
2-AAF 
avg -6.15 -5.54 n.a. 
2.8 active unknown 
%CV 0.1% 3.6% n.a. 
at-RA 
avg -6.26 -6.25 n.a. 
5.9E-1 active unknown 
%CV 0.3% 0.4% n.a. 
T4 
avg -9.01 -9.75 -9.05 
5.8 active active 
%CV 0.4% 0.6% 0.1% 
TRIAC 
avg -10.8 -11.6 -10.9 
3.5E-1 active active 
%CV 0.5% 0.7% 0.3% 
TETRAC 
avg -9.30 -9.73 -9.02 
2.2E+1 active active 
%CV 0.3% 1.2% 3.7% 
Note: Average represents the average values and %CV corresponds to the calculated coefficient of 
variation for two comprehensive measurements. 
 
Figure 4. Dose-response curves of positive compounds obtained in the agonist mode of the 
TRβ CALUX bioassay. 
 
 






























Determination of thyroid receptor antagonistic activity of pure compounds 
using TRβ CALUX bioassay 
The accuracy and reliability of the antagonistic mode of the TRβ CALUX bioassay were 
investigated using the reference compound deoxynivalenol along with 15 pure chemicals (see 
Annex 2. Table 2.). Deoxynivalenol was first assessed alone in three separate experiments 
performed by at least two technicians. Both prescreen and comprehensive tests gave similar 
dose-response curves, resulting in low variation between the calculated log IC50 (%CV = 1.4%) 
(Table 3. Fig. 5). The repeatability of the method was reflected by an overall %CV ≤ 4.1% while 
the calculated reproducibility %VCR was even lower (=1.35%). These finding confirm the 
stability of the antagonistic TRβ CALUX bioassay in generating reproducible results. 
Table 3. Log IC50, PC50, PC80 values for deoxynivalenol in the antagonist mode of the TRβ 
CALUX bioassay. 
Run log IC50 (M) log PC50 (M) log PC80 (M) 
Pre-screen -6.28 -6.29 -6.68 
Comprehensive 1 -6.14 -6.15 -6.58 
Comprehensive 2 -6.14 -6.18 -6.18 
Average -6.18 -6.21 -6.48 
%CV 1.3% 1.2% 4.1% 
Note: Average represents the average values and %CV corresponds to the calculated coefficient of 
variation for three measurements.  
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Figure 5. Dose-response curves of deoxynivalenol obtained in the antagonist mode of the TRβ 
CALUX bioassay. The reference compound was analyzed at least twice for the prescreen and 
each comprehensive. Each point represents the average of these measurements. 
Fifteen pre-selected chemicals were tested in the TRβ CALUX bioassay in order to 
determine their thyroid receptor antagonistic potential. Nine chemicals showed antagonistic 
activity with different potency and shape of dose-response curves (Table 4, Fig. 6.a.b.). None 
of the tested compounds were found to be cytotoxic in the assessed concentration range 
indicating that the decrease in activity represents antagonistic activity. 1-850, at-RA, 
amiodarone, BPA and zearalenone all scored positive but did not give a full-dose response 
curve as their higher concentration did not induce full antagonism. Alongside with 4-
nonyphenol and deoxynivalenol, TBBPA showed a full dose-response curve indicating the 
complete inhibition of the TRβ receptor activation. The mycotoxin T2 showed activity in the 
anti-TRβ CALUX bioassay which was higher in logIC50 than any in the compound set. Six 
compounds (aflatoxin B1, dibutylphthalate, dronedarone, endosulfan, pinoresinol and T3) did 
not show activity nor fit the preset criteria of the bioassay. 
As a quality criterion, %CV was calculated for each compound and an average z-factor 
was given (0.72). All chemicals showed good repeatability in their results and thereby showed 
a good stability of the antagonistic TRβ CALUX bioassay (0≤%CV≤3.5%).  
 


























Table 4. Log IC50, PC80 and PC50 values for positive expected and tested compounds in the 
antagonist mode of the TRβ CALUX bioassay. 
 














avg -6.22 -6.54 -6.21 
1 active active 
%CV 0.60% 0.70% 3.50% 
1-850 
avg -5.02 -5.19 -4.93 
4.50E-02 active active 
%CV 1.00% 0.20% 0.30% 
4-nonylphenol 
avg -5.45 -5.63 -5.45 
1.20E-01 active active 
%CV 1.00% 2.70% 1.60% 
at-RA 
avg -4.75 -4.96 -4.75 
2.60E-02 active unknown 
%CV 1.10% 0.20% 3.50% 
amiodarone 
avg -5.59 -5.95 -5.59 
2.60E-01 active active 
%CV 2.30% 0.70% 3.50% 
BPA 
avg -4.96 -4.73 -4.45 
1.50E-02 active active 
%CV 0.50% 1.70% 0.00% 
TBBPA 
avg -6.07 -6.62 -6.15 
1.2 active active 
%CV 1.00% 0.70% 3.50% 
zearalenone 
avg -4.51 -4.8 -4.51 
1.80E-02 active active 
%CV 0.30% 1.10% 0.40% 
T2-toxin 
avg -8.47 -10.38 -10.5 
6.90E+03 active unknown 
%CV 0.00% 0.10% 0.00% 






 Figure 6.a.b. Representative dose-responsive curves of tested chemicals obtained using the 
antagonist mode of the TRβ CALUX bioassay. Each data point is the mean of at least two 
measurements. 
 
Evaluation of the TTR-TRβ CALUX bioassay 
The test design of the evaluation of the TTR-TRβ CALUX bioassay was based on eleven 
pure compounds selected on their abilities to interact with TTR according to the literature (see 
Annex 2. Table 3). As a start, the performance of the reference compound TBBPA was 
investigated in three independent experiments performed by at least two different technicians. 
The shape of the dose-response curves was similar between the individual experiments, giving 


























































These results indicate the stability of the TTR bioassay when used in combination with the TRβ 
CALUX. 
Table 5.  Log IC50, PC50 and PC80 values for TBBPA reference compound measured in the TTR-
TRβ CALUX bioassay. 
Run log IC50 (M) log PC50 (M) log PC80 (M) 
Pre-screen -7.66 -7.66 -8.10 
Comprehensive 1 -7.77 -7.64 -7.92 
Comprehensive 2 -7.57 -7.59 -8.0 
Average -7.67 -7.63 -8.01 
%CV 1.3% 0.5% 1.1% 
Note: Average represents the average values and %CV corresponds to the calculated coefficient of 
variation for three measurements. 
 
Figure 7. Dose-response curves obtained with the reference compound TBBPA in TTR-TRβ 
CALUX. TBBPA was analyzed at least twice for the prescreen and each comprehensive. Each 
point represents the average of these measurements. 
In addition, a panel of potential T4-TTR binding competition positive chemicals was 
assessed following the same procedure. Associated TTR-binding potencies were expressed as 
log concentration at 50% inhibition for T4 (Table 6). A general z-factor value of 0.74 was 
calculated. For each compound, %CV were calculated for logIC50, logPC80 and logPC50. All test 
chemicals (4-nonyphenol, BPA, DES, PBP, PCP, PFOA, PFOS, T2-toxin, TBBPA and TCBPA) 
with the exception of alachlor, showed binding inhibition responses and were reported as 
competitors for T4-TTR binding (Fig. 8). BPA demonstrated capacity to compete with T4 for 


























binding TTR, however no IC50 could be calculated due to the fact that this compound did not 
give a full dose-response curve (data not shown). Out of eleven compounds tested, ten showed 
T4-competing properties with a stronger effect from perfluorinated chemicals PFOA and PFOS 
and the reference chemical TBBPA. 
Table 6. Log IC50, PC80 and PC50 values for positive expected and tested compounds in TTR-
TRβ CALUX bioassay. 
 








avg -7.81 -8.06 -7.79 
1  active  active  
%CV 0.50% 0.30% 0.10% 
4-
nonylphenol 
avg -4.12 -4.54 -4.23 
3.00E-04  active  active  
%CV 3.70% 17.30% 9.90% 
BPA  
avg  -4.27 -3.32 
1.60E-04  active  active  
%CV   5.60% 5.10% 
DES  
avg -6.68 -7.03 -6.67 
9.30E-02  active  active  
%CV 1.50% 2.00% 0.70% 
PBP  
avg -6.59 -6.9 -6.61 
6.90E-02  active  active  
%CV 0.50% 3.30% 1.50% 
PCP  
avg -4.47 -4.79 -4.47 
5.40E-04  active  active  
%CV 0.30% 1.30% 0.20% 
PFOA  
avg -7.5 -7.74 -7.41 
4.80E-01  active  active  
%CV 1.30% 1.10% 2.20% 
PFOS  
avg -7.22 -7.45 -7.15 
2.50E-01 active active  
%CV 0.80% 0.50% 0.40% 
T2-toxin  
avg -6.0 -6.08 -5.91 
1.00E-02  active  unknown  
%CV 0.50% 1.20% 0.50% 
TCBPA  
avg -6.77 -7.03 -6.73 
9.30E-02  active  active  
%CV 1.80% 1.10% 1.40% 
Note: Avg represents the average and %CV corresponds to coefficient of variation for two comprehensive 
measurements. For abbreviations refer to 2.4. 
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Figure 8. Dose-response curves of DES, PFOA, PBP, TBBPA and TBCPA in the TTR-TRβ 
CALUX. Each data point is the mean of at least two measurements. 
 
Demonstration study: water samples 
Spiked water sample 
Water (HPLC-grade) was spiked with a mixture of three compounds (DES, TCBPA and 
PBP) with dilution steps of 1, 3, 10, 30, 100, 300, 1000, 3000, 10000 and 30000. After the 
extraction procedure, extract obtained from spiked water was tested in the TTR-TRβ bioassay 
alongside the original spiking mixture (Fig. 9). So as to evaluate the quality of the SPE 
extraction, results obtained from the mixture itself and the spiked water sample were 
compared revealing a recovery value of 101.3% based on PC80 values. The global potency of the 
mixture was calculated and expressed as TBBPA equivalent, giving a value of 3.17E-05M. 
Overall, this experiment suggested that the TTR-TRβ bioassay used in combination with SPE-






























Figure 9. Dose-response curves from reference compound TBBPA, mixture and extract from 
spiked water sample tested in TTR-TRβ-CALUX. The mixture consisted of DES, PBP and 
TCBPA at a final individual concentration of 4.1e-7M. 
 
Environmental water samples 
To determine the applicability of the TTR-TRβ bioassay for analysis of potential thyroid 
disrupting chemicals in environmental waters, two wastewater treatment plant samples were 
analyzed. Along with these samples, HPLC-water was used as a procedure blank control and 
did not show any binding activity towards TTR. Both samples from the wastewater treatment 
plant demonstrated a significant dose-dependent T4-TTR binding competition (Fig. 10).  
Figure 10. Dose-response relationships of wastewater and HPLC-water samples analyzed in 
TTR-TRβ CALUX bioassay. 
 






















































Regarding the fact that no set of recommended chemicals for thyroid disruption was 
available at the time the study began (2015), a preliminary review was performed so as to 
generate a list of reference compounds suitable for the evaluation of each aspect of the thyroid 
panel. From literature, nine, twelve and ten compounds were chosen for assessing the 
agonistic, antagonistic TRβ CALUX and TTR-TRβ CALUX assays. Along with these reference 
chemicals, nine, three and one other compounds were respectively added to the sets. These 
compounds were considered of interest based on results obtained during an internal screening. 
While jointly evaluated on the panel, none of these additional chemicals were used in 
predictability nor accuracy calculations, which were strictly based on the compounds properly 
reported in literature. The evaluation of each thyroid-related bioassay relies on this 
preliminary work.  
In 2016, Wegner et al. reviewed Tier 1 endocrine screening assays and generated a list 
of 34 reference chemicals to be used to assess thyroid system’s alterations, however it is unclear 
which mechanism were involved in this disruption. In this paper, we focused on assessing the 
(ant)agonistic potency of compounds on one TH receptor using a reporter gene assay (TRβ 
CALUX) and one non-receptor-based TH- response (TTR assay), the later one based on 
previous research of our group on competitive binding interference of compounds to TTR. 
Hence, it was crucial for our study to select compounds with available in vitro information 
regarding their potential receptor or transporter disrupting activities. Nevertheless, it would 
be of interest to analyze the set of chemicals provided by Wegner et al. (2016) in the future. 
Within this study, we have developed a robust CALUX-based test method to assess the 
agonistic and antagonistic potency of chemicals towards the TRβ, as well as T4-TTR binding 
competition potencies of chemicals. The evaluation of both agonistic and antagonistic TRβ 
CALUX assays showed low variations in EC50 (≤0.8%) and IC50 (≤4.1%) measurements and 
high z-factor values (0.89 and 0.72, respectively), indicating a good reproducibility of the 
methods.  
The TRβ CALUX assay generated consistent results in comparison with existing data. 
The rank order of agonistic potency of active THs (T3 and T4) and chemicals with similar 
structure (TETRAC and TRIAC) was established as TRIAC>T3>TETRAC>T4, matching the 
results found in literature (Cheek et al. 1999; Gutleb et al. 2005). Unlike these very active 
compounds (logEC50≥9.00), at-RA and 2-AAF showed a weak activity in the TRβ CALUX 
bioassay (logEC50=6.26 and 6.15, respectively). at-RA is a well-established ligand for retinoic 
X receptors (RXR), receptor able to act as heterodimer with TRβ (Hsu et al. 1995; Zhang et al. 
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1992). In our case, although a higher concentration of at-RA led to cytotoxicity (Annex 1. Table 
1), we observed that this compound elicits an aberrant transactivation of the TRβ which may 
be the result of RXR binding rather than a direct interaction with TRβ itself. 2-AAF also showed 
two points above 10% in the TRβ bioassay suggesting at least a partial agonistic activity towards 
the TRβ. In a general way, even though at-RA and 2-AAF were slightly active on the TRβ 
CALUX bioassay, we were not able to classify them with certainty due to the lack of available 
data at the time of the study. Overall, besides these six compounds (2-AAF, at-RA, T3, T4, 
TETRAC and TRIAC), all chemicals tested scored negative when assessed for TRβ agonistic 
activity. Although only few reports have related TRβ agonists, most of these negatively scored 
compounds were clearly reported antagonists and thus, were expected to be inactive in the 
agonist TRβ bioassay. As examples, amiodarone, BPA and TBBPA were all reported TRβ 
antagonists in literature, as well as the well-established antagonist reference compound 1-850 
(Drvota et al. 1995; Moriyama et al. 2002; Schapira et al. 2003; Sun et al. 2009). No data were 
available regarding agonistic activity towards TRβ of the aflatoxin B1, T2-toxin, hydroquinone 
or valproic acid preventing us from comparing our results with existing data. Whereas these 
compounds require a closer examination to be part of the evaluation, we still classified them 
as inactive for the agonistic TRβ bioassay.  
Overall, out of eighteen compounds tested, half (2-AAF, at-RA, aflatoxin B1, dieldrin, 
hydroquinone, methoxyacetic acid, T2-toxin, valproic acid and vinclozolin) were not used in 
predictivity and accuracy calculations due to the lack of reference data. For the compounds for 
which reference values were available, the agonist mode of the TRβ-CALUX bioassay showed 
a predictivity and accuracy of 100% (9/9). This study allowed the classification of yet unknown 
compounds, dieldrin, hydroquinone, methoxyacetic acid, T2-toxin, valproic acid and 
vinclozolin as non-responders and 2-AAF and at-RA as a weak TRβ agonist. It is not excluded 
that 2-AAF might act using an RXR-like dependent pathway, since it showed a similar dose-
response curve as at-RA. Although we used a limit set of compounds, the results obtained from 
this intra-laboratory appraisal were promising and consistent with currently available data. 
Outcomes acquired through the anti-TRβ CALUX evaluation showed a good correlation 
with existing data. In line with previously reported results, compound 1-850, BPA and TBBPA 
all scored positive in the antagonistic TRβ CALUX bioassay (Moriyama et al. 2002; Schapira 
et al. 2003; Sun et al. 2009). Alongside with the known antagonist deoxynivalenol, 4-
nonylphenol and TBBPA showed a complete inhibition of the TRβ receptor activation resulting 
in a full dose response curve (Demaegdt et al. 2016). Surprisingly, at-RA was active on both 
agonist and antagonist modes of the TRβ CALUX bioassay. Amiodarone and zearalenone also 
showed TR antagonistic activity in the TRβ CALUX bioassay. Previous studies reported these 
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two compounds as antagonist of the TRβ which matched our results (Demaegdt et al. 2016; 
Drvota et al. 1995; Kiss et al. 2018). Interestingly, whereas mycotoxins like deoxynivalenol and 
zearalenone were already reported as TRβ antagonist, no prior data about were found T2-toxin 
at the time of writing (Demaegdt et al. 2016; Kiss et al. 2018). According to our results, T2-
toxin is the most potent compound from the tested set (log IC50=8.47). Along with 
deoxynivalenol and zearalenone, mycotoxins seem to present strong endocrine disrupting 
activities targeting TRβ. In this way, mycotoxins including T2-toxin will be of particular 
interest for further studies. Contrary, dibutylphthalate, endosulfan, pinoresinol and T3 were 
all found not to be antagonistic in the TRβ-CALUX bioassay. Whereas dibutylphthalate, 
endosulfan and pinoresinol were reported as antagonists in former studies no activity was 
measured in our bioassay (Kiss et al. 2018; Ogungbe et al. 2014; USEPA 2020). No data 
allowed us to confirm the antagonistic potential of these two compounds neither of at-RA, 
aflatoxin B1 nor T2-toxin. In this respect, these three compounds were excluded from 
predictivity calculations. Overall, the intra-laboratory evaluation demonstrated a good 
consistency with a global accuracy of 75% (9/12). 
Used in combination with the TRβ CALUX, the TTR-binding assay reported consistent 
results based on comparison with existing data. In 1999, Meerts et al. classified TBBPA and 
TCBPA as T4 competitors in a radioactivity-based study, which entirely matched with our 
results (Meerts et al. 2000). In 2011, Cao et al assessed BPA using fluorescence probes and 
reported it as a weak competitor for TTR. In the present study, this compound also 
demonstrated capacity to compete with T4 at high concentration (1E-4M and higher) in the 
TTR-TRβ CALUX bioassay. As a whole, although we were not able to define an IC50 value, BPA 
matched our acceptance criteria of at least 20% diminution of TRβ activation and thus, was 
classified as a T4-TTR competitor (Cao et al. 2011). 4-nonyphenol, DES, PBP and PCP also 
showed T4-TTR binding competition activity with a calculated IC50 in the same range as data 
found in prior TTR-related studies (Ishihara et al. 2003; Meerts et al. 2000; Simon et al. 2013; 
van den Berg 1990). Perfluorinated chemicals PFOA and PFOS showed a high potency to bind 
TTR, confirming what has already been reported in prior study using a combination of TTR-
binding and radiolabeled assays (Weiss et al. 2009). T2-toxin based measurements gave an 
IC50 of 1.00E-06M suggesting competitive properties towards T4, which has never been 
reported in literature at the time of the study. In contrast, alachlor is known not to compete for 
TTR-binding which was coherent with our results generated using the TTR-TRβ CALUX 
(Cheek et al. 1999). TTR seems to be an important target for compounds who interfere with 
the thyroid system, emphasizing the importance of developing test tool for assessing potential 
T4 competitors. Results obtained from our study demonstrated the reproducibility and 
stability of the TTR-TRβ CALUX while showing a good correlation with existing data.  
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The newly developed panel allows the assessement of yet unknown chemicals towards 
TRβ, as well as their possible interferences with T4/TTR binding. Using TRβ CALUX bioassay, 
a compound can be assessed for both agonistic and antagonistic activities. With the natural 
thyroid hormone T3 as a reference, an increase of at least 10% in TRβ activation allows to score 
the chemical as a TRβ agonist. Based on PC10 or EC50 values, it is possible to calculate the 
compound’s relative potency expressed as a percentage of the reference’s activity. A relative 
potency value above 1 suggests that the compound is more potent than the natural ligand while 
if below 1, a higher concentration is required to affect TRβ the same way as T3. This calculation 
provides an easy way to determine the potency of a new chemical, and to compare it with other 
compounds or existing data. In a similar way, antagonistic potential can be assessed in the TRβ 
CALUX bioassay. A decrease in TRβ activiation of more than 20% of the maximal effect of the 
reference compound deoxynivalenol suggests that the test compound presents antagonistic 
properties towads the receptor. Relative potency can be calculated based on either PC80 or IC50 
values, allowing to compare the unknown chemical potency to others. A new chemical can be 
also assessed for T4 competition regarding TTR binding using the TTR-TRβ CALUX bioassay. 
Two points below 80% of the reference TBBPA’s activity implies a competitive activity from 
the unknown compound. Its potency can be calculated and expressed as a TBBPA’s potency 
percentage using PC80 or IC50 values. Overall the present panel is able to generate data 
regarding direct activity towards TRβ, while giving informations about their potential capacity 
to bind TTR thus, to pass through the blood brain barrier and the uterine-placental wall. 
The demonstration study using water samples as an example, showed a positive case 
regarding potential thyroid hormones disrupting compounds activity in wastewater. No sign 
of TTR-binding potency was registered in HPLC water. An interesting follow-up of this case-
study would be to collect waste water samples at different stages of treatment in a waste water 
treatment plant and analyze them in all variants of the panel in order to first determine the 
agonistic or antagonistic potential of these samples and secondly, evaluate the efficiency of 
various treatment procedures.   
Overall, the in vitro TTR-TRβ CALUX assay appears to be a simple efficient method for 
assessing TTR binding disruption, giving a cheaper and safer alternative to other currently 
available bioassays mostly using radioactivity. This system was added to the (anti-)TRβ 
CALUX set so as to develop a mini test panel to assess the thyroid disruptive potential of 
various compounds at multiple levels. Also, the proposed battery can be performed alongside 
with the AR- and ER- CALUX bioassays in order to cover a variety of endpoints related to EATS 
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Per- and polyfluoroalkyl substances (PFAS) have been detected in body fluids (e.g. 
serum, cord blood, breast milk) and were hypothesised to interfere with the thyroid hormone 
(TH) system in plasma, by disrupting the transthyretin (TTR)-based TH-transport. In the 
present study, we investigated the effects of a set of PFAS compounds on the thyroid system by 
evaluating their capacity to compete with thyroxine (T4) for binding and transport on TTR as 
well as directly interacting with the thyroid receptor β (TRβ) in target cells. We also 
investigated whether human breast milk samples would contain TH-disrupting activity 
possibly associated with the presence of PFAS and related TH disrupting contaminants. 
Thirteen PFAS compounds were evaluated for their potential interactions with TRβ using the 
in vitro TRβ CALUX® reporter gene assay. This same set of compounds was subsequently 
analyzed on the TTR-TRβ CALUX assay to investigate the binding competition potency of each 
chemical compared to T4 to TTR. Subsequently, possible endocrine active compounds (EACs), 
including PFAS, were extracted from ten breast milk samples collected from mothers 
participating in the Norwegian HUMIS birth cohort. Extracts were analyzed in the TRβ- and 
TTR-TRβ CALUX assays. The concentration of perfluorooctanoic acid (PFOA) and 
perfluorooctane sulfonate (PFOS) in each sample was used to evaluate their possible 
contribution to the observed activity. None of the tested PFAS compounds demonstrated a 
direct agonistic activity towards the TRβ receptor in the TRβ CALUX reporter gene assay. 
However, seven PFAS compounds showed antagonistic activity in the anti-TRβ CALUX assay. 
All the PFAS compounds showed competitive binding properties with T4 on TTR using the 
TTR-TRβ-CALUX assay, albeit with different potencies. Antagonistic, but no agonistic activity, 
was observed in most breast milk extracts in the TRβ CALUX assay, with a potency equivalent 
to 0.41-3.6 µg deoxynivalenol eq./g of milk. Measurements demonstrated that all samples but 
one showed T4-TTR binding competitive potency, ranging from 0.41 to 9.1 µg PFOA eq./g of 
milk however, only a small percentage of the activity could be explained by PFAS. These results 
showed that PFAS are potent disruptors of the thyroid system by being able to compete with 
TH for TTR-transportation and by antagonizing TRβ activation. Moreover, our study indicates 
that breast milk from Norwegian mothers commonly have thyroid-disrupting activity, which 





Poly- and perfluoroalkyl substances (PFAS) are industrial surfactants commonly used 
in a myriad of commercial products, e.g., textiles, food packaging, fire-fighting foam since the 
1950s (Kissa 2001). PFAS are toxic at low concentration for both humans and animals, this 
together with the fact that they are practically non-biodegradable and extremely persistent in 
the environment, has lead to the implementation of manufacturing limitations under the 
Stockholm Convention on Persistent Organic Pollutants (Stockholm Convention 2008) in 
2009 and by the US Environmental Protection Agency in 2013 (US EPA 2013). Despite these 
restrictions in manufacturing and use, humans and wildlife continue to be affected by PFAS 
accumulated in sediments, agricultural soil, ground- and surface water, contributing to the 
increase of body burdens and associated deleterious effects (Skutlarek et al. 2006; Zareitalabad 
et al. 2013).  
The majority of PFAS including the most studied ones, perfluorooctanoic acid (PFOA) 
and perfluorooctane sulfonate (PFOS), share a polar hydrophobic structure allowing their 
interaction with various binding proteins e.g. albumin and globulins (Luebker et al. 2002). 
Over the past decades, toxicological studies, using rodents and primates, have shown the 
impact of PFAS on the thyroid hormone (TH) system, such as a significant decrease in 
circulating TH levels (Chang et al. 2008; Thibodeaux et al. 2003). Further investigations 
proved PFAS to be able to disrupt transport of the natural ligand 5’,3’,5’,3-tetraiodo-[L]-
thyronine (thyroxine, T4) by TTR (Weiss et al. 2009). T4 and its bioactive form 3’,5,3-triiodo-
[L]-thyronine (triiodothyronine, T3) are essential in the activation of the thyroid hormone 
receptor alpha (TRα) and beta (TRβ) (Kim and Cheng 2013). Upon activation, these nuclear 
receptors modulate the transcription of thyroid-responsive genes essential for e.g., proper fetal 
development. Being the only thyroid transporter capable of mediating the delivery of TH to the 
fetus across the uterine-placental wall and the blood-brain barrier, TTR constitutes an 
essential actor of fetal maturation and a highly-sensitive target of endocrine active chemicals 
(EDCs) (Bergman et al. 2012; Landers et al. 2013).  
Over the course of the last years, PFAS concentrations have been measured in various 
human fluids including cord blood, plasma and breast milk (White et al. 2011). Mogensen et 
al. (2015) and Papadopoulou et al. (2016) showed that serum-PFAS levels in children were co-
incidentally increasing with the period of breastfeeding, indicating that breast milk is an 
important source of PFAS exposure in infants. More recently, evidence from an 
epidemiological study conducted in a Danish Birth Cohort showed associations between PFAS 
exposure and thyroid-stimulating hormone (TSH) levels in maternal blood samples (Inoue et 
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al. 2019). These findings indicate a transfer of the mother’s load of PFAS to the offspring 
through body fluids, which may lead to a disruption of the thyroid system in the offspring. 
Fluctuations in TH circulating concentrations is the major studied endpoint with respect 
to the thyroid system. To date there is relatively little data assessing direct interactions of PFAS 
with thyroid receptors. While TRα is predominant in the heart and brain tissues, TRβ is more 
widely distributed across the body and was proven to cause abnormal thyroid functions in 
patients with TRβ-resistance, indicating that this isoform could be a key element in PFAS-
driven thyroid disruption (Ortiga-Carvalho et al. 2014). As a first step to investigate PFAS 
potential interaction with thyroid receptors, we examined the potential agonistic and 
antagonistic effects of a set of thirteen PFAS pure compounds against the nuclear receptor TRβ 
using the highly selective TRβ CALUX® reporter gene assay. Subsequently, we confirmed PFAS 
competitive properties towards T4 using the combination of T4-TTR-binding and TRβ CALUX® 
assays, developed and described earlier (Collet et al. 2019). In addition, a small pilot study was 
performed using ten breast milk samples originating from Norwegian mothers participating in 
the HUMIS birth-cohort study. Endocrine active compounds (EACs), including PFAS and 
endogenous hormones, were extracted from each breast milk sample. Extracts were analyzed 
to evaluate their potential disrupting activity towards TRβ and T4 competitive properties for 
TTR binding, using the TTR-TRβ CALUX assays. Finally, the extent of daily exposure of a child 




Material and methods 
Chemicals 
Thirteen PFAS were selected for evaluation of their potency towards TRβ and their 
binding competition activity for T4 on TTR. Purchase information as well as abbreviations are 
detailed in Table 1. For all chemicals, 0.1M stock solutions were prepared in DMSO. Bisphenol 
A (BPA) (CAS no.: 80-05-7), deoxynivalenol (DON) (CAS no.: 4330-21-6), 17β-estradiol 
(estradiol) (CAS no.: 50-28-2), testosterone (CAS no.: 58-22-0), triiodothyronine (T3) (CAS 
no.: 6893-02-3) and thyroxine (T4) (CAS no.: 51-48-9) were purchased from Sigma-Aldrich. 
Table 1. Information about the poly- and perfluoroalkyl substances selected for thyroid-







PFBA Perfluorobutyric acid 375-22-4 214.04 Campro Scientific 
PFPeA Perfluoropentanoic acid 2706-90-3 264.05 Campro Scientific 
PFHxA Perfluorohexanoic acid 307-24-4 314.05 Fluorochem 
PFHpA Perfluoroheptanoic acid 375-85-9 364.06 Sigma-Aldrich 
PFOA Perfluorooctanoic acid 335-67-1 414.07 Sigma-Aldrich 
PFNA Perfluorononanoic acid 375-95-1 464.08 Sigma-Aldrich 
PFDA Perfluorodecanoic acid 335-76-2 514.09 Sigma-Aldrich 
     
PFBS Perfluorobutanesulfonic acid 375-73-5 300.10 Sigma-Aldrich 
PFHxS Perfluorohexanesulfonic acid 355-46-4 400.11 Campro Scientific 
PFHpS Perfluoroheptanesulfonic acid 375-92-8 500.13 Dr. Ehrenstorfer 




27619-97-2 428.16 Dr. Ehrenstorfer 
PFOSA Perfluorooctanesulfonamide 754–91-6 499.14 Dr. Ehrenstorfer 
 
Human milk samples 
Breast milk samples were randomly selected from the mother-child birth-cohort study 
HUMIS (Human Milk Study), previously described by Eggesbø et al. (2009). HUMIS is a 
population-based birth-cohort study conducted between 2002 and 2009. Women involved in 
the study were asked to collect 25 mL of milk every morning for eight consecutive days between 
the first two weeks and two months after giving birth. Mothers were encouraged to avoid 
electrical pumping equipment and to report details regarding method and time of sampling. 
Milk samples were collected in 250 mL natural HDPE Packaging Bottles (Cat. no.: 967-21244, 
Thermo Scientific Nalgene®) made from plasticizer-free high-purity resins and posted by the 
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mothers. Bottles were stored at -20°C in a Biobank of the Norwegian Institute of Public Health 
upon arrival. The study was approved by the Norwegian Data Inspectorate (ref. 2002/1398) 
and Regional Ethics Committee for Medical Research (ref. S-02122).   
PFOS and PFOA concentrations from HUMIS cohort samples were analyzed at the 
Research Centre for Toxic Compounds in the Environment, Masaryk University in the  Czech 
Republic  during a previous study (Forns et al. 2015). From the total biobank of breast milk 
samples, ten samples were included randomly. 
Sample preparation 
Endocrine active compounds (EACs) were extracted according to their polarity (apolar 
and polar) and combined to obtain a mixture closer to the original sample. 
Polar compounds from breast milk samples were extracted according to a method 
described earlier (Collet et al. 2020). In short, a QuEChERS (Quick Easy Cheap Effective 
Rugged and Safe) solid phase extraction and cleaning method was slightly modified to allow 
the extraction of polar analytes from breast milk samples (Anastassiades et al. 2003). Samples 
were homogenized and 5 mL were transferred to a clean 50 mL tube Greiner and 15 mL of 
acetonitrile (ACN) (CAS no.: 75-05-8, BioSolve) were added. After quick homogenization one 
QuEChERS EN 15662 extraction packet (Cat. no.: 5982-5650, Agilent) was added. The tubes 
were shaken for 15 min using a circular shaker prior to a five-minute centrifugation at 4000 
rpm, 4°C. The upper liquid layer was transferred to a clean tube and the solid lower phase 
mainly constituted of salts and water was re-dissolved by adding 15mL of ACN. After addition 
of an extra extraction packet, tubes were shaken and centrifuged one more time following the 
same procedure. Upper layers were combined and evaporated until ± 8 mL. The remaining 
volume was transferred to a 15 mL QuEChERS dispersive solid phase extraction (d-SPE) (Cat. 
no.: 5982-5158, Agilent) clean-up tube and vortex for 1 min. The d-SPE tubes were centrifuged 
for 5 min at 4000 rpm at 4°C and the upper layer was collected and evaporated until dryness 
using a gentle flow of nitrogen. All extracts were reconstituted in 30 µL of DMSO and stored at 
-20°C until analysis.  
Procedure control consisting of 5 mL of spiked breast milk was included to assess the 
efficiency of the extraction. 100 µL of a mixture of internal standards of bisphenol A (CAS no.: 
80-05-7, Sigma-Aldrich) (100 µg/mL), 17β-estradiol (E2) (CAS no.: 50-28-2, Sigma-Aldrich) 
(100 µg/mL)  and testosterone (CAS no.: 58-22-0, Sigma-Aldrich) (100 µg/mL) was used, 
similar to the pilot study (Collet et al. 2020). Controls were analyzed by liquid chromatography 
using a Kinetex Biphenyl column (150x4.6mm 2.6µ particle size) (Cat. no.: 00F-4622-E0, 
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Phenomenex) following the procedure detailed earlier (Collet et al. 2020). Recovery values 
were evaluated by comparing the peak height in the control samples with the initial internal 
standard solution. BPA, E2 and testosterone were extracted with a recovery of 35±13, 50±6.8 
and 59±5.9%, respectively.  
Regarding apolar compounds, breast milk samples were first homogenized, and 5 mL 
was transferred to a clean 60 ml glass tube filled with 5 mL of 2-propanol (CAS: 67-63-0, 
BioSolve). After ten-minute shaking (200±20 strokes per minute), 14 mL of n-hexane (CAS: 
110-54-3, BioSolve) was added and tubes were shaken for an extra hour. The upper layer was 
collected and transferred to a clean collecting tube. Another volume of n-hexane was added to 
the remaining phase and tubes were put back to shaking for 30 min. Upper layers were pooled 
and evaporated until dryness under a gentle flow of nitrogen. Samples were reconstituted in 1 
mL of n-hexane and cleaned-up using 5 g of 2% deactivated silica column preliminary 
conditioned with 12 mL of n-hexane. Samples were eluted with 30 mL of a combination of n-
hexane and dichloromethane (CAS no.: 75-09-2, BioSolve) to a ratio of 3:1. Solvents were 
evaporated until dryness and the final extract reconstituted in 30 µL of DMSO and stored at -
20°C until analysis.  
A set of controls consisting of 5 mL of breast milk primarily spiked with 50 µL of a solution 
of 13C-labeled internal standard containing PCB153 and PCB180 (200 ng/ml) (MBP-D7, 
Wellington Laboratories) were also analyzed. Controls were processed as described earlier 
(Collet et al. 2020). In brief, controls were extracted following the same procedure as the 
samples with the exception that the final fraction was reconstituted in isooctane (CAS no.: 540-
84-1, BioSolve). Recoveries were evaluated using a gas chromatograph/mass spectrometer 
(GC-MS) system using gas chromatograph GC-2010 Plus and gas chromatograph mass 
detector GCMS-TQ8050 (Shimadzu) controlled by the program GCMS Real Time Analysis 
(Shimadzu) and a CTC CombiPal autosampler controlled by the software Cycle Composer 
(Agilent Technologies). Parameters and settings used for the analysis were similar to those 
described by (Collet et al. 2020). Overall, recovery values were evaluated to be 96±13 and 
115±21% for PCB153 and PCB180, respectively.  
TRβ CALUX® reporter gene assay 
TRβ CALUX reporter gene assay is based on human osteoblastic osteosarcoma U2-OS cells 
(American Type Culture Collection) stably transfected with a full-length human TRβ 
expression vector (pSG5-neo-hTRβ) and a luciferase reporter construct containing two copies 
of thyroid responsive elements (TRE) (Pgl3-2xTRE-Luc). The agonistic (TRβ CALUX) and 
antagonistic (anti-TRβ CALUX) versions of the bioassay were essentially performed as 
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described previously (Collet et al. 2019). In short, a suspension of TRβ cells (1x105 cells/mL) 
was prepared in assay medium consisting of DMEM/F12 without phenol red indicator (Cat 
no.: VX1041025, Fisher) supplemented with 10U/mL penicillin and 10 μg/mL streptomycin 
(P/S) non-essential amino acids (NEAA) (Cat no.: 11140-03, Gibco) and 5% charcoal-stripped 
fetal calf serum (DCC). Cells were seeded in 96-well plates and incubated for 20±4 hours at 
37°C and 5% CO2. On the following day, cells were exposed to serial dilutions of the test item 
in exposure medium consisting of assay medium without DCC. Pure chemicals were diluted 
following a 0.5 log unit increments method. To perform the antagonistic mode of the TRβ 
CALUX, exposure medium was supplemented with a fixed concentration of T3 (EC50; 1.7E-9M 
in the well). Plates were placed back into the incubator for 22±2 hours. On the third day, 
medium was discarded and replaced by 30 µL/well of Triton-lysis buffer and plates were 
shaken for 10 mins. Luciferase signal in cellular lysates was measured using a luminometer 
InfinitePro coupled to a Connect Stacker (TECAN). A ten-point calibration line of the reference 
compound, T3 for agonist mode and DON for antagonistic mode, was added to each plate 
(Collet et al. 2019).  
TTR-TRβ CALUX assay  
 The TTR-TRβ CALUX assay was essentially performed as described earlier (Collet et al. 
2020) with the exception that, for the purpose of the study, PFOA was used as the reference 
compound. Prior to analysis, dilution series from each PFAS stock solution (0.1M) were 
prepared (x1-3-10-30-100-300-1000-3000-10000-30000). Each concentration was 
incubated overnight at 4 °C in Tris buffer supplemented with a fixed concentration of T4 (0.05 
µM in incubate) and TTR (0.06 µM in incubate) (CAS no.: 87090-18-4, Sigma Aldrich). Tris 
buffer consists of a mixture of Tris buffer (CAS no.: 77-86-1, Sigma Aldrich), NaCl (CAS no.: 
7647-14-5, Sigma Aldrich) and ethylenediaminetetraacetic acid (CAS no.: 60-00-4, Sigma 
Aldrich) diluted in HPLC water (J.T Baker) and adjusted to pH 8.0. The next day, T4- and 
PFAS-bound TTR complexes were separated from free T4 molecules using self-made Bio-Gel 
P-6DG (Cat no.: 150-0739, BioRad) columns. Eluates resulting from this separation were 
taken-up in 500 µL of exposure medium (final volume 640 µL) and immediately analyzed on 
the TRβ CALUX reporter gene assay.  
 A dose-response curve of the reference compound PFOA was added to each 96-well 
plate. One negative control consisting of the highest concentration of the tested chemical 
without the addition of T4 in incubate, was added to each procedure. PFAS were tested in 
duplicate in two independent runs. 
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PFAS cytotoxicity in the TTR-TRβ CALUX were evaluated assuming that all PFAS 
molecules bonded to TTR and ended up in the incubate. For each compound, the highest 
concentration analyzed on the TTR-TRβ CALUX (0.1M), equivalent to 4.1E-4M in incubate, was 
also tested on the Cytotox CALUX bioassay. None of the tested PFAS concentration was 
sufficient to cause cytotoxicity in the TTR-TRβ CALUX bioassay.  
Data analysis 
Luciferase measurements were corrected for background signal using pure DMSO as a 
blank. Activity derived from each test item was expressed as relative induction to the maximum 
signal response (100% for agonist mode, 0% for antagonist) set by the reference compound. 
Results from each pure chemical or epidemiological sample were interpolated in the associated 
calibration curve using the statistical software package GraphPad Prism V5.03 (non-linear 
regression, variable slope, 4 parameters, robust fit). Using the same program, EC50 (i.e. 50% of 
the maximal effective concentration) (agonist) or IC50 (50% of the maximal inhibitor 
concentration) (antagonist) were calculated. For measurements on the TRβ CALUX assay, a 
compound was defined as positive if two consecutive points reached PC10 (i.e. increase of at 
least 10% in receptor activation) or PC80 (i.e. decrease of at least 20% in receptor activation) 
for agonist and antagonist mode, respectively. Data derived from TTR-TRβ CALUX analysis 







PFAS agonistic and antagonistic activity towards TRβ 
The agonistic and antagonistic potential of selected PFAS were individually 
investigated using the (anti-)TRβ CALUX bioassays (Table 2.). Measurements showed that 
none of the compounds led to TRβ activation. In contrast, more than half of the tested PFAS 
(PFHpA, PFHxA, PFHpA, PFHxS, PFHpS, PFOS, H4PFOS, PFOSA) demonstrated 
antagonistic properties towards TRβ. However, only three compounds, PFNA, PFDA and 
PFOSA, showed a full-dose response curve allowing the calculation of a log IC50 value. In 
conclusion, none of the PFAS from the test set was found to be TRβ agonist however, most of 
them were able to inhibit TRβ.  
Table 2.  Effect of PFAS congeners in the (anti-)TRβ CALUX bioassays, expressed as log 
EC50/PC10 and IC50/PC80 values. 




               TRβ CALUX anti-TRβ CALUX 
Reference 
compound 
LOG [EC50] LOG [PC10]] LOG [IC50] LOG [PC80]] 
T3 -9.00 -9.77   
DON   -6.16 -6.49 
     
Test compound     
PFBA NA NA NA NA 
PFPeA NA NA NA NA 
PFHxA NA NA NA NA 
PFHpA NA NA NA -5.12 
PFOA NA NA NA NA 
PFNA NA NA -4.93 -5.17 
PFDA NA NA -5.43 -5.61 
     
PFBS NA NA NA NA 
PFHxS NA NA NA -4.8 
PFHpS NA NA NA NA 
PFOS NA NA NA -5.15 
H4PFOS NA NA NA -4.38 
PFOSA NA NA -5.28 -5.40 
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PFAS competitive potency for T4-TTR binding 
Thirteen PFAS were individually tested in the TTR-TRβ CALUX assay (Figure 1 a.b). 
All tested PFAS compounds showed capacities to interfere with the thyroid system. Using 
PFOA as a reference and IC50 as a basis, the relative potency (REP) of each PFAS was evaluated 
(Table 3.). These calculations ranked PFHxS, PFHpS and PFOS as the most potent compounds 
among the tested PFAS with a REP value equal to 2.7, 1.7 and 2.2, respectively. On the contrary, 
PFBA, H4PFOS, and carboxylic-based PFAS showed a REP value ≤0.94, i.e., lower than the 
PFOA binding potency.  
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Figure 1.a.b. Dose-response curves for thirteen PFAS tested on the TTR-TRβ CALUX assay. 
 
Note: PFAS were tested in duplicate in two independent runs. Each point represents the average of these 
measurements. 
PFOA: Perfluorooctanoic acid; PFBA: Perfluorobutyric acid; PFPeA: Perfluoropentanoic acid, PFHxA: 
Perfluorohexanoic acid; PFHxA: Perfluoroheptanoic acid; PFNA: Perfluorononanoic acid PFDA: 
Perfluorodecanoic acid. PFBS: Perfluorobutanesulfonic acid; PFHxS: Perfluorohexanesulfonic acid; 
PFHpS: Perfluoroheptanesulfonic acid; PFOS: Perfluorooctanesulfonic acid; H4PFOS: 1H,1H,2H,2H-






Table 3. log IC50, log PC80 and IC80-based relative potency values for thirteen PFAS tested in 
TTR-TRβ CALUX assay. 
 
Compound LOG [IC50] LOG [PC80]] Relative Potency (REP) 
PFOA (reference) -5.81 -6.47 1 
    
PFBA -2.94 -4.01 0.00091 
PFPeA -4.45 -5.11 0.035 
PFHxA -4.98 -5.77 0.12 
PFHpA -5.92 -6.69 0.94 
PFOA -5.92 -6.55 1.0 
PFNA -5.50 -6.01 0.35 
PFDA -4.86 -5.58 0.088 
    
PFBS -4.79 -5.25 0.075 
PFHxS -6.37 -6.92 2.7 
PFHpS -6.15 -6.69 1.7 
PFOS -6.25 -6.78 2.3 
H4PFOS -4.28 -4.76 0.024 
PFOSA -5.86 -6.44 0.90 
Note:    IC50: concentration at 50% TRβ inhibition 
PC80: concentration at a decrease of 20% of TRβ activation 
REP based on IC50 values 
 
Antagonistic effects towards TRβ on breast milk samples 
A total of ten breast milk sample extracts were individually screened in the agonistic 
and antagonistic mode of the TRβ CALUX reporter gene assay (Table 4). Samples were 
analyzed in three fractions: apolar endocrine active compounds (EACs), polar EACs and 
reconstituted mixture consisting of the combination of apolar and polar EACs. All samples 
regardless of the fraction were below the limit of quantification (LOQ) (≤0.28) of the TRβ 
CALUX bioassay in agonistic mode. In contrast, more than half of the polar fractions scored 
positive on the anti-TRβ CALUX, with an activity ranging from 0.86 to 2.02 µg DON eq./g of 
milk. The apolar fractions did not show activity above the LOQ. All reconstituted samples (i.e. 






Table 4. (Anti-)TRβ CALUX activity assessment in mixture, apolar and polar fractions from 





(µg T3 eq./g of milk) 
Anti-TRβ CALUX 
(µg DON eq./g of milk) 
 Mixture Apolar Polar Mixture Apolar Polar 
1 LOQ (<0.17) LOQ (<0.24) LOQ (<0.17) 1.2 LOQ (<0.28) LOQ (<0.28) 
2 LOQ (<0.24) LOQ (<0.25) LOQ (<0.23) 3.6 LOQ (<0.28) 0.87 
3 LOQ (<0.23) LOQ (<0.25) LOQ (<0.23) 1.2 LOQ (<0.28) 0.86 
4 LOQ (<0.23) LOQ (<0.25) LOQ (<0.23) 1.6 LOQ (<0.28) 1.2 
5 LOQ (<0.23) LOQ (<0.25) LOQ (<0.23) LOQ (<0.55) LOQ (<0.54) 1.5 
6 LOQ (<0.24) LOQ (<0.26) LOQ (<0.23) 1.9 LOQ (<0.24) 2.0 
7 LOQ (<0.21) LOQ (<0.26) LOQ (<0.23) 1.4 LOQ (<0.24) 1.3 
8 LOQ (<0.21) LOQ (<0.26) LOQ (<0.23) 0.91 LOQ (<0.28) LOQ (<0.48) 
9 LOQ (<0.21) LOQ (<0.26) LOQ (<0.23) 1.1 LOQ (<0.24) LOQ (<0.48) 
10 LOQ (<0.21) LOQ (<0.26) LOQ (<0.26) LOQ (<0.55) LOQ (<0.25) LOQ (<0.47) 
Average LOQ LOQ LOQ 1.4 LOQ 0.94 
Note: LOQ: Below the limit of quantification of the bioassay. 
 
T4-TTR binding competing activity in human milk samples  
Extracts derived from ten breast milk samples were also individually analysed for 
interferences with TTR transportation using the TTR-TRβ CALUX bioassay (Table 5.). Most 
apolar fractions did not reach LOQ value (LOQ=0.03) with the exception of two samples 
demonstrating a very low signal (≤0.07 µg PFOA eq./g of milk). On the contrary, every polar 
fraction scored positive in the TTR-TRβ CALUX assay with an activity ranging from 1.3 to 11.5 
µg PFOA eq./g of milk. Interestingly, mixtures showed different behaviours depending on the 
assessed sample. Indeed, four samples exhibited significantly higher activity in the mixture 
than in the apolar and polar fractions alone. In contrast, six mixtures demonstrated diminished 
effects compared to their corresponding single fractions. On average, thyroid disrupting 
properties measured in mixtures were slightly lower in comparison with polar measurements 
(3.4 µg PFOA eq./g of milk versus 4.6 µg PFOA eq./g of milk). Overall, all reconstituted human 
milk samples but one showed potential disrupting properties targeting the thyroid hormone 
transport system. 
 Subsequently, we estimated the contribution of PFOA and PFOS to the measured 
thyroid-interfering activity (Table 6). Sample n°5 is the only one with a higher REP (7.02E-10 
mol PFOA eq./L of milk) than overall activity (LOQ). In general, less than 1% of thyroid 
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disrupting activity in the measured TTR-TRβ CALUX assay could be explained by the presence 
of these two PFAS chemicals. 





(µg PFOA eq./g of milk) 
 Mixture Apolar Polar 
1 0.67 LOQ (<0.03) 1.3 
2 1.5 LOQ (<0.03) 3.7 
3 3.7 0.04 3.2 
4 3.3 LOQ (<0.03) 3.0 
5 LOQ (<0.03) 0.07 3.2 
6 2.9 LOQ (<0.03) 8.1 
7 9.1 LOQ (<0.03) 4.7 
8 6.7 LOQ (<0.03) 3.5 
9 0.41 LOQ (<0.03) 2.1 
10 2.1 LOQ (<0.03) 11.5 
Average 3.0 0.035 4.4 
 
Table 6. Estimation of thyroid-disrupting activity in the TTR-TRβ CALUX bioassay by 
extracts from breast milk samples based on earlier reported PFOA and PFOS concentration 





(ng/L of milk) 
Total activity* 
(mol PFOA/L of milk) 
REP** 
(mol PFOA eq./L of milk) 
 PFOS PFOA   
1 46 16 1.6E-06 2.2E-10 
2 150 30 3.0E-06 6.8E-10 
3 53 23 8.8E-06 2.7E-10 
4 180 90 8.0E-06 9.4E-10 
5 120 90 LOQ (<0.55) 7.0E-10 
6 130 42 6.9E-06 6.3E-10 
7 69 16 2.2E-05 3.2E-10 
8 150 60 1.6E-05 7.5E-10 
9 49 - 9.9E-07 NA 
10 150 70 5.1E-06 7.8E-10 
Note:     *based on disrupting activity of reconstituted mixtures 
**Relative Potency based on PFOS/PFOA concentration in the sample 





Estimation of daily intake of anti-thyroid chemicals through breastfeeding 
during the first year of life 
The World Health Organization (WHO) strongly recommends exclusive breastfeeding 
for every child during their first year of life. According to reported guidelines, an infant should 
ingest approximatively 150 mL of milk per kg of body weight (bw) per day (WHO 2011). 
Previous findings showed that breast milk originating from Norwegian mothers for the HUMIS 
cohort could be contaminated with anti-TRβ toxicants as well EDCs with T4-TTR competing 
properties for TTR binding, equivalent to 1.4 µg DON eq./g of milk and 3.02 µg PFOA eq./g of 
milk, respectively. We further estimated a child’s average exposure to thyroid-disrupting EDCs 
during the first year of life (Table 7, 8). 
 
Table 7. Estimation of a child’s daily intake of anti-thyroid EDCs through breastfeeding at one 
month, six months and twelve months. 
Average activity 
Anti-TRβ CALUX  














Nursing child dose 
per day 
(µg DON eq./kg 
bw/day) 
1.4 1 525 735 3.5 210 
1.4 6 1125 1575 7.5 210 
1.4 12 1380 1932 9.2 210 
Note: *Assuming that the child is exclusively breastfed. 
** Average body weight at 1, 6 or 12 months. 
DON: deoxynivalenol; T3: triiodothyronine 
 
 
Table 8. Estimation of a child’s daily intake of TTR disrupting EDCs through breastfeeding at 
one month, six months and twelve months. 
Average activity on 
TTR-TRβ CALUX 















dose per day 
(µg PFOA eq./kg 
bw/day) 
3.02 1 525 1585 3.5 453 
3.02 6 1125 3398 7.5 453 
3.02 12 1380 4168 9.2 453 
Note: *Assuming that the child is exclusively breastfed. 
** Average body weight at 1, 6 or 12 months. 






The present manuscript demonstrates the ability of PFAS to interfere with two 
biomolecular levels of the thyroid system, i.e., plasma transport and thyroid receptor 
inhibition. Seven PFAS (PFHpA, PFNA, PFDA, PFHxS, PFOS, H4PFOS and PFOSA) showed 
antagonistic activity towards TRβ, indicating that this nuclear receptor might be a potential 
target of PFAS-driven endocrine disruption. Furthermore, using the TTR-TRβ CALUX 
bioassay, we confirmed that individual PFAS have competitive properties towards T4 for 
binding to TTR, an important plasma carrier of thyroid hormones to e.g. the fetus. Further 
analysis showed that human milk sample extracts caused TRβ inhibition and T4-TTR binding 
competitive properties. However only 1 % of the observed TH disrupting activity by extracts 
from breast milk samples could be explained by the measured levels of PFOA and PFOS, thus 
the culprit(s) causing thyroid disruption is largely unknown. 
None of the thirteen investigated PFAS were active as agonists in the TRβ CALUX 
reporter gene assay. A previous extensive screening performed amongst 8305 features 
demonstrated that only chemicals with high homology to thyroid natural ligands could 
potentially act as TRβ agonists (Paul-Friedman et al. 2019). On the contrary, seven showed 
antagonistic activity towards the same receptor. Results suggest that PFAS containing a 
carboxylic acid functional group and with a carbon chain length of nine or higher (PFNA, 
PFDA) are potent TRβ antagonists. Similarly, analysis of sulfonate based PFAS presenting 
eight carbons, PFOS (log PC80 -5.15) and H4PFOS (log PC80 -4.38), were also reported as 
antagonists although to a lower extend. Only in the case of PFOSA the dose-response curves 
reached an IC50 value (log IC50 -5.28) suggesting that the attached amine functional group 
could influence chemical potency. Overall, our data clearly reveal the capacity of some PFAS 
to act as TRβ antagonists, although their potency may vary depending on their structural 
properties.  
Using PFOA as a reference compound, the TTR-TRβ CALUX analysis revealed that 
PFHpS, PFHxS and PFOS have a higher TTR binding potency (REP≥1.7) than carboxylic and 
other sulfonic compounds (REP≤1). These results are similar to the ranking reported by Weiss 
et al. (2009) placing PFHxS as the most potent of the test set, followed by PFOS. Overall, 
findings show that the TTR-disrupting potency is associated with PFAS with a carbon chain 
reaching a maximum length at eight carbons, PFOA (REP=1) and PFOS (REP=2.3). However, 
H4PFOS, a sulfonate PFAS with the same carbon chain length (n=8) but different degree of 
fluorination showed lower competitive binding properties (REP=0.024) in comparison with 
PFOS (REP=2.3). These findings confirmed the importance of the carbon chain length, degree 
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of fluorination and the attached functional group in  TTR-binding competition potency, as 
reported earlier by Weiss et al. (2009).  
While none of the breast milk extracts presented agonistic properties, antagonistic 
activity towards TRβ was detected in most breast milk samples (0.91-3.6 µg DON eq./g of 
milk). Based on these results, we estimated DON daily intake of a nursing child through 
breastfeeding to 210 µg DON eq./kg bw/day. All reconstituted mixtures of extracts from breast 
milk samples, except one, showed T4 competitive activity for TTR-binding ranging from 0.41 
to 9.1 µg PFOA eq./g of milk. These results suggest that human milk from HUMIS participants 
contain compounds able to disrupt TRβ and TTR plasma T4-carrier by mimicking natural 
thyroid ligands. However, considering the myriad of chemicals present in body fluids, it is 
challenging to assess the importance of PFAS in these findings. Moreover, only two of the PFAS 
compounds, e.g., PFOA and PFOS concentrations were measured in the breast milk samples. 
Nevertheless, these findings lead to an estimation a nursing child’s daily intake of 453 µg PFOA 
eq./kg bw/day. This value largely exceeds the tolerable PFAS daily intake of 0.63 ng/kg bw/day 
established in 2020 by the European Food Safety Authority Panel on Contaminants in the Food 
Chain (EFSA CONTAM Panel) (PFAS tolerable week intake: 4.4 ng/kg bw/week) (Schrenk et 
al. 2020). The fact that PFOA and PFOS could only justify a small fraction (1%) of the observed 
thyroid disrupting activity in breast milk, can partially be explained by the lack of information 
on the presence of the other PFAS compounds, which constitute a complex mixture containing 
more than 6000 congeners. Moreover, several other classes of contaminants are capable of 
interfering with the thyroid transport system, such as brominated flame retardants, dibenzo-
p-dioxins (PCDDs), and organochlorine pesticides (aldrin, chlordane, α-endosulfan, 
methoxychlor, etcetera) which have been identified in milk from Norwegians mothers 
(Čechová et al. 2017; Iszatt et al. 2016; Maroni et al. 2000; Vollset et al. 2019). Overall, these 
results suggest an important contamination of Norwegian women’s breast milk by 
anthropogenic toxicants, highlighting a possible threat for the nursing infant during the 
sensitive period of his first months of life. In future more work should be devoted to try to 
discern which culprit chemicals in breast milk are causing the thyroid disrupting activity. 
Conclusion 
In this manuscript we demonstrated that PFAS are potent disruptors of the thyroid 
system by being able to compete with T4 for TTR-transportation but also to antagonize TH for 
TRβ activation. This double hit could result in a significant drop of TH circulating levels and a 
reduced TRβ activity in target tissues. Overall, extracts of breast milk from the participating 
Norwegian mothers contain a clearly measurable potency to interfere with T4 binding to TTR, 
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as well as antagonizing TRβ suggesting that environmental EDCs, such as PFAS may be 
involved in this thyroid disrupting activity, which is of high concern due to the vulnerability of 
the newborn baby. Further studies are needed to identify the culprit chemicals causing the 
thyroid disruption, as well as human epidemiological studies focusing on possible thyroid-
related adverse health outcomes in breast-fed infants. 
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Summary, Conclusions and Future Outlook
This thesis investigates the presence and potential effects of endocrine disrupting 
chemicals (EDCs) in human milk using samples derived from the Norwegian HUMIS cohort. 
This study is based on a two-step approach involving firstly the extraction of hormonally active 
compounds according to their polarity. Secondly, apolar, polar and the combination of both 
extracts (mixture) were analyzed using in vitro human-based reporter gene CALUX bioassays 
covering key endpoints of the endocrine system: estrogens, androgens, and thyroid hormones 
(THs).  
Chapter summary 
Chapter one provides background on contaminants with endocrine disrupting 
properties while introducing the steroid- and thyroid signaling pathways. This chapter also 
details previous findings of the Norwegian HUMIS birth-cohort and the main objectives of the 
present thesis. In addition, due to their importance in the studies presented in this thesis, 
effect-based bioassays as well as effect-directed fractionation are introduced. 
Chapter two constitutes a pilot study performed on ten human milk samples using the 
(anti-)ERβ and (anti-)AR CALUX bioassays. While nearly no estrogenic activity was detected, 
this work shows that all samples except one contained quantifiable amounts of anti-androgenic 
activity of unknown origin. Interestingly, measurements demonstrate higher activity in polar 
fractions in comparison to reconstituted apolar-polar extracts while none of the tested apolar 
fractions was active in the anti-AR CALUX bioassay. Further investigation involving effect-
directed fractionation and exclusion methods showed that the observed anti-androgenic 
activity could not be explained by the presence natural hormones (androstenedione, DHEA, 
E1, E2, pregnenolone, progesterone, testosterone) and/or metabolites thereof. Therefore, 
these results suggest that the observed anti-AR activity in human milk samples is more likely 
to be caused by as yet unidentified, polar anthropogenic contaminants.   
There is growing in vitro and in vivo evidence suggesting that early exposure to anti-
androgens may result in reproductive impairments such as cryptorchidism (Borch, Metzdorff, 
Vinggaard, Brokken, & Dalgaard, 2006; Fisher, 2004; Welsh et al., 2008). Therefore, in 
Chapter three, 199 human milk samples originating from the HUMIS cohort, including a 
subset 94 mothers who gave birth to boys with undescended testis and a subset of 105 mothers 
‘controls’ who gave birth to boys with no cryptorchidism, were selected to perform a case-study. 
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In this chapter a potential association between anti-androgenic activity, measured by the anti-
AR CALUX in mother milk and prevalence of cryptorchidism in the offspring was evaluated. 
Although statistical analysis showed no significant difference between the human milk-based 
anti-AR activity measured in control and cryptorchid samples, a possible association between 
the presence of apolar compounds in human milk and undescended testis prevalence could not 
be ruled out. Overall, anti-androgenic activity was measured in the majority of the milk 
samples. Analysis of fractions with different polarity, i.e. apolar, polar and combined extracts, 
confirmed previous findings in chapter two, highlighting that polar compounds contributed 
most to the anti-androgenic activity in breast milk. While the origins of such compounds are 
still unclear, this study demonstrates the importance of assessing mixtures rather than 
investigating individual chemicals or subclasses.  
Although sex steroids have been found to be particularly sensitive targets of endocrine 
disruption in early life, the past years raised an additional concerned regarding EDCs targeting 
the thyroid system, causing amongst other alterations of circulating thyroid hormone levels 
and interferences with the serum transporters of THs, in particular transthyretin (TTR). In 
Chapter four, the development and validation of a novel thyroid CALUX testing panel was 
evaluated, specifically designed to assess EDCs capabilities to interact with the thyroid receptor 
β (TRβ) (TRβ CALUX assay) and/or TTR (TTR-TRβ CALUX assay). The TRβ CALUX assay 
consists of an endogenously expressing TRβ expressing U2OS osteosarcoma cell line, which 
was stably transfected with a luciferase reporter gene, linked to thyroid responsive elements. 
This TRβ CALUX assay is capable of assessment of thyroid hormone receptor-based agonistic 
activity by quantification of the luciferase activity produced. The TRβ CALUX assay can also 
be used to measure antagonistic activity, through cell pre-stimulation with natural ligand T3 
(anti-TRβ CALUX assay), or to evaluate T4 binding competition activities for TTR, when used 
in combination with the TTR binding assay. Each bioassay (TRβ and TTR-TRβ) was validated 
using a range of known positive and negative thyroid-disrupting compounds and showed a 
very good predictability suggesting that the newly developed CALUX panel can be a powerful 
tool in predicting the effects of EDCs on endogenous thyroid hormonal actions.     
In Chapter five, the newly developed thyroid-specific CALUX assay panel, was used to 
investigate a set of per- and polyfluoroalkyl substances (PFAS), hypothesised to be thyroid 
disruptors. None of the tested PFAS showed agonistic activity towards TRβ in the TRβ CALUX 
reporter gene assay however, seven PFAS presented antagonistic activity on TRβ. TTR-TRβ-
CALUX analysis showed that all PFAS have T4 competitive binding properties for TTR binding, 
albeit with different potencies. In this chapter, we also investigated whether human breast milk 
samples from the Norwegian HUMIS cohort contained TH-disrupting activity possibly 
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associated with the presence of contaminants, including PFAS. While no TRβ agonistic activity 
was detected, most breast milk extracts showed antagonistic activity towards TRβ and all of 
them but one presented T4-TTR binding competitive potency, equal to 0.41 to 9.1 µg PFOA 
eq./g of milk. Considering their abilities to compete with TH for TTR-transportation and to 
antagonize TRβ activation, results presented in chapter five suggest that PFAS can be potent 
thyroid disruptors. Although the sample size was quite small (ten samples), the pilot study 
performed on HUMIS samples showed the presence of thyroid-disrupting activity in extract 
from breast milk. Further calculations based on PFOA (perfluorooctanoic acid) and PFOS 
(perfluorooctane sulfonate) sample concentrations demonstrated that only a small percentage 
of the TRβ antagonistic activity could be explained by PFAS contamination, suggesting the 
additional presence of unknown thyroid-disrupting chemicals in human milk. 
Conclusions and Future Outlook 
Antiandrogenic activity of anthropogenic origin detected in Norwegian human milk 
samples 
This research demonstrates for the first time the ubiquitous presence of anti-
androgenic activity in human milk samples originating from the Norwegian HUMIS cohort. 
The studies conducted in Chapter two (pilot-study) and in Chapter three (case-control study), 
covering more than 200 participants, showed unexpected antagonistic activity towards the AR 
highlighting human milk contamination with as yet unidentified anthropogenic EDCs of high 
polarity. These findings suggest that breastfeeding may pose a potential route of early human 
exposure to mixtures of anti-androgenic contaminants.  
In 1995, Sonawane (1995) established an extensive list of human milk contaminants 
identifying pesticides, polychlorinated biphenyls (PCBs) and dioxins as the most prominent 
compounds. Over the past decades, these toxicants were proven to interfere with the androgen 
signaling pathway via AR binding (Hotchkiss et al., 2004; Kelce, Gray, & Wilson, 1998; Van 
der Burg et al., 2010). Considering their physico-chemical properties, dioxins, dioxin-like PCBs 
and PCBs are unlikely to be responsible for the anti-androgenic activity measured in the polar 
fractions of milk samples (Sohoni & Sumpter, 1998; Sultan et al., 2001). On the contrary, high 
polarity pesticides e.g. aldrin, dieldrin, endrin, fenarimol, linuron and methoxychlor, as well 
as xenoestrogens may have contributed to the anti-AR activity found in the Norwegian human 
milk samples. More recently, some ester-based flame retardants were reported to also 
antagonize AR activation (Rosenmai et al., 2021). Although there are little to no toxicological 
data regarding their potential anti-androgenic activity, we cannot exclude that contaminants 
such as brominated flame retardants (BFRs) and phthalates esters, previously identified in 
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human milk, could also be potential actors in the measured anti-AR activity (Main et al., 2006; 
Norén & Meironyté, 2000; Thomsen et al., 2010). In the present thesis, we showed the 
presence of anti-androgenic activity in human milk extracts and were able to exclude a 
potential contribution of major sex hormones and their metabolites to the observed activity. 
Further calculations based on anti-AR CALUX findings estimated the daily exposure of a 
nursing child (1-12 months old) to 78 µg flutamide eq./kg of body weight/day. This level was 
found to largely exceed the NOAEL (no adverse effects level) of 0.025mg/kg/day reported in 
2017 for humans (Zacharia, 2017). Although the estimated anti-androgenic activity is 
surpassing acceptable daily doses, it is of main importance to supplement this research with 
targeted and untargeted analysis in the near future to precisely characterize the chemical 
nature of the observed anti-AR activity in human milk in order to identify their origin and 
better advice regulatory authorities on necessary further chemical restrictions. 
Investigation of a possible association between anti-androgenic activity in breast 
milk and prevalence of cryptorchidism based on a subset of 199 samples participants of the 
Norwegian HUMIS cohort 
The case-control study presented in this thesis evaluates a possible association between 
anti-androgenic activity in human milk extracts and prevalence of cryptorchidism in children. 
Although no significant differences between case and control groups were observed, further 
statistical analysis revealed a possible, but yet non-significant, association between anti-AR 
activity from apolar compounds and undescended testis in the offspring. There are various 
limitations which may have hampered our study and reduced its statistical power. Firstly, the 
limited sample size (199 samples) might not have been enough to detect a possible relationship, 
if any, between anti-androgenic activity in milk and the prevalence of cryptorchidism in human 
offspring. Moreover, while breast milk is usually defined as a suitable matrix for monitoring 
late fetal exposure e.g., based on a proven correlation between breast milk and umbilical cord 
concentrations of persistent chemicals, important stages of the sexual development occurring 
during earlier fetal developmental windows (8 – 10 weeks) might have been overlooked (Kanja, 
Skaare, Ojwang, & Maitai, 1992; Verner et al., 2013; Waliszewski, Aguirre, Infanzon, Silva, & 
Siliceo, 2001). Lastly, a child’s undescended, or late descendent testicle condition was based 
on self-observation and self-reported data by the mother, which can be inclined to bias. 
Therefore, it may require a larger case-control study, involving self-reported as well as medical 
professional-based reporting of cryptorchidism to more definitely be able to draw conclusions 
on a possible relationship between anti-androgenic activity in milk and the risk of 




Several PFAS are potent T4-TTR binding competitors and TRβ antagonists  
This thesis demonstrated PFAS ability to interfere with the thyroid system at several 
biomolecular levels, i.e. TTR-based plasma transportation and TRβ activation. Similar to 
previous findings reported by Weiss et al. (2009), TTR-TRβ CALUX analyses performed in 
chapter five revealed that PFHxS and PFOS have a higher T4 binding competition potency for 
TTR than their carboxylic and other sulfonic perfluorinated analogues. We also demonstrated 
that PFHpS was also a potent T4 competitor for TTR binding. In addition, an antagonistic 
activity on the TRβ was observed for several PFAS (PFHpA, PFNA, PFDA, PFHxS, PFOS, 
H4PFOS and PFOSA) to inhibit TRβ activation. To our knowledge, this is the first study 
reporting on TRβ antagonism by PFAS congeners. Results detailed in chapter five suggest a 
potential correlation between carbon chain length and functional group of the PFAS congeners 
and antagonistic potency towards TRβ. We demonstrated that perfluorinated carboxylic acids 
presenting a carbon chain length of nine or higher i.e. PFNA, PFDA, are potent TRβ inhibitors. 
To a lesser extend, perfluorinated sulfonic acids of eight i.e. PFOS and H4PFOS were also 
reported to antagonize TRβ activation. The high TRβ antagonistic potency of PFOSA, superior 
to other PFAS of the set, suggests a possible influence of the attached amine functional group 
in chemical thyroid-disrupting potency. Overall, we demonstrated that PFAS can be potent 
endocrine disruptors able to interfere at different biomolecular levels of the thyroid system. 
Besides their known T4-competitive binding interferences on TTR, i.e., the thyroid hormone 
transport protein facilitating T4 delivery to the fetus, PFAS were proven to influence TRβ 
activation implying a possible double hit for the growing fetus. Further investigation is 
necessary to better understand mechanisms underlying PFAS-based thyroid disruption. 
Moreover, complementary effect-based analysis and toxicological studies are required in order 
to establish or adjust existing exposure threshold limit values. 
Thyroid-disrupting activities measured in extracts of human milk from the 
Norwegian HUMIS cohort, seem mostly independent from PFAS action  
The second pilot case-study performed in this thesis highlighted the presence of 
thyroid-disrupting activities in milk samples from the HUMIS cohort. Out of ten participants, 
eight human milk TRβ CALUX measurements demonstrated antagonistic activity towards 
TRβ. Similarly, nine reconstituted mixtures showed competitive properties targeting the 
natural hormone T4 for TTR binding. The present work suggests that environmental 
contaminants, such as PFAS, are present in human milk and can be a possible source of 
exposure for a nursing child. Although chemical analyses performed and reported in earlier 
studies showed the presence of PFAS in most HUMIS milk samples (PFOS and PFOA), our 
work revealed that observed PFAS levels could only explain a trivial fraction of thyroid 
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disrupting activities measured in our study. While this result could be partially explained by 
the lack of information on the presence of other PFAS compounds in the milk, it is more likely 
that many other classes of contaminants e.g. organochlorine pesticides and BFRs, previously 
identified in HUMIS milk samples, may also have contributed to the measured anti-thyroid 
activity (Eggesbø et al., 2011; Forns et al., 2015; Iszatt et al., 2016). Overall, this case-study 
estimated thyroid-disrupting activities in Norwegian breast milk to 210 µg DON eq./kg bw/day 
(antagonistic activity) as well as 453 µg PFOA eq./kg bw/day (competitive activity towards T4 
for TTR binding), largely exceeding the current threshold values established by regulatory 
authorities (Schrenk et al., 2020). Therefore, it is of major interest to conduct target chemical 
analyses aiming to identify classes of bioaccumulating contaminants causing the thyroid 
disrupting activities observed in human milk so as to further provide better directives to 
sensitive populations, including mothers and their nursing child. 
Apolar EDCs could interfere with polar EDCs by muting their effects when combined 
as mixtures 
For the purpose of this thesis, we developed a two-step method capable of extracting 
EDCs from human milk samples. Developing one suitable universal method capable of 
extracting EDCs with widely different polarity appeared to be very challenging. Thus, we 
designed a method allowing the extraction of apolar EDCs in one fraction and polar EDCs, 
including endogenous hormones, in a separate fraction. In addition, to also get a realistic EDC 
representation for each participant, we reconstituted a mixture derived from the combination 
of both fractions. Early results indeed showed that assessing apolar and polar fractions 
separately could bring valuable additional information. Therefore, throughout the present 
work, apolar EDCs, polar EDCs and the combination of both were assessed separately on 
CALUX reporter gene assays. As none of the apolar fractions of milk samples were active on 
the (anti-)AR and (anti-)TRβ bioassays (values <LOQ), results suggested that the anti-
androgenic activity as well as anti-TRβ and T4-TTR competitive properties detected in human 
milk samples could be solely due to the presence of polar anthropogenic EDCs. Further analysis 
on the anti-AR CALUX demonstrated that reconstituted mixtures overall were significantly 
less active than the polar fraction itself. These findings highlighted a possible interaction 
between EDCs of different polarity, whereby apolar extracts acted as potential inhibitors of the 
polar fractions. On the contrary, anti-TRβ analysis gave the opposite result showing a possible 
synergy between apolar and polar fractions when combined as a mixture. Overall, these 
findings suggest a complex mode of action of EDCs on different endocrine endpoints, greatly 
depending on mixture composition. Results matched with previous studies, reporting that the 
sole investigation of specific classes of contaminants could lead to misinterpretations by 
overlooking inhibiting or synergistic effects caused by a potential mixture effect (Kortenkamp, 
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2014; Rajapakse, Silva, & Kortenkamp, 2002). Overall, this thesis demonstrates the 
importance of measuring hormonal activity derived from total EDCs content rather than 
focusing on a more selective subset of chemicals. Through total activity evaluation, bioassay-
based monitoring methods such as CALUX reporter gene assays offer a more realistic overview 
of the potential effects of a biofluid’s contamination by anthropogenic toxicants, in comparison 
with traditional chemical analysis. Nevertheless, it is undeniable that a more comprehensive 
analysis of mixture composition and EDC combined effects, using both biological- and 
chemical-based methods, is needed to further elucidate EDC potency and effects on key 
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Chapter Two: Antagonistic Activity Towards the Androgen Receptor 
Independent from Natural Sex Hormones in Human Milk Samples 
from the Norwegian HUMIS Cohort 
 
Appendix A.1  
Table 1. Instrumental settings for UHPLC-Q-TOF-MS/MS chemical analysis   
Q-TOF  
Instrument  
maXis 4G equipped with HD collision cell (Bruker, Leiderdorp, the 
Netherlands)  
Ionization  
ESI positive and negative  
Nebulizer gas flow: 1 Bar  
Dry gas flow: 8.0 l/min  
Dry heater: 200°C  
Capillary voltage: 3250V / 3500V (positive/negative)  
End Plate Offset: -500V  
Funnel RF  250 Vpp  
Multipole RF  250 Vpp  
Collision cell  
Cell RF 400 Vpp  
Transfer time: 80 µs  
Pre pulse storage time: 10 µs  
Scan range  80 – 1200 m/z  
Spectra rate  4 Hz  
Mass calibration  
Automatic internal calibration with 2 mM sodium formate in 1:1 
water/methanol solution  
MS/MS  AutoMS/MS mode (data-dependent)  
AutoMS/MS settings  
Cycle time: 1.0 sec  
Threshold: 7500 cts  
Smart exclusion: 5x  
Active exclusion: Exclude after 3 spectra; Release after 0.50 min; 
Reconsider Precursor if Current intensity / Previous intensity = 5x  
CID interpolated list:  
 
100: type=Base; width=8; CE=15  
500: type=Base; width=8; CE=35  
1000: type=Base; width=10; CE=50  
2000: type=Base; width=15; CE=75  
  
Precursor Acquisition Control: Low: 10000 cts; scan at 2 Hz; High: 
500000 cts; scan at 8 Hz  
UHPLC  
Instrument  Nexera (Shimadzu, Den Bosch, the Netherlands)  
Flow, column, mobile phase, column 
temperature  
Phenomenex Kinetex Fluor 5  
100x2.1mm 1.7u particle size  
0.250mL/min  
Injection vol. 20 µL  
UV detection  254 nm  
Injection volume  20 µl  
Gradient program  
T=0: 20%B; T=25: 100%B; T=28: 100%B; T=28.5: 20%B  
Equilibration between injections: 10 min  
First minute diverted to waste  
  
  
 Appendix A.2 
Appendix A.2 can be found online at https://doi.org/10.1016/j.envint.2020.105948. 
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Chapter Three: Anti-Androgenic Compounds in Breast Milk and 
Possible Association with Cryptorchidism Among Norwegian Boys in 
the HUMIS Birth Cohort 
 
Supplementary Table 1. Profile of study participants for anti-AR case-control study 
compared to the eligible and entire cohort. 
 
  
Enrolled in HUMIS 
cohort  
Eligible (mother-son) 
Cohort   
Case-control study 
participants   
N=2,606  N=1,262  N=199  
Maternal age (years)  30 (27-33)  30 (26-33)  30 (26-33)  
Maternal Education level           
Low  223 (8.6%)  113 (9.0%)  19 (9.5%)  
Middle  319 (12.2%)  158 (12.5%)  26 (13.1%)  
High  1,952 (74.9%)  970 (76.9%)  150 (75.4%)  
Missing  112 (4.3%)  21 (1.7%)  4 (2.0%)  
Birth weight            
<2500  178 (6.8%)  56 (4.4%)  5 (2.5%)  
2500-4000  1,853 (71.1%)  876 (69.4%)  146 (73.4%)  
> 4000  574 (22.0%)  329 (26.1%)  48 (24.1%)  
Missing  1 (0.0%)  1 (0.1%)     
Parity  1,063 (42.5%)  531 (43.6%)  78 (40.0%)  
Gestational age (days)  281 (273-288)  282 (274-288)  281.5 (273-288)  
Small for gestational age  261 (10.0%)  113 (9.0%)  19 (9.5%)  
Preterm   242 (9.3%)  101 (8.0%)  13 (6.5%)  
Caesarean section  434 (16.7%)  205 (16.2%)  27 (13.6%)  
Pre-pregnancy BMI           
Under weight  80 (3.1%)  39 (3.1%)  4 (2.0%)  
Normal  1,536 (58.9%)  750 (59.4%)  125 (62.8%)  
Overweight  565 (21.7%)  280 (22.2%)  39 (19.6%)  
Obese  260 (10.0%)  127 (10.1%)  22 (11.1%)  
Missing  165 (6.3%)  66 (5.2%)  9 (4.5%)  
Smoking in pregnancy            
never smoking  1,557 (59.7%)  747 (59.2%)  132 (66.3%)  
past smoker  682 (26.2%)  342 (27.1%)  52 (26.1%)  
occasional  63 (2.4%)  35 (2.8%)  3 (1.5%)  
daily smoker LE 10  208 (8.0%)  97 (7.7%)  8 (4.0%)  
daily smoker >10  32 (1.2%)  17 (1.3%)  2 (1.0%)  
Missing  64 (2.5%)  24 (1.9%)  2 (1.0%)  
Preeclampsia  115 (4.4%)  55 (4.4%)  7 (3.5%)  







Supplementary Table 2. Missing-value patterns of the data.  
 Pattern 
Percent 1 2 3 4  5 6 7 8  9 
            
17 1 1 1 1  1 1 1 1  1 
41 1 1 1 1  1 1 1 0  0 
23 1 1 1 1  1 1 1 1  0 
11 1 1 1 1  1 1 1 0  1 
2 1 1 1 1  1 1 0 1  0 
1 1 1 1 0  1 1 1 1  0 
1 1 1 1 1  1 1 0 0  0 
<1 0 1 1 1  1 1 0 1  0 
<1 1 0 1 1  0 0 0 0  0 
<1 1 0 1 1  1 1 1 0  0 
<1 1 1 0 1  1 1 1 0  1 
<1 1 1 0 1  1 1 1 1  0 
<1 1 1 0 1  1 1 1 1  1 
<1 1 1 1 0  0 0 0 0  0 
<1 1 1 1 0  1 1 1 0  0 
<1 1 1 1 1  0 0 0 0  0 
<1 1 1 1 1  0 0 1 0  0 
<1 1 1 1 1  1 0 1 0  0 
            
100            
 
Note: 17% of the data is complete for all variables while 83% are missing for either one or more of the 
variables. 
1. Gestational age 2. Smoking 3. Fat content percent 4. Maternal education 5. Number of siblings 6. 
Antibiotics use during pregnancy 7. Pre-pregnancy BMI 8. PCB194 9. Alcohol consumption.  
 
However, the 83% missing was reduced to 7% when variables with high missing (alcohol use, smoking, 
antibiotics, maternal toxicants, and fat content) were removed after Sensitivity analysis showed that 
including them in the model didn’t change the result (See below Supp. Figure 1-5). Therefore, after 




Supplemental Table S3. Unadjusted and adjusted estimates from logistic regression for 
the associations between anti-AR activity from different fractions (mixture, polar, apolar) and 
the risk of cryptorchidism among cases (n=94) and controls (n=105) in HUMIS cohort.  
 
    Crude  Adjusteda  Further adjustedb  
    OR  95% CI  p-value  OR  95% CI  p-value  OR  95% CI  p-value  
  Cumulative cryptorchidism                        
  Mixed fraction  0.87  0.36  2.07  0.75  0.65  0.25  1.71  0.39  0.59  0.22  1.61  0.31  
  Polar fraction  1.01  0.82  1.24  0.89  1.00  0.80  1.24  0.99  1.00  0.80  1.25  0.97  
  Apolar fraction  1.49  0.26  8.44  0.65  1.77  0.30  10.39  0.53  2.18  0.36  2.58  13.3  
Note: aMinimal adjusted model: Maternal age, socio economic status, Pre-pregnancy BMI, 
gestational age and parity  
bFully adjusted model: Additional adjustment including gestational diabetes and preeclampsia.  
OR: Odd Ratio; 95% CI: 95% Confidence interval  
Sensitivity Analysis was performed on the multiple imputed data set to check if including 
some of the variables (alcohol use, smoking, antibiotics, maternal toxicants, and 
fat content) would lead to changes in the result. 
 
 




Supplemental Figure 2. Sensitivity analysis for smoking in pregnancy 
 












Chapter Four: Evaluation of A Panel of In Vitro Methods for Assessing 
Thyroid Receptor Β and Transthyretin Transporter Disrupting 
Activities 
 Annex 1 
Table 1. Cytotoxicity results of test compounds for TRβ CALUX evaluation, agonistic mode. 
Compound Minimum (M) Maximum (M) Cytotoxicity (M) 
1-850 1.0E-12 1.0E-05 ≥1.0E-05 
2-AAF 1.0E-12 1.0E-05 - 
aflatoxin b1 3.0E-12 3.0E-05 - 
amiodarone 3.0E-13 3.0E-06 - 
at-RA 3.0E-12 3.0E-05 ≥3.0E-05 
BPA 3.0E-12 3.0E-05 - 
dieldrin 3.0E-12 3.0E-05 - 
endosulfan 3.0E-12 3.0E-05 - 
hydroquinone 3.0E-12 3.0E-05 - 
methoxyacetic acid 3.0E-12 3.0E-05 - 
T2-toxin 1.0E-01 1.0E-04 ≥1E-7 
T3 1.0E-12 1.0E-05 - 
T4 1.0E-12 1.0E-05 - 
TBBPA 1.0E-12 1.0E-05 ≥1.0E-05 
TETRAC 1.0E-12 1.0E-05 - 
TRIAC 1.0E-11 1.0E-04 ≥1.0E-04 
valproic acid 1.0E-12 1.0E-05 - 
vinclozolin 1.0E-12 1.0E-05 - 
Note: Concentration range and cytotoxicity results for all test compounds analyzed in the TRβ CALUX. 





Table 2. Cytotoxicity results of test compounds for TRβ CALUX evaluation, antagonistic 
mode. 
Compound Minimum (M) Maximum (M) Cytotoxicity (M) 
1-850 1.0E-12 1.0E-05 - 
4-nonylphenol 3.0E-12 3.0E-05 ≥3.0E-05 
aflatoxin b1 3.0E-12 3.0E-05 - 
amiodarone 3.0E-12 3.0E-06 - 
at-RA 3.0E-12 3.0E-05 - 
bisphenol A 3.0E-12 3.0E-05 - 
deoxynivalenol 1.0E-09 3.0E-06 - 
dibutylphthalate 3.0E-12 3.0E-05 - 
dronedarone 1.0E-12 1.0E-05 ≥1.0E-05 
endosulfan 3.0E-12 3.0E-05 ≥3e-6 
pinoresinol 3.0E-12 3.0E-05 - 
T2-toxin 1.0E-11 1.0E-04 ≥1e-5 
T3 1.0E-12 1.0E-05 - 
TBBPA 1.0E-12 1.0E-05 - 
zearalenone 1.0E-11 1.0E-04 ≥1e-5 
Note: Concentration range and cytotoxicity results for all test compounds analyzed in the anti-TRβ 
CALUX. Cytoxicitiy was determined by Cytotox CALUX assay, background control and/or visual 
observation. 
 
Table 3. Cytotoxicity results of test compounds for TTR-TRβ CALUX evaluation. 
Compound Minimum (M) Maximum (M) Cytotoxicity (M) 
4-nonyphenol 1.1E-07 3.2E-04 - 
alachlor 1.1E-07 3.2E-04 - 
BPA 1.1E-06 3.2E-03 - 
DES 1.1E-08 3.2E-05 - 
PBP 1.1E-09 3.2E-06 - 
PCP 1.1E-07 3.2E-04 - 
PFOA 1.1E-08 3.2E-05 - 
PFOS 1.1E-10 3.2E-06 - 
TCBPA 1.1E-09 3.2E-06 - 
TBBPA 1.1E-09 3.2E-06 - 
t2-toxin 1.1E-09 3.2E-06 - 
Note: Concentration range and cytotoxicity results for all test compounds analyzed in the TTRTRβ 






Table 1. Selection of active and non-active compounds for TRβ CALUX evaluation, agonistic 
mode. 
Compound CAS number Reported activity Reference 
1-850 251310-57-3 Non-active Schapira et al., 2003 [1] 
2-AAF 53-96-3 Active BDS internal database 
aflatoxin B1 1162-65-8 Non-active BDS internal database 
amiodarone 96027-74-6 Non-active Drvota et al., 1995 [2] 
at-RA 302-79-4 Active BDS internal database 
BPA 80-05-7 Non-active Sun et al., 2009 [3] 
dieldrin 60-57-1 Non-active BDS internal database 
endosulfan 959-98-8 Non-active ToxCast [4] 
hydroquinone 123-31-9 Unknown BDS internal database 
methoxyacetic acid 625-45-6 Non-active BDS internal database 
T2-toxin 21259-20-1 Unknown BDS internal database 
T3 5714-08-9 Active Cheek et al., 1999 [5] 
T4 51-48-9 Active Cheek et al., 1999 
TBBPA 79-94-7 Non-active Sun et al., 2009 
TETRAC 67-30-1 Active Cheek et al., 1999 
TRIAC 51-24-1 Active Cheek et al., 1999 
valproic acid 99-66-1 Non-active BDS internal database 
vinclozolin 50471-44-8 Non-active BDS internal database 
Note: All compounds were selected based on either available data, prior intra-laboratory studies or 
chemical properties. In italics, the reference compound T3. Compounds referred as “BDS internal 
database” will not be used for predictivity calculations. Report to 2.3 for chemicals abbreviation. All 
compounds were purchased from Sigma Aldrich with the exception of 2-AAF and 1-850 which were 





Table 2. Selection of active and non-active compounds for TRβ CALUX evaluation, 
antagonistic mode. 
Compound CAS number Reported activity Reference 
1-850 251310-57-3 Active Schapira et al., 2003 
4-nonylphenol 104-40-5 Active ToxCast [5] 
aflatoxin B1 1162-65-8 Non-active BDS internal database 
amiodarone 96027-74-6 Non-active Drvota et al., 1995 
At-RA 302-79-4 Unknown BDS internal database 
BPA 80-05-7 Active Sun et al., 2009 
deoxynivalenol 4330-21-6 Active Demaegdt et al., 2016 [5] 
dibutylphthalate 84-74-2 Active Shen et al., 2009 2016 [7] 
dronedarone 141626-36-0 Non-active Droggrell & Hancox, 2004 2016 [8] 
endosulfan 959-98-8 Active ToxCast 
pinoresinol 487-36-5 Active Ogungbe et al., 2014 2016 [9] 
T2-toxin 21259-20-1 Active BDS internal database 
T3 5714-08-9 Non-active Cheek et al., 1999 
TBBPA 79-94-7 Active Sun et al., 2009 
zearalenone 17924-92-4 Active Kiss et al., 2018 [10] 
Note: All compounds were selected based on either available data, prior intra-laboratory studies or 
chemical properties. In italics, the reference compound deoxynivalenol. Compounds referred as “BDS 
internal database” will not be used for predictivity calculations. Report to 2.3 for chemicals 
abbreviation. All compounds were purchased from Sigma Aldrich with the exception of 1-850 which 
was obtained from Cayman.  
Table 3. Selection of active and non-active compounds for TTR-TRβ CALUX evaluation. 
Compound CAS number Reported activity Reference 
4-nonyphenol 25154-52-3 Active Simon et al., 2013 [11] 
alachlor 15972-60-8 Non-active Cheek et al., 1999 
BPA 80-05-7 Active Cao et al., 2011 [12] 
DES 56-53-1 Active Ishihara et al., 2003 [13] 
PBP 608-71-9 Active Meerts et al., 2000 [14] 
PCP 87-86-5 Active Van den Berg, 1990 [15] 
PFOA 335-67-1 Active Weiss et al., 2009 [16] 
PFOS 1763-23-1 Active Weiss et al., 2009 
T2-toxin 21259-20-1 Unknown BDS internal database 
TBBPA 79-94-7 Active Meerts et al., 2000 
TCBPA 79-95-8 Active Meerts et al., 2000 
 
Note: All compounds were selected based on either available data, prior intra-laboratory studies or 
chemical properties. In italics, the reference compound TBBPA. Compounds referred as “BDS internal 
database” will not be used for predictivity calculations. Report to 2.3 for chemicals abbreviation. All 





[1] M. Schapira, B.M. Raaka, S. Das, L. Fan, M. Totrov, Z. Zhou, S.R. Wilson, R. Abagyan, H.H. 
Samuels, Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking, 
Proceedings of the National Academy of Sciences. 100 (2003) 7354–7359. 
doi:10.1073/pnas.1131854100. 
[2] V. Drvota, B. Carlsson, J. Häggblad, C. Sylvén, Amiodarone is a dose-dependent noncompetitive 
and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas 
disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect, 
J. Cardiovasc. Pharmacol. 26 (1995) 222–226. 
[3] H. Sun, O.-X. Shen, X.-R. Wang, L. Zhou, S. Zhen, X. Chen, Anti-thyroid hormone activity of 
bisphenol A, tetrabromobisphenol A and tetrachlorobisphenol A in an improved reporter gene assay, 
Toxicology in Vitro. 23 (2009) 950–954. doi:10.1016/j.tiv.2009.05.004. 
[4] ToxCast, (n.d.). https://actor.epa.gov/dashboard/#chemical/104-40-5 (accessed September 
20, 2018). 
[5] A.O. Cheek, K. Kow, J. Chen, J.A. McLachlan, Potential mechanisms of thyroid disruption in 
humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-
binding globulin, Environ Health Perspect. 107 (1999) 273–278. 
[6] H. Demaegdt, B. Daminet, A. Evrard, M.-L. Scippo, M. Muller, L. Pussemier, A. Callebaut, K. 
Vandermeiren, Endocrine activity of mycotoxins and mycotoxin mixtures, Food Chem. Toxicol. 96 
(2016) 107–116. doi:10.1016/j.fct.2016.07.033. 
[7] O. Shen, G. Du, H. Sun, W. Wu, Y. Jiang, L. Song, X. Wang, Comparison of in vitro hormone 
activities of selected phthalates using reporter gene assays, Toxicol. Lett. 191 (2009) 9–14. 
doi:10.1016/j.toxlet.2009.07.019. 
[8] S.A. Doggrell, J.C. Hancox, Dronedarone: an amiodarone analogue, Expert Opin Investig 
Drugs. 13 (2004) 415–426. doi:10.1517/13543784.13.4.415. 
 [9] I.V. Ogungbe, R.A. Crouch, T. Demeritte, (−) Arctigenin and (+) Pinoresinol Are Antagonists of 
the Human Thyroid Hormone Receptor β, J Chem Inf Model. 54 (2014) 3051–3055. 
doi:10.1021/ci500537e. 
[10]  D.S. Kiss, E. Ioja, I. Toth, Z. Barany, G. Jocsak, T. Bartha, T.L. Horvath, A. Zsarnovszky, 
Comparative Analysis of Zearalenone Effects on Thyroid Receptor Alpha (TRα) and Beta (TRβ) 
Expression in Rat Primary Cerebellar Cell Cultures, Int J Mol Sci. 19 (2018). 
doi:10.3390/ijms19051440.  
[11]  E. Simon, M. van Velzen, S.H. Brandsma, E. Lie, K. Løken, J. de Boer, J. Bytingsvik, B.M. 
Jenssen, J. Aars, T. Hamers, M.H. Lamoree, Effect-directed analysis to explore the polar bear 
exposome: identification of thyroid hormone disrupting compounds in plasma, Environ. Sci. Technol. 
47 (2013) 8902–8912. doi:10.1021/es401696u. 
[12]  J. Cao, L.-H. Guo, B. Wan, Y. Wei, In vitro fluorescence displacement investigation of thyroxine 
transport disruption by bisphenol A, J Environ Sci (China). 23 (2011) 315–321. 
[13]  A. Ishihara, N. Nishiyama, S. Sugiyama, K. Yamauchi, The effect of endocrine disrupting 
chemicals on thyroid hormone binding to Japanese quail transthyretin and thyroid hormone receptor, 
Gen. Comp. Endocrinol. 134 (2003) 36–43. 
[14]  I.A. Meerts, J.J. van Zanden, E.A. Luijks, I. van Leeuwen-Bol, G. Marsh, E. Jakobsson, A. 
Bergman, A. Brouwer, Potent competitive interactions of some brominated flame retardants and related 
compounds with human transthyretin in vitro, Toxicol. Sci. 56 (2000) 95–104. 
[15]    K.J. van den Berg, Interaction of chlorinated phenols with thyroxine binding sites of human 
transthyretin, albumin and thyroid binding globulin, Chem. Biol. Interact. 76 (1990) 63–75. 
[16]     J.M. Weiss, P.L. Andersson, M.H. Lamoree, P.E.G. Leonards, S.P.J. van Leeuwen, T. Hamers, 
Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein 




Dit proefschrift onderzoekt de aanwezigheid en potentiële effecten van 
hormoonverstorende chemicaliën (EDC) in humane melk, gebruikmakend van monsters uit 
het Noorse HUMIS cohort. Deze studie is gebaseerd op een tweestapsbenadering, waarbij als 
eerste stap de extractie van hormoon actieve stoffen plaatsvindt gebaseerd op hun polariteit. 
Als tweede stap worden de apolaire- en polaire extracten en een combinatie van beide 
geanalyseerd met behulp van in vitro humaan-gebaseerde reportergen CALUX bioassays die 
belangrijke eindpunten van het endocriene systeem omvatten: oestrogenen, androgenen en 
schildklierhormonen. 
 Hoofdstuk één geeft achtergrond over contaminanten met hormoonverstorende 
eigenschappen en introduceert de steroïde- en schildklier signaleringsroutes. Dit hoofdstuk 
beschrijft ook eerdere bevindingen van het Noorse HUMIS geboorte-cohort en de 
belangrijkste doelstellingen van dit proefschrift. Bovendien worden, gezien hun belang in de 
studies die in dit proefschrift worden gepresenteerd, effect-gebaseerde bioassays en effect-
gestuurde fractionering geïntroduceerd. 
 Hoofdstuk twee beschrijft een teststudie uitgevoerd op tien humane melkmonsters 
gebruik makend van de (anti-)ERβ en (anti-) AR CALUX bioassays. Hoewel er nagenoeg geen 
oestrogene activiteit werd gedetecteerd, geeft deze studie aan dat alle monsters behalve één 
kwantificeerbare hoeveelheden anti-androgene activiteit van onbekende oorsprong bevatten. 
Interessant is dat de metingen een hogere activiteit lieten zien in de polaire fracties in 
vergelijking met de gereconstitueerde apolaire-polaire extracten, terwijl geen van de apolaire 
fracties actief was in de anti-AR CALUX bioassay. Verder onderzoek met behulp van effect-
gestuurde fractionering en uitsluitingsmethoden toonde aan dat de waargenomen anti-
androgene activiteit niet verklaard kon worden door de aanwezigheid van natuurlijke 
hormonen (androstendion, DHEA, E1, E2, pregnolon, progesteron, testosteron) en/of 
metabolieten daarvan. Deze resultaten suggereren daarom dat het meer waarschijnlijk is dat 
de waargenomen anti-AR activiteit in humane melkmonsters wordt veroorzaakt door nog niet 
geïdentificeerde polaire antropogene contaminanten. 
 Er is toenemend in vitro en in vivo bewijs dat suggereert dat vroegtijdige blootstelling 
aan anti-androgenen kan resulteren in reproductieve stoornissen, zoals cryptorchisme. Om 
die reden werden er, in Hoofdstuk drie, 199 humane melkmonsters uit het HUMIS cohort 
geselecteerd voor een casestudy, inclusief een subset van 94 moeders die bevallen zijn van 
jongens met niet-ingedaalde testikels en een subset van 105 moeders ‘controle’ die bevallen 
zijn van jongens zonder cryptorchisme. In dit hoofdstuk werd een potentieel verband tussen 
anti-androgene activiteit, gemeten met behulp van anti-AR CALUX in moedermelk, en 
cryptorchisme geëvalueerd. Hoewel statistische analyse geen significant verschil liet zien 
tussen de op humane melk gebaseerde anti-AR activiteit in de controle- en cryptorchisme 
monsters, kon een mogelijk verband tussen de aanwezigheid van apolaire verbindingen in 
humane melk en een prevalentie van niet-ingedaalde testikels niet worden uitgesloten. Over 
het algemeen werd er een anti-androgene activiteit in het merendeel van de melkmonsters 
gemeten. Analyse van fracties met verschillende polariteit, d.w.z. apolaire, polaire en 
gecombineerde extracten, bevestigde de eerdere bevindingen uit hoofdstuk twee, en werd 
benadrukt dat polaire verbindingen het meest bijdragen aan de anti-androgene activiteit in 
moedermelk. Hoewel de herkomst van zulke verbindingen nog steeds onduidelijk is laat deze 




 Hoewel gebleken is dat geslachtshormonen bijzonder gevoelige doelwitten zijn van 
hormoonverstoring in het vroege levensstadium zijn er in de afgelopen jaren ook zorgen 
gerezen over de invloed van hormoonverstorende stoffen op het schildklierstelsel door onder 
meer veranderingen in de circulerende schildklierhormoonspiegel te veroorzaken en te 
interfereren met het serumtransport van het schildklierhormoon, in het bijzonder 
transthyretin (TTR). In Hoofdstuk vier, werd de ontwikkeling en validatie van een nieuw 
schildklier CALUX panel geëvalueerd, specifiek ontworpen om het vermogen tot interactie van 
hormoonverstorende stoffen met de schildklierreceptor β (TRβ) (TRβ CALUX assay) en/of 
TTR (TTR-TRβ CALUX assay) te beoordelen. De TRβ CALUX assay bestaat uit een U2OS 
osteosarcoomcellijn die endogeen TRβ tot expressie brengt en stabiel is getransfecteerd met 
een aan schildklier responsieve elementen gekoppelde luciferase reportergen. Deze TRβ 
CALUX assay is in staat om de op schildklierhormoonreceptor gebaseerde agonistische 
activiteit te beoordelen door middel van het kwantificeren van de geproduceerde luciferase 
activiteit. TRβ CALUX assay kan ook gebruikt worden voor het meten van de antagonistische 
activiteit door middel van pre-stimulatie van de cellen met natuurlijk ligand T3 (anti-TRβ 
CALUX assay) of voor de evaluatie van de T4-TTR bindingscompetitie in combinatie met de 
TTR bioassay. Elke bioassay (TRβ and TTR-TRβ) werd gevalideerd met behulp van een reeks 
bekende positief en negatief schildklierverstorende stoffen en vertoonde een zeer goede 
voorspelbaarheid wat suggereert dat het nieuw ontwikkelde CALUX panel een krachtig 
hulpmiddel kan zijn bij het voorspellen van de effecten van hormoonverstorende stoffen op de 
endogene schildklierhormoon werking. 
 In Hoofdstuk vijf, werd het nieuw ontwikkelde schildklier-specifieke CALUX assay 
panel gebruikt om een set van per- en polyfluoralkyl verbindingen te onderzoeken, waarvan 
verondersteld werd dat ze mogelijk schildklierverstoorders zijn. Geen van de geteste PFAS 
vertoonde een agonistische activiteit in de TRβ CALUX reportergen assay, terwijl zeven PFAS 
antagonistische activiteit vertoonden op TRβ. TTR- TRβ CALUX analyses toonde aan dat alle 
PFAS de eigenschappen hebben om de competitie aan te gaan met T4 bij de TTR binding, zij 
het met verschillende potentie. In dit hoofdstuk, hebben we ook onderzocht of humane 
melkmonsters uit het Noorse HUMIS cohort schildklierhormoon verstorende activiteit bevat 
die mogelijk verband houdt met de aanwezigheid van contaminanten, waaronder PFAS. 
Hoewel er geen TRβ agonistische activiteit werd gedetecteerd vertoonden de meeste 
moedermelk extracten wel antagonistische activiteit en alle behalve één vertoonden een 
competitieve T4-TTR bindingspotentie van 0.41 tot 9.1 µg PFOA eq./g melk. Gezien hun 
vermogen de competitie aan te gaan met het schildklierhormoon bij het TTR transport en TRβ 
activatie tegen te gaan suggereren de in hoofdstuk vijf gepresenteerde resultaten dat PFAS 
potente schildklierhormoon verstoorders kunnen zijn. Hoewel het aantal monsters vrij klein 
was (tien) toonde de teststudie uitgevoerd op de HUMIS monsters de aanwezigheid van 
schildklierhormoon verstorende activiteit aan in extracten van moedermelk. Verdere 
berekeningen gebaseerd op PFOA (perfluoroctaanzuur) en PFOS (perfluorsulfonaat) 
monsterconcentraties toonden aan dat slechts een klein percentage van de TRβ 
antagonistische activiteit verklaard kon worden door PFAS contaminatie, wat kan duiden op 






Fondée sur des échantillons de lait provenant de la cohorte norvégienne HUMIS, cette 
thèse étudie la présence de perturbateurs endocriniens (PEs) dans le lait maternel ainsi que 
leurs potentiels effets sur le développement du nourrisson. Les différents chapitres de ce projet 
sont basés sur une approche en deux étapes permettant dans un premier temps de préparer 
les échantillons en isolant leurs composés chimiques actifs en fonction de leur polarité. Dans 
un second temps, les extraits apolaires, polaires et leur combinaison (mélange) découlant de 
cette extraction sont étudiés à l’aide de méthodes d’analyse in vitro reposant sur l’utilisation 
de lignées cellulaires humaines. Ces essais biologiques dits ‘CALUX’ permettent l’étude des 
principaux acteurs du système endocrinien : les œstrogènes, les androgènes et les hormones 
thyroïdiennes (HTs). 
Le premier chapitre contextualise notre sujet en introduisant les éléments majeurs 
nécessaires à la compréhension du projet à savoir la notion de perturbateurs endocriniens, les 
voies de signalisation stéroïdienne et thyroïdienne, ainsi que les méthodes d’analyses utilisées 
tout au long de l’étude (essais biologiques et fractionnement dirigé). Ce chapitre présente 
également les résultats découlant de précédentes études sur la cohorte HUMIS et détaille les 
principaux objectifs de cette thèse. 
Le deuxième chapitre constitue une étude pilote réalisée sur dix échantillons de lait 
maternel à l’aide de deux essais biologiques CALUX : récepteur oestrogénique beta (ERβ) 
CALUX et récepteur androgénique (AR) CALUX. Bien que presqu’aucune activité 
œstrogénique n’ait été détectée, ce travail montre que tous les échantillons sauf un présentent 
une activité anti-androgénique (anti-AR) d’origine inconnue. Aucune fraction apolaire testée 
n’a été interprétée comme active. Fait intéressant, les résultats démontrent que ce type 
d’activité est plus élevée dans les fractions polaires que dans les mélanges avec les extraits 
apolaires supposant une potentielle interaction entre les deux types de composés. Une étude 
plus approfondie impliquant des méthodes de fractionnement et d’exclusion dirigés montre 
que l’activité anti-androgénique observée dans les échantillons ne pouvait pas s’expliquer par 
la présence d’hormones naturelles (androstènedione, DHEA, E1, E2, pregnenolone, 
progestérone, testostérone) et/ou de métabolites associés. Par conséquent, ces résultats 
suggèrent que l’activité anti-AR présente dans les échantillons de lait maternel est plus 
susceptible d’être causée par des contaminants anthropiques polaires encore non identifiés 
que par des composés présents naturellement dans le corps.   
De plus en plus de preuves in vitro et in vivo suggèrent qu’une exposition précoce à 
des anti-androgènes peut s’avérer néfaste pour le bon développement et fonctionnement de 
l’appareil reproducteur masculin, pouvant engendrer des malformations congénitales telles 
que la cryptorchidie i.e. défaut de migration du testicule. Par conséquent, 199 échantillons de 
lait maternel provenant de 94 mères ayant donné naissance à des garçons avec des testicules 
non-descendus ainsi que 105 mères dites « contrôles », c’est-à-dire ayant donné naissance à 
des garçons sans cryptorchidie, ont été sélectionnés pour effectuer une étude de cas présentée 
dans le troisième chapitre. Dans ce chapitre, nous évaluons la possible relation entre 
l’activité anti-androgène détectée dans le lait maternel, et le risque de cryptorchidie chez le 
nouveau-né. Dans l’ensemble, une activité anti-androgénique a été mesurée dans la majorité 
des échantillons de lait. Bien que l’analyse statistique n’ait montré aucune différence 
significative entre l’activité mesurée dans les échantillons témoins et celle dans les 
échantillons dits ‘cas’, nous avons observé une éventuelle association entre la présence de 
composés apolaires dans le lait maternel et le risque de cryptorchidie. L’analyse des différentes 
fractions, c’est-à-dire des extraits apolaires, polaires et combinés, a confirmé les résultats 
rapportés dans le chapitre deux, soulignant que les composés polaires seraient en grande 
majorité responsable de l’activité anti-AR présente dans le lait maternel. Bien que les origines 
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de ces composés ne soient pas encore claires, cette étude démontre l’importance d’évaluer les 
mélanges de PEs dans leur ensemble plutôt que d’étudier les composés individuellement. 
Bien que les stéroïdes soient une cible particulièrement prisée des PEs, ces dernières 
années ont mis en lumière la capacité des PEs à cibler le système thyroïdien, causant entre 
autres des modifications des niveaux des HTs circulantes ainsi que des interférences avec leurs 
transporteurs, en particulier la protéine de transport transthyrétine (TTR). Ainsi, un nouveau 
panel d’essais biologiques CALUX spécialement conçus pour évaluer les capacités des PEs à 
interagir avec le récepteur thyroïdien β (TRβ) (TRβ CALUX) ou avec le transporteur TTR 
(TTR-TRβ CALUX) a été développé et validé dans le quatrième chapitre de cette thèse. Le 
TRβ CALUX est basé sur une lignée cellulaire U2OS exprimant TRβ et stablement transfectée 
avec le gène rapporteur de la luciférase, lié aux éléments de réponse thyroïdiens. Grâce à ce 
gène rapporteur, il est possible de quantifier l’activité des PEs sur TRβ en mesurant la quantité 
de lumière produite. Il est également possible de mesurer l’activité dite ‘antagoniste’ des PEs 
en pré-stimulant les cellules avec le ligand naturel T3 ainsi que d’évaluer leur capacité à entrer 
en compétition avec T4 pour leur transport via TTR. Chaque essai (TRβ et TTR-TRβ CALUX), 
a été validé à l’aide d’une gamme de composés positifs connus pour être des perturbateurs 
thyroïdiens, ainsi que des substances voulues négatives. Cette évaluation a montré une très 
bonne prédictivité suggérant que ce nouveau panel CALUX peut être un outil puissant dans la 
prédiction des effets des PEs sur le système thyroïdien.     
Dans le cinquième chapitre, le panel thyroïdien CALUX a été utilisé pour étudier 
treize substances per- et poly-fluoroalkylées (PFAS), possibles perturbateurs thyroïdiens. 
Aucun des PFAS testés n’a engendré l’activation du TRβ cependant, sept PFAS ont été 
identifiés comme antagonistes du récepteur. L’analyse TTR-TRβ CALUX a montré que tous 
les PFAS testés peuvent entrer en compétition avec le ligand naturel T4 pour liaison avec TTR, 
bien que leur niveau d’activité soit dépendant de leur structure chimique. Dans ce chapitre, 
dix échantillons de lait maternel ont également été analysés sur le panel thyroïdien. Bien 
qu’aucune activité agonistique n’ait été détectée, la majorité des extraits ont montré une 
activité antagoniste envers TRβ et tous, sauf un, ont été actifs sur le TTR- TRβ CALUX ce qui 
équivaut à une activité de 0,41 à 9,1 μg PFOA équivalent/g de lait. Compte tenu de leurs 
capacités à rivaliser avec les HTs pour le transport TTR et à inhiber TRβ, les résultats présentés 
dans le chapitre cinq suggèrent que les PFAS peuvent être de puissants perturbateurs 
thyroïdiens. Bien que la taille de l’échantillon soit relativement limitée, cette étude pilote 
démontre la présence d’une activité anti-thyroïdienne dans le lait maternel. De plus amples 
calculs basés sur les concentrations de PFOA et PFOS présentes dans les échantillons de la 
cohorte HUMIS ont démontré que seul un faible pourcentage de l’activité antagoniste pouvait 
s’expliquer par une contamination aux PFAS, suggérant la présence d’autres produits 
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